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1. Introduction 
For many of us, experiencing fatigue, muscle pain, or digestive problems is an everyday occurrence. If 
they are not part of any chronic illness, most of these somatic sensations or complaints are transient, 
non-disturbing, and do not affect any major aspects of life. On the other hand, there is overwhelming 
evidence to suggest that in some cases, these complaints grow into a significant problem for the 
individuals affected and for societies worldwide. In Germany, over 22% of the general population 
suffers from at least one complaint causing severe impairment over the course of one week (Hiller, 
Rief, & Brähler, 2006). Ongoing distress or impairment due to these complaints is likely to result in 
health care visits by affected persons. However, with 36% of patients seeking help from their general 
practitioner, a clear-cut medical explanation cannot be established (Toft et al., 2005). Consequently, 
symptoms are designated as “medically unexplained”. The implications of this are manifold. In 
patients, the initial relief of not having “anything organic” gives way to uncertainty, frustration, and 
helplessness (Dwamena, Lyles, Frankel, & Smith, 2009), and these feelings are often equally 
encountered by the treating physicians (Olde Hartman, Hassink-Franke, Lucassen, van Spaendonck, 
& van Weel, 2009). In some cases, this eventually leads to a referral to different specialised health 
care services, the choice of which depends on the most debilitating symptom. In specialised hospital 
clinics (e.g., gastroenterology), patients with MUS make up 52% of new attendees (Nimnuan, Hotopf, 
& Wessely, 2001). They often undergo multiple, invasive testing, and various treatments are offered, 
which sometimes inflict iatrogenic harm on patients. One outcome of this exhaustive process may be 
that patients are provided with a diagnosis of a so-called “functional somatic syndrome” (FSS). 
Wessely, Nimnuan, and Sharpe (1999) define a functional somatic symptom as “one that, 
after appropriate medical assessment, cannot be explained in terms of a conventionally defined 
medical disease” (p. 936). Barsky and Borus (1999) choose a slightly different wording, stating that 
FSS “are characterized more by symptoms, suffering, and disability than by disease-specific, 
demonstrable abnormalities of structure or function” (p. 910). Together, these definitions suggest two 
main criteria that must be met for a condition to fall into the category of FSS: a) the presence of at 
least one somatic symptom (positive criterion), and b) the absence of any disease or structural and 
functional abnormalities that fully account for the somatic symptom(s) (negative criterion). It is 
important to note that it needs to be ruled out that the presence of symptoms are feigned, and the 
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absence of a medical explanation should, of course, not be the mere consequence of inadequate or 
inaccurate diagnostic procedures. 
Case definitions for numerous different FSS have been formulated by various expert 
committees over the past decades (see also 1.1.2.1). A non-exhaustive list of syndromes 
encompasses conditions such as chronic fatigue syndrome (Fukuda et al., 1994), fibromyalgia 
syndrome (Wolfe et al., 2010), functional chest pain (Galmiche et al., 2006), functional dyspepsia 
(Tack et al., 2006), globus (Galmiche et al., 2006), irritable bowel syndrome (Longstreth et al., 2006), 
multiple chemical sensitivity (Bartha et al., 1999), persistent idiopathic facial pain (International 
Headache Society, 2004), premenstrual syndrome (World Health Organization, 1992), 
temporomandibular disorder (Dworkin & LeResche, 1992), and tension-type headache (International 
Headache Society, 2004). All of these different case definitions share the positive (at least one 
somatic symptom is present) and negative criterion (no disease fully accounts for the somatic 
symptoms) of FSS. However, as implied by some of these names (e.g., “irritable bowel syndrome”, 
“multiple chemical sensitivity”), in each syndrome, specific organ systems are presumably involved in 
the pathophysiology, or certain circumstances serve as symptom-triggering events. The existence of 
these case definitions has resulted in numerous lines of research, each focusing on one particular 
FSS. 
 
1.1 The question of nosology – “one versus many” 
The nosology of FSS is inconclusive. As, to date, none of the above-mentioned case definitions have 
the status of nosological entities, there are currently two approaches to the classification of FSS in 
Germany and other European countries (see Fig. 1): a) unified as a mental or, more precisely 
“somatoform disorder”, described in the fifth chapter (F) of the tenth edition of the International 
Classification of Diseases (ICD-10; World Health Organization, 1992), or b) individually as diseases 
according to other chapters of the ICD-10. For instance, in clinical practice, chronic fatigue syndrome 
(CFS) is given the label of neurasthenia (F48.0) or a disease of the nervous system (G93.3). 
Fibromyalgia syndrome (FMS) is categorized as a persistent somatoform pain disorder (F45.4) or as a 
disease of the musculoskeletal system and connective tissue (M79.7). Irritable bowel syndrome (IBS) 
is classified as a somatoform autonomic dysfunction (F45.3) or a disease of the digestive system 
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(K58). Importantly, the case definitions and ICD-10 diagnoses overlap to varying degrees but cannot 
be considered as identical. 
 
Figure 1 Exemplary classification of the three functional somatic syndromes chronic fatigue syndrome (CFS), fibromyalgia 
syndrome (FMS), and irritable bowel syndrome (IBS) in terms of the current editions of the International Classification of 
Diseases (ICD) and the Diagnostic and Statistical Manual of Mental Disorders (DSM) 
In the USA, mental disorders are classified within the Diagnostic and Statistical Manual of 
Mental Disorders (DSM). It is noteworthy that while according to the previous edition of this manual 
(DSM-IV), a somatoform disorder was, in essence, identical to an ICD-10 somatoform disorder, this 
changed dramatically with the latest version (DSM-5), which was released in 2013. As with many other 
diagnostic categories, an intense debate preceded the publication of this DSM-5 chapter. Doubts were 
raised about the key defining feature of somatoform disorders: medically unexplained symptoms 
(MUS). Not only was the distinction between MUS and medically explained symptoms found to be 
unreliable in clinical practice, but it was said to fuel mind-body dualism and make patients feel 
marginalised (Dimsdale et al., 2013). The second major criticism concerned the number of sub-
diagnoses (e.g., somatization disorder, pain disorder), which was deemed “both confusing and 
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clinically unhelpful” (Dimsdale et al., 2013, p. 224). With the revised category, named “somatic 
symptom disorder”, the distinction between MUS and medically explained symptoms was therefore 
abolished and sub-diagnoses were merged together. Furthermore, “psychological criteria”, such as 
excessive or disproportionate cognitions, emotions, and behaviour that are dedicated to somatic 
symptoms, were added (American Psychiatric Association, 2013). However, by questioning the tenet 
of the previous somatoform disorders (i.e., MUS) and lowering the threshold in terms of the number of 
somatic symptoms that are required (only one in DSM-5), it attracted harsh criticism, which mainly 
concerned the potential of over-inclusion and mislabelling of patients with conventionally defined 
medical diseases and the so-called “worried well” (Frances, 2013; Frances & Chapman, 2013). 
It is clear from this short summary of how FSS are classified that their nosology poses both an 
inter- and intra-disciplinary challenge. The reason for this lies in their current conceptualisation. The 
most recent conceptual controversy began with a seminal article by Wessely et al. (1999). They 
argued that conditions such as CFS, FMS, or IBS should not be considered as nosological entities in 
their own right, since they constitute a mere by-product of medical specialisation. By this, Wessely et 
al. meant that depending on the specialist to whom the individual patient is referred, he/she will 
receive a different label for the presented MUS. To give an example: A patient complaining of chronic 
fatigue, diffuse pain in multiple body sites, and gastrointestinal problems will receive a diagnosis of 
CFS by an infectious disease specialist, a diagnosis of FMS by a rheumatologist, and a diagnosis of a 
functional gastrointestinal disorder (e.g., IBS) by a gastroenterologist. 
Wessely et al. (1999) presented several arguments to substantiate their hypothesis. For 
instance, they reported that patients with different FSS all share a history of childhood trauma, and 
certain pathophysiological alterations, suggesting a common aetiopathogenesis. They also mentioned 
phenomenological similarities: Patients with an FSS often seem to fulfil case definitions for other, 
additional FSS (so-called “syndrome overlap”). Moreover, patients with different FSS apparently share 
other characteristics, such as comorbidity with depression and anxiety disorders, or difficulties in 
interpersonal interactions, including the patient-doctor relationship. Taken together, Wessely et al. 
argued in favour of a general FSS, instead of numerous different FSS, and this position has 
sometimes been referred to as the “lumpers’ position”. Their article caused quite a stir among patient 
associations, but also among some researchers (e.g., Goudsmit & Shepherd, 1999; Jason, Taylor, 
Song, Kennedy, & Johnson, 1999). 
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The following scientific dispute is best illustrated in an “in debate” article by Wessely and 
White (2004), which appeared in the British Journal of Psychiatry. In the article, Wessely’s position 
was contradicted by White, who preferred to view CFS, FMS, and IBS as distinct nosological entities 
(sometimes called “splitters’ position”). White claimed that “a general functional somatic syndrome can 
be consistent only with psychogenesis, since it is difficult to conceive of a pathophysiological 
mechanism that would be common to all functional somatic syndromes”, which he feared would result 
in “a deteriorating doctor-patient relationship” (both p. 96). He further emphasised that only by 
scrutinising each FSS separately can advances in the elucidation of aetiopathogenetic mechanisms 
be made. Another point made by White was that the phenomenological similarities among FSS (i.e., 
syndrome overlap, comorbidity with depression and anxiety disorders) were a methodological artefact, 
as patient samples were mostly drawn from specialised health care services, which harbour only the 
most severely disabled patients, who are likely to have comorbidities. 
In sum, the state of research in 2004 was sufficiently inconsistent for two diametrically 
opposite positions to develop regarding the conceptualisation of FSS. The greatest amount of 
progress in resolving this ambiguity is likely to be made by a) aetiopathogenetic, and b) 
phenomenological research, that is, by finding out how FSS develop and by identifying similarities and 
differences in the way they present. In the following sub-chapters, a selective overview of the state of 
research since the publication of the article by Wessely et al. (1999) will be given. In the first sub-
chapter, a theoretical framework that is able to integrate seemingly different aetiopathogenetic findings 
belonging to FSS will be presented. The second sub-chapter will focus on relevant phenomenological 
findings in FSS, such as syndrome overlap and their relationship with depression and anxiety. The 
main findings, gaps in the literature, and methodological limitations will be summarised after each sub-
chapter in order to derive implications for future research. 
 
1.1.1 Aetiopathogenesis – the role of stress 
The apparent absence of a medical explanation has created an ever-increasing body of literature on 
predisposing, precipitating, and perpetuating factors in individual FSS over the past decades. Although 
in the early days, research was driven by mono-factorial hypotheses involving neurological or 
immunological causative agents for symptoms, the last two decades have witnessed a shift towards a 
multi-factorial understanding of each FSS. Current aetiopathogenetic accounts can be sub-divided into 
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two broader categories: cognitive-behavioural and biologically oriented models (see Witthöft & Hiller, 
2010 for a review of the most influential models). While cognitive-behavioural models emphasise the 
importance of personality characteristics, maladaptive attention and interpretation biases regarding 
somatic sensations, and avoidance behaviour, biological models give more weight to the role of genes 
and dysfunctional somatic systems, such as the central nervous system (CNS), the autonomic 
nervous system (ANS), the hypothalamic-pituitary-adrenal (HPA) axis, and the immune system. The 
complex aetiopathogenesis of FSS, however, can only be addressed by overcoming the mind-body 
dualism that is implicitly maintained by these different lines of research. 
An important concept that is able to bridge the gap between cognitive-behavioural and 
biological explanations for any FSS is stress. Figure 2 brings together two influential theories about 
stress: the cognitive-transactional stress theory by Lazarus (1966) and Lazarus and Folkman (1984) 
and the allostatic load model by McEwen (1998) and McEwen and Stellar (1993). In a nutshell, the 
cognitive-transactional stress theory (Lazarus, 1966; Lazarus & Folkman, 1984) posits that stress 
manifests whenever a stimulus is perceived as stressful (primary appraisal) and the resources to deal 
with it are interpreted as inadequate (secondary appraisal). Examples of stimuli that are able to elicit 
stress are trauma, chronic stress, critical life events, or daily hassles, and these can be understood as 
“psychosocial stressors”. Stress includes a so-called “stress response”, which can be described in 
terms of emotions, behaviour, and biology. 
The biological stress response and its role in illnesses, including FSS, are further elaborated 
by the allostatic load model (McEwen, 1998; McEwen & Stellar, 1993). In this model, stress-
responsive biological systems are conceptualised as “allostatic systems”, meaning that they enable 
the body to adequately respond to stress (the term “allostasis” refers to the ability to achieve stability 
through change). The model claims that the adaptive process of allostasis turns into the maladaptive 
state of “allostatic load” when stress-responsive systems are chronically hyper- or hypoactive. In other 
words, allostatic load describes the wear and tear of stress-responsive systems, such as the ANS and 
the HPA axis, as a consequence of ongoing stress (e.g. due to trauma or chronic stress). 
The concept of stress seems to allow for the reconciliation of many of what appear at first 
glance to be numerous incoherent findings on FSS (see Fischer & Nater, 2013 for a more 
comprehensive review of aetiopathogenetic factors in FSS that are stress related). The most important 
findings that can be discussed within the framework illustrated below will be briefly reviewed in the 
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following paragraphs. Both psychosocial stressors and stress-responsive systems that are assumed to 
play a predisposing, precipitating, and perpetuating role in FSS will be presented. Although not part of 
this thesis, the potential role of immune functioning in FSS will be briefly mentioned in order to 
facilitate the overall understanding of assumed pathophysiological mechanisms. The term “MUS” will 
be used whenever pathophysiological mechanisms are described; the term “FSS” will be used when 
findings are summarised. Notably, the vast majority of aetiopathogenetic research focuses on CFS, 
FMS, or IBS rather than on general FSS, but there have been some efforts to summarise these 
findings on a more general level (i.e., in the form of review articles) as similarities among different FSS 
have become increasingly apparent. 
 
Figure 2 Integrated conceptualisation of stress according to Lazarus and Folkman (1984) and McEwen (1998), grey colour and 
dotted lines were used for all elements that are not directly relevant to the present thesis 
 
1.1.1.1 Childhood trauma 
A traumatic event is the most severe psychosocial stressor that can be experienced by any human 
being. The DSM-5 (American Psychiatric Association, 2013) defines trauma as “exposure to actual or 
threatened death, serious injury, or sexual violation” (p. 271), which “causes clinically significant 
distress or impairment in social, occupational, or other important areas of functioning” (p. 272). If an 
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event corresponding to this definition occurs during childhood, the term “childhood trauma” may be 
applied. It refers to interpersonal trauma, such as emotional, physical, and sexual abuse, and 
emotional and physical neglect. According to Bernstein and Fink (1998), these terms are understood 
as “verbal assaults on a child’s sense of worth or well-being” (emotional abuse), “bodily assaults on a 
child by an older person that pose a risk of, or result in, injury” (physical abuse), “sexual contact or 
conduct between a child and an older person” (sexual abuse), “failure to provide a child’s basic 
psychological and emotional needs” (emotional neglect), and “failure to provide a child’s basic physical 
needs” (physical neglect; all p. 2). Childhood trauma is usually measured via clinical interviews or 
questionnaires. 
The sequelae of childhood trauma are known to be manifold. For instance, there is a 
burgeoning literature on dysfunctional stress reactivity developing from early life events, including 
persistent changes in stress-responsive systems. More specifically, Heim and Nemeroff (2001) and 
Heim, Shugart, Craighead, and Nemeroff (2010) have shown that childhood trauma exerts long-term 
effects on HPA axis reactivity in genetically predisposed individuals (see 1.1.1.4). Altered stress 
reactivity may render these individuals more vulnerable to the effects of psychosocial stressors 
occurring during adulthood. Apart from these biological effects of childhood trauma, specific cognitive 
schemata seem to evolve from these early life experiences (e.g., self-sacrifice). These schemata are 
reflected by maladaptive interpersonal behaviour in adulthood (e.g., over-commitment at work). It is 
conceivable that this behaviour may, in turn, be a source of chronic stress (see 1.1.1.2). Taken 
together, childhood trauma may enhance the probability of experiencing chronic stress and of 
inadequately reacting towards it. 
The notion of childhood trauma as an aetiopathogenetic factor in medically unexplained 
conditions traces back to Breuer and Freud and their 19th-century studies of “hysteria” (1895/2011). A 
recent meta-analysis showed that the chance of having an FSS is increased almost threefold in 
individuals exposed to childhood trauma (Afari et al., 2014). Interestingly, although significant 
methodological heterogeneity across studies was detected by the authors, neither sample type 
(community vs. other) nor diagnostic approach (clinician-administered vs. self-report) seemed to 
impact the very robust trauma-FSS relationship. However, studies using non-validated questionnaires 
consistently reported higher associations than studies using validated questionnaires or interviews, 
highlighting the importance of using methodologically sound measures for the assessment of 
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childhood trauma in future studies. There is thus substantial evidence that childhood trauma is a 
predisposing factor of FSS. However, its direct ramifications (e.g., altered stress reactivity and chronic 
stress) have rarely been assessed within the same studies. One is therefore left wondering how the 
transition from experiences of childhood trauma to the development of FSS occurs. 
 
1.1.1.2 Chronic stress 
Chronic stress is defined in several ways, although a period of prolonged stress is the core feature 
contained in any definition. Chronic stress can be distinguished from acute stress insofar as it is often 
characterised by a gradual onset, an unforeseeable ending, and embedded within day-to-day life 
(Schulz, Schlotz, & Becker, 2004). Generally speaking, sources of chronic stress are social role 
conflicts (e.g., between the work and family domain) or unmet personal needs (e.g., recognition). As 
mentioned above, cognitive schemata that evolved as a result of childhood trauma and maladaptive 
interpersonal behaviour that goes along with it may directly foster experiences of chronic stress. A 
simplified example is a person who learns that affection is dependent on performance (emotional 
neglect) and later goes on to over-commit at school or work (self-sacrifice). Chronic stress is usually 
measured via questionnaires or by the use of different naturalistic paradigms, such as social isolation, 
caregiving, or academic stress. 
As outlined above, the biological ramifications of chronic stress are often subsumed under the 
term “allostatic load” (McEwen, 1998; McEwen & Stellar, 1993). This term refers to the wear and tear 
of stress-responsive systems such as the ANS and the HPA axis. According to Miller, Chen, and Zhou 
(2007), chronic stress is normally accompanied by hyperactivity of the HPA axis. However, over time, 
this initial pattern may turn into one that is characterised by hypo-activity. Importantly, these processes 
may be influenced by previous exposure to stressors, such as childhood trauma, and subsequent 
alterations in stress reactivity. Both hypo-activity of the parasympathetic part of the ANS (see 1.1.1.3) 
and hypocortisolism (see 1.1.1.4) have been directly linked to MUS such as fatigue and pain, 
suggesting a role for chronic stress in their manifestation. In addition, it has often been claimed that 
somatic sensations created by a state of general arousal (e.g., due to chronic stress) are subject to 
misinterpretation in individuals who go on to develop MUS (Rief & Barsky, 2005). An interesting 
concept in this context is somatosensory amplification, which describes a cognitive style that is 
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characterised by experiencing somatic sensations as more intense, and evaluating them as more 
negative (Barsky, Goodson, Lane, & Cleary, 1988; Barsky, Wyshak, & Klerman, 1990). Taken 
together, it can be hypothesised that chronic stress fosters the development of MUS via alterations in 
stress-responsive systems and cognitive bias. 
As with childhood trauma, FSS (back then often referred to as “neurasthenia”), were viewed 
as a consequence of modern life stress as early as in the 19th century (Beard, 1869). We reviewed the 
literature on different psychosocial stressors in FSS, including childhood trauma, chronic stress, critical 
life events (e.g., a viral infection, sudden unemployment), and daily hassles (e.g., being late, having an 
argument; Nater, Fischer, & Ehlert, 2011). In general, the literature seemed consistent insofar as 
childhood trauma and critical life events were frequently reported by patients with FSS. Chronic stress 
levels, on the other hand, were only investigated by a handful of studies, and the vast majority of these 
were cross-sectional. Although plausible from an allostatic load model perspective, evidence that 
chronic stress acts as a precipitating or perpetuating factor in FSS currently remains scarce. In other 
words, it is still unknown whether chronic stress precedes the initial manifestation of FSS and 
aggravates symptoms once they are present, or whether the reverse is the case. 
 
1.1.1.3 Autonomic nervous system 
The ANS comprises central and peripheral parts, which are referred to as the central autonomic 
network, and the parasympathetic and sympathetic nervous system (SNS), respectively (Benarroch, 
1997; Fischer & Nater, in press). Both afferents and efferents of the ANS are involved in vital 
processes such as the regulation of arousal, pain perception, digestion, and respiration. The 
parasympathetic system and SNS interact in a complementary fashion to maintain homeostasis. 
Whenever the body is challenged by an acute stressor, the locus coeruleus/noradrenaline (LC/NA) 
sympathetic system is activated. Noradrenaline is secreted in specific networks of the CNS and from 
sympathetic nerve endings in the periphery (sympathetic-neural system). Adrenaline is consequently 
released from chromaffin cells in the adrenal medulla (sympatho-adrenomedullary system). Both 
catecholamines produce adjustments in the body to restore homeostasis (e.g., via gluconeogenesis or 
increasing muscle tension). 
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Disturbances of the ANS may originate from the central or peripheral part of the body and are 
referred to as “dysautonomias” when they adversely affect health (Goldstein, Robertson, Esler, Straus, 
& Eisenhofer, 2002). As outlined above, it has been suggested that subtle alterations in ANS 
functioning are stress-related, that is, they develop from experiences of childhood trauma or chronic 
stress (see 1.1.1.1 and 1.1.1.2). The LC/NA system is known to regulate arousal and pain perception 
via descending anti-nociceptive pathways; failure of this system may thus create or enhance MUS 
such as fatigue or pain (Clauw & Chrousos, 1997; Clauw & Crofford, 2003). Moreover, NA and 
adrenaline act in concert with cortisol (see 1.1.1.4) to influence immune functioning (see 1.1.1.5), 
which is most likely relevant to the pathophysiology of MUS. Autonomic markers are often obtained in 
the periphery. An example is the determination of NA and adrenaline in the peripheral blood stream, or 
the calculation of heart rate variability. Another, rather novel and easily accessible biomarker that has 
been suggested to reflect SNS functioning is salivary alpha-amylase (sAA), an enzyme that is 
secreted by salivary glands and involved in the digestion of starch (Nater & Rohleder, 2009). 
As reviewed by others and us (Nater, Fischer, & Ehlert, 2011; Tak & Rosmalen, 2010), in the 
last two or three decades, research into autonomic alterations in individual FSS has been quite 
extensive. Both ANS activity and reactivity have been tested in case-control studies, mostly via indirect 
parameters (i.e., heart rate variability). There is accumulating evidence of an association between 
relative parasympathetic hypo-activity and a diagnosis of FSS. This may reflect a state of general 
hyper-arousal in patients. However, as the parasympathetic system and SNS interact in a synergistic 
manner, more information about the latter system is needed to be able to draw this conclusion. The 
literature on autonomic reactivity is sparse and inconsistent. There have been attempts to test specific 
aspects of autonomic functioning in the laboratory; an example is tilt table testing, where patients are 
being strapped onto a horizontal board and then tilted up in order to evaluate orthostatic responses. 
However, such paradigms are unable to provoke a stress response as defined above. This is 
unfortunate, as the identified basal dysfunctions of the ANS certainly raise the important question of 
whether patients with FSS are able to mount adequate autonomic responses when experiencing 
stress. Clearly, more research is needed to answer this question; even more so, as in the only 
available meta-analysis on ANS functioning in FSS, the overall methodological quality of studies was 
deemed to be poor (Tak et al., 2009). 
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1.1.1.4 Hypothalamic-pituitary-adrenal axis 
The HPA axis stretches from the CNS into the periphery (Chrousos, 2009; Chrousos & Gold, 1992). It 
serves numerous homeostatic purposes, among which are the coordination of energy expenditure 
(e.g., gluconeogenesis) and immunological processes (e.g., anti-inflammation). Acute stress poses a 
threat to homeostasis, leading to the secretion of corticotropin-releasing hormone (CRH) and 
vasopressin from the paraventricular nucleus of the hypothalamus, which in turn stimulate the release 
of adrenocorticotropic hormone (ACTH) in the anterior pituitary. The latter hormone is carried through 
the periphery, and cortisol is secreted from cells in the zona fasciculata in the adrenal cortex to exert 
its effect on target tissues. Cortisol ultimately engages in a negative feedback loop to suppress central 
input to the HPA axis. As mentioned above, the HPA axis closely interlocks with the ANS and immune 
system. 
Disturbances of the HPA axis may originate in the CNS or periphery, and mostly manifest as 
either relative hypo- or hyper(re-)activity of cortisol. They are found in the most prevalent diseases and 
disorders in Western societies (Chrousos, 2009; Chrousos & Gold, 1992), and it has been suggested 
that some of these more subtle alterations are promoted by experiences of childhood trauma or 
chronic stress (see 1.1.1.1 and 1.1.1.2). In the context of MUS, deficiencies of the CRH and LC/NA 
system (see 1.1.1.3) have been claimed to negatively impact on arousal and pain perception (Fries, 
Hesse, Hellhammer, & Hellhammer, 2005; Heim, Ehlert, & Hellhammer, 2000). Moreover, the 
gluconeogenetic, anti-nociceptive, and anti-inflammatory (see 1.1.1.5) effects of cortisol in the 
periphery may be disturbed and directly contribute to MUS such as fatigue and pain. As the CNS is 
less accessible than the periphery, levels of total or free cortisol are often determined in individuals’ 
bodily fluids. In the last two decades, the assessment of salivary cortisol has become rather popular, 
as it is non-invasive and merely reflects the fraction of free (unbound) cortisol that is able to exert its 
effects on target cells and organs of the body (Hellhammer, Wust, & Kudielka, 2009). 
The issue of HPA axis functioning in individual FSS has attracted the attention of many 
researchers over the years, resulting in a plethora of published studies (Nater, Fischer, & Ehlert, 2011; 
Tak & Rosmalen, 2010). Again, both the activity and reactivity of the HPA axis have been scrutinised 
in case-control studies. It is now quite safe to assume that a pattern referred to as relative 
“hypocortisolism” is prevalent in many different FSS. This pattern describes “a hyporesponsiveness on 
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different levels of the HPA axis” (Fries et al., 2005, p. 1010) when compared to healthy individuals, 
including lowered basal levels of cortisol and attenuated stress reactivity. A meta-analysis on this topic 
confirmed this general impression, although the authors found hypocortisolism to be confined to cases 
with CFS and females with FMS (but not patients with IBS; Tak et al., 2011). Interestingly, however, it 
seems that the question of whether HPA axis functioning is involved in the manifestation of FSS and 
its symptoms remains unanswered. In other words: Although thinking along the lines of the allostatic 
load model would imply that HPA axis functioning is directly involved in symptoms of FSS, there is 
barely any correlational evidence to support this notion. 
 
1.1.1.5 Immune system 
The immune system consists of an innate and adaptive part (Dhabhar, 2007). Within these two sub-
systems, cellular and humoral processes operate to protect the body from external (e.g., bacteria) and 
internal (e.g., carcinogenic cells) pathogens, and to promote wound healing. Communication between 
and within the two sub-systems is enabled by cytokines, a large group of different cell-signalling 
proteins. These are secreted by various cell types including immune cells and are crucial in the 
regulation of inflammation. Functionally, cytokines can be divided into pro- and anti-inflammatory 
types, although some are involved in both enhancing and inhibiting inflammation (e.g., interleukin 6, 
IL-6). Acute stress is known to induce a redistribution of immune cells from lymphoid organs to the 
peripheral blood and skin and to lead to a short-term increase in circulating inflammatory markers 
(Dhabhar, 2007; Steptoe, Hamer, & Chida, 2007). 
An important stress-related immune dysfunction is referred to as “chronic low-grade 
inflammation” (Rohleder, 2014). As the term implies, the disturbances manifest as long-term, subtle, 
systemic inflammation in the absence of any causative pathogens or injuries. Both the ANS (see 
1.1.1.3) and HPA axis (see 1.1.1.4) are able to regulate immune functioning. Although the exact 
mechanisms of how this occurs are far from being fully understood, Glaser and Kiecolt-Glaser (2005) 
have highlighted two important interfaces that are relevant to these processes. First, NA that is 
released from the sympathetic-neural system innervates lymphoid organs. Second, NA, adrenaline, 
and cortisol all bind to receptors on different cells of the immune system. Given these eminent links, it 
seems that permanent alterations in catecholamines and cortisol would have implications for immune 
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cell trafficking and cytokine expression. Taken together, it is tempting to assume that an inability of 
NA, adrenaline, and cortisol to exert their anti-inflammatory potential results in inflammation, which is 
well known to be associated with symptoms such as fatigue and pain ("sickness response"; Irwin, 
2011). However, as shown above, evidence on the role of ANS and HPA axis functioning in FSS is still 
insufficient and requires further investigation. 
There is a long history of studying the immune system in FSS. In fact, in the early days of 
aetiopathogenetic research into FSS, many syndromes were understood as infectious diseases (e.g., 
CFS was called “chronic mononucleosis”). In the absence of serological abnormalities indicating the 
presence of, for example, a virus, researchers eventually turned to alternative hypotheses. However, 
interest in more subtle alterations of immune functioning has been re-awakened in the past two or 
three decades. Studies in patients with FSS have, for the most part, focused on assessing circulating 
pro-inflammatory cytokines. Findings from case-control studies generally point to heightened pro-
inflammatory activity (Nater, Fischer, & Ehlert, 2011). However, research into the reactivity of the 
immune system and its potential role in symptoms of FSS is still in its infancy. 
 
1.1.1.6 Conclusion 
The framework presented here seems to enable the integration of many factors that have been 
identified as relevant in research on individual FSS. The reviewed studies provide a sense of how 
pervasively psychosocial stressors in childhood and adulthood impact on the lives of some of these 
patients, and point to important mechanisms that may translate the experience of stress into MUS. 
Based on the presented findings, it may be hypothesised that childhood trauma permanently alters an 
individual’s reactivity to stress occurring later on in life (e.g., chronic stress). Dysfunctional stress-
responsive systems, such as the ANS and HPA axis, may then directly contribute to symptoms of FSS 
via central and peripheral pathways. 
However, several unanswered questions and a series of methodological caveats concerning 
previous research preclude us from drawing these conclusions. First, the understanding of autonomic 
reactivity has, in general, been lagging. A major problem with this line of research is the choice of 
laboratory paradigms: Although suitable for testing specific aspects of autonomic functioning, most 
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paradigms were not appropriate to induce and evaluate stress responses. These studies are thus of 
limited use in terms of answering the question of whether patients with FSS are characterised by 
altered autonomic stress reactivity. Second, the role of the HPA axis (and indeed of the ANS) in 
symptom manifestation is completely under-studied, which is rather surprising given the clinical 
importance of this question. Third, the multidimensional nature of the stress concept has been 
neglected by previous research. This has resulted in an incoherent series of (mostly cross-sectional) 
findings which, as yet, have not been brought together into a comprehensive framework depicting the 
role of stress in the aetiopathogenesis of FSS. 
 
1.1.2 Phenomenology – syndrome overlap and the role of depression and anxiety 
There is a variety of phenomenological findings in FSS. A lot of recent research along these lines has 
been spurred by the seminal publication of Wessely et al. (1999), in which the authors advocated the 
conceptualisation of FSS as one general syndrome. All FSS have in common that they are defined by 
the presence of somatic symptoms (positive criterion) and absence of any structural or functional 
abnormalities that fully explain these symptoms (negative criterion). However, as emphasised by 
White (2004), they differ in terms of specific cardinal symptoms that are required by individual case 
definitions. For instance, the cardinal feature of CFS is fatigue, while FMS is primarily characterised by 
widespread pain and IBS by abdominal pain. 
Beyond symptom overlap, there have been increasing efforts to assess the co-occurrence of 
FSS (i.e., syndrome overlap) in order to reveal similarities or differences. This was all the more 
important as most research up to this date suffered from methodological limitations. For instance, 
syndrome overlap was, for the most part, studied in treatment-seeking (i.e., clinical) samples, which 
are likely to contain more severe cases of FSS and thus potentially over-estimate the degree of co-
occurrence among FSS (so-called “referral bias”). For similar reasons, the comorbidity of FSS with 
depressive and anxiety disorders was continuously scrutinised. Although similar sample selection 
problems had occurred in the past (referral bias), the sheer amount of literature rendered the finding of 
high comorbidity rates much more robust. Over time, the question of temporal order became most 
pressing, as it promised to provide more insight into the reasons for the high comorbidity that had 
repeatedly been observed. 
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Taken together, there is a rapidly growing body of research that is dedicated to the 
phenomenology of FSS (see Fischer & Nater, 2013 for a more comprehensive review on syndrome 
overlap and comorbidity of FSS). The most important phenomenological findings will be outlined in the 
following sub-chapters. First, a brief overview of symptoms belonging to the most recognised FSS, 
that is, CFS, FMS, and IBS, will be presented, as these syndromes are most relevant to the present 
thesis. Next, methodologically sound studies on syndrome overlap will be summarised. Finally, current 
knowledge on the role of depression and anxiety in FSS will be briefly illustrated by means of the most 
significant studies in the field. 
 
1.1.2.1 Symptoms of CFS, FMS, and IBS 
The first case definition of CFS dates back to 1988 (Holmes et al., 1988), but since 1994, studies have 
relied on its revised version, the so-called “CDC criteria” formulated by a consensus group of the 
Centers for Disease Control and Prevention (Fukuda et al., 1994). According to this definition, a 
person is classified as a case with CFS if he/she has persistent or relapsing impairing fatigue of at 
least six months (but not lifelong) that is not attributable to current exertion and cannot be helped by 
resting. In addition, four out of eight symptoms that are connected to chronic fatigue are required: 
cognitive problems (memory, concentration), sore throat, tender glands, muscle pain, multi-joint pain 
(no swelling or redness), headaches of a new kind, non-restorative sleep, and post-exertional malaise 
lasting longer than 24 hours. In order to exclude any medical disease, a thorough medical history and 
a mental and physical examination, including blood testing, is recommended by the guidelines, and a 
number of exclusionary diseases are listed in the original article. Notably, alternative proposals for the 
definition of CFS have accumulated during the past two decades, with some proposing different 
symptoms (e.g., post-exertional malaise) as core features of CFS (Christley, Duffy, & Martin, 2012). 
Similar to CFS, controversy was initially invoked by the case definition of FMS (Wolfe, 2010), 
which was drafted in 1990 by the American College of Rheumatology (ACR; Wolfe et al., 1990). 
However, most researchers and clinicians eventually embraced the “ACR 1990 criteria”, which 
required at least three months of pain in all quadrants of the body, axial skeletal pain, and 11 out of 18 
tender points upon manual palpation. Contrary to the CFS case definition, no laboratory tests to 
exclude medical diseases were recommended by the consensus group. In 2010, important changes 
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were introduced by the ACR (Wolfe et al., 2010). With the new operationalised criteria, symptoms 
other than pain (i.e., fatigue, cognitive problems, non-restorative sleep, and general somatic 
symptoms) came into focus, and the tender point examination was abandoned altogether. More 
specifically, in order to satisfy the new criteria, for at least three months, 7 out of 19 pain sites and a 
symptom severity score of at least 5 (out of 12) are required. Alternatively, three to six pain sites, 
combined with a severity score of at least nine suffices to meet the “ACR 2010 criteria”. 
Finally, the most widely acknowledged case definition for IBS are the “Rome III criteria” 
(Longstreth et al., 2006), a revised version of original guidelines that date back to 1989 (Thompson, 
Dotevall, Drossman, Heaton, & Kruis, 1989). The Rome III criteria require an onset of recurrent lower 
abdominal pain or discomfort at least six months before a diagnosis can be given. Abdominal pain or 
discomfort is typically experienced on more than three days per month during at least three months, 
and accompanied by at least two of the following features: it is improved with bowel movement, and its 
onset is associated with changes in the frequency of stool and with changes in the consistency of 
stool. The latest version of the Rome criteria distinguishes four subtypes: constipation, diarrhoea, 
mixed, and un-subtyped. A careful clinical examination including a detailed history, but parsimonious 
physical examinations and laboratory testing are suggested. The Rome III criteria, although criticised 
by many, have undoubtedly been adopted by the largest proportion of studies on IBS (Thompson, 
2006). 
 
1.1.2.2 Syndrome overlap 
Significant overlap between CFS, FMS, IBS, and other FSS has been noted since the beginning of 
systematic research into these illnesses (see also Aaron & Buchwald, 2001; Rodriguez, Afari, & 
Buchwald, 2009). However, as mentioned above, these observations were largely based on 
specialised care patients. A few well-conducted studies have appeared since the one versus many 
debate article (Wessely & White, 2004). These have identified cases from non-clinical samples, thus 
eliminating referral bias. 
In two of these studies, which were based in the US, CFS was found to co-occur with chronic 
widespread pain (CWP), the cardinal clinical feature of FMS, to the extent of 16% to 41% (Dansie et 
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al., 2012; Jason, Taylor, & Kennedy, 2000). The overlap with IBS was found to be 16% (Dansie et al., 
2012), while 41% had multiple chemical sensitivity, a syndrome in which seemingly allergic reactions 
are provoked by various chemical substances (Jason et al., 2000). Chronic widespread pain, in turn, 
was found to co-occur with CFS in 22% of cases, with IBS in 25% of cases, and with tension-type 
headache (i.e., bilateral, pressing or tightening pain in the head) in 17% of cases identified from the 
Swedish Twin Registry (Kato, Sullivan, Evengard, & Pedersen, 2006). In a similar study conducted in 
the US, a much higher proportion of overlap was found, with 60% of participants with FMS 
simultaneously having CFS (White, Speechley, Harth, & Ostbye, 2000). In a Norwegian study, the co-
occurrence of IBS with FMS was 20% (Vandvik, Lydersen, & Farup, 2006). An Asian study identified 
14% of women with IBS as being simultaneously affected by functional dyspepsia, a syndrome that is 
characterised by pain in the upper abdomen (Lee, Lee, Kim, & Cho, 2009). Data from European 
communities, on the other hand, suggested a much higher overlap with functional dyspepsia, of 45% 
to 87% (Agreus, Svardsudd, Nyren, & Tibblin, 1995; Caballero-Plasencia et al., 1999; Hillila, Siivola, & 
Farkkila, 2007), whereas a US-based study yielded an intermediate proportion of 31% (Koloski, Talley, 
& Boyce, 2002).  
Based on this overview, it seems that the notion of generally high syndrome overlap is 
questionable. Although at least 20 different FSS are known in the literature, rarely have more than two 
FSS been examined concomitantly. Moreover, there is a bias as to which FSS were preferably studied 
together (e.g., CFS and FMS, which already overlap in terms of ancillary symptoms, see 1.1.2.1). 
Furthermore, there is considerable variation in overlaps across studies (14% to 87%). Although it is 
conceivable that some inconsistencies are attributable to real differences in prevalence rates (i.e., due 
to cultural differences), comparisons of studies conducted in the same countries suggest 
methodological bias. One of the most salient sources of methodological bias may be the diagnostic 
approach chosen to identify cases with FSS. This is a problem specific to large-scale epidemiological 
studies on FSS: As comprehensive clinical examinations are not feasible, researchers differ to a great 
extent in how they operationalise the positive criterion (presence of somatic symptoms) and negative 
criterion (absence of any disease that fully accounts for the somatic symptoms) of FSS. However, the 
potential ramifications of this have never been evaluated. 
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1.1.2.3 The role of depression and anxiety 
There is a wealth of studies showing high levels of comorbidity with depressive and anxiety disorders 
in patients with different FSS (see also Henningsen, Zimmermann, & Sattel, 2003). In population-
based studies, 32% of CFS patients were found to have an affective disorder, 29% to 46% an anxiety 
disorder, and 15% to 18% concomitant PTSD (Nater et al., 2009; Taylor, Jason, & Jahn, 2003). In one 
study, nineteen percent of cases with FMS were found to have a concomitant major depressive 
episode, the comorbidity with any anxiety disorder was 12%, and none had PTSD (Raphael, Janal, 
Nayak, Schwartz, & Gallagher, 2006). The comorbidity of IBS with affective disorders was 40% 
(Koloski, Boyce, & Talley, 2006), while the comorbidity with anxiety disorders was found to range 
between 17% and 43% (Koloski et al., 2006; Lee, Wu, et al., 2009). 
Although studies on comorbidity rates offer a valuable impression of how frequently patients 
with FSS are affected by mental disorders, they cannot answer the question of how depression and 
anxiety relate to FSS. Two studies using 1946 and 1958 British birth cohort data demonstrated that 
psychopathology through early and mid-adulthood predicted the incidence of CFS at age 42 and 53, 
respectively (Goodwin, White, Hotopf, Stansfeld, & Clark, 2011; Harvey, Wadsworth, Wessely, & 
Hotopf, 2008). Similarly, epidemiological data from a Norwegian cohort study established depression 
and anxiety as prognostic factors for the development of CWP (Mundal, Grawe, Bjorngaard, Linaker, & 
Fors, 2014), which is in line with findings from similar studies conducted in Great Britain (Gupta et al., 
2007; McBeth, Macfarlane, Benjamin, & Silman, 2001). Moreover, both depression and anxiety 
appeared to be significantly associated with a de novo diagnosis of IBS in two large-scale 
epidemiological studies (Goodwin, White, Hotopf, Stansfeld, & Clark, 2013; Koloski et al., 2012; 
Nicholl et al., 2008). In one of these studies, the reversed causation hypothesis (IBS predates 
depression and anxiety) was simultaneously tested and not confirmed (Koloski et al., 2012). 
Taken together, the co-existence of FSS with depressive and anxiety disorders does appear 
to be quite substantial, although there is some variation across syndromes and studies. There is initial 
evidence of a temporal precedence of depression and anxiety, although caution is warranted when 
interpreting these findings, as diagnoses of FSS were often merely established by single-item 
questions (“Do you have CFS/FMS/IBS?”, “Has your physician ever told you that you have 
CFS/FMS/IBS?”). These studies therefore need to be interpreted in light of the fact that neither the 
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positive criterion (presence of somatic symptoms) nor the negative criterion (absence of any disease 
that fully accounts for the somatic symptoms) of FSS have adequately been accounted for. In general, 
most studies have again focused on one specific FSS. Obviously, these isolated observations do not 
allow the conclusion that depression and anxiety are relevant to all kinds of different FSS. 
 
1.1.2.4 Conclusion 
In sum, current case definitions suggest that ancillary symptoms of CFS, FMS, and IBS overlap to 
some extent, while core features are specific to each of these FSS. Syndrome overlap, as summarised 
above, ranges from 14% to 87%. Comorbidity with depression and anxiety also varies across studies, 
albeit to a lower extent. There is initial evidence that depression and anxiety temporally precede FSS. 
Although the overall knowledge on the phenomenology of FSS has substantially increased in 
the past 15 years, there are major methodological issues that are likely to account for the observed 
inconsistencies and are thus worthy of mention. First and foremost, there is a dearth of research 
examining several FSS at the same time. Although findings from samples consisting of two different 
FSS are important, in particular, the question of syndrome overlap can only be comprehensively 
addressed in multiple-syndrome samples. Second, it appears that certain syndromes have preferably 
been studied concomitantly, while other FSS have been neglected altogether. Unfortunately, the 
studied syndromes are often the ones that already show considerable symptom overlap (i.e., 
overlapping case definitions), which renders findings somewhat ambiguous. Third, there is substantial 
heterogeneity in diagnostic approaches to FSS, meaning that the ways in which the positive and 
negative criteria of FSS are assessed vary substantially across studies. It seems plausible that this is 
one of the most important sources of methodological bias, but this hypothesis remains to be tested. 
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2. Summary and research aim 
Functional somatic syndromes are debilitating illnesses that are characterised by the presence of 
somatic symptoms and the absence of any demonstrable abnormalities of organ structure or function 
that would allow an attribution to a conventionally defined medical disease. There are numerous case 
definitions for different FSS, including CFS, FMS, or IBS; however, to date, these do not have the 
status of nosological entities. The reason for this is that there is no universal consensus on how FSS 
should best be understood. The most extreme positions are those held by “lumpers”, who advocate 
the concept of one general FSS, and “splitters”, who are in favour of a concept that distinguishes 
between specific FSS. 
The overall aim of this thesis was to identify similarities and differences of FSS by studying 
aetiopathogenetic and phenomenological features across a variety of syndromes. Regarding 
aetiopathogenesis, stress has emerged as an important factor that may be involved in the 
predisposition, precipitation, and perpetuation of FSS. A psychobiological understanding of stress 
enables the integration of numerous isolated findings that have accumulated over the years. When 
taken together, they suggest that childhood trauma and chronic stress contribute to FSS via alterations 
in stress-responsive somatic systems. However, several important pieces of this puzzle are still 
missing, and the overall validity of what may be a promising theoretical framework to illustrate the 
translation of psychosocial stress into FSS awaits empirical confirmation. The first goal of this thesis 
was therefore to test specific parts of this framework in different patient samples. 
Regarding the phenomenology of FSS, research has tried to evaluate the extent of their 
overlaps (syndrome overlap), and to illuminate their relationship depression and anxiety in order to 
identify the amount of similarity among syndromes. Unfortunately, the findings are still equivocal: 
Barely any research has been conducted in samples that allow multiple (i.e., more than two) FSS to be 
studied at the same time. Furthermore, methodological problems specific to the complex topic of FSS 
(e.g., divergent diagnostic approaches) may hamper the interpretation of findings in this area. The 
second goal of this thesis was therefore to provide an in-depth phenomenological account of FSS by 
studying somatic symptoms and a number of concomitantly measured syndromes in great detail. 
A multi-methodological approach, including experimental, ambulatory assessment, and survey 
research designs, was chosen to answer these research questions. In the first study (Strahler, Fischer, 
Nater, Ehlert, & Gaab, 2013), we looked at autonomic reactivity to two different laboratory stressors in 
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patients with CFS. The objective of the second study (Fischer et al., ready to be submitted) was to 
clarify whether everyday stress and autonomic or HPA axis functioning exacerbate pain in patients 
with FMS. In the third study (Fischer, Lemmer, Gollwitzer, & Nater, 2014), a multidimensional model 
concerning the role of stress in FSS in general was tested in a sample of young adults. In the fourth 
study (Fischer, Gaab, Ehlert, & Nater, 2013), we determined syndrome overlap and predictors of 
incident FSS. The aim of the fifth study (Fischer & Nater, 2014) was to evaluate the implications of 
using divergent diagnostic approaches in epidemiological studies on FSS. Finally, in the sixth study 
(Witthöft, Fischer, Jasper, Rist, & Nater, under revision), we illuminated the latent structure of somatic 
symptoms and their relationship with depression, anxiety, somatosensory amplification and different 
FSS. 
Four of these studies (I, III, IV, V) were published in 2013 and 2014. One study (VI) is 
currently under revision, and one study (II) is ready to be submitted. Importantly, results regarding 
prevalence rates of FSS and comorbidity with mental disorders (see original articles of studies IV and 
V) have already been presented in my Master thesis and are irrelevant to this doctoral thesis. As they 
are not part of the present thesis, they will not be summarised in the following chapters. 
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3. Summary of empirical studies 
3.1 Study I 
As briefly described in the introduction (1.1.2.1), CFS includes disabling symptoms, such as severe 
fatigue that is aggravated by exertion, pain, and cognitive symptoms (Fukuda et al., 1994). Patients 
often make repeated efforts to find organic abnormalities underlying their symptoms, and 
understandably so. Unfortunately, physicians are rarely able to provide patients with satisfactory 
explanations as to what the factors underlying the symptoms of CFS are. This is in part due to the fact 
that, as with all FSS, the exact pathophysiology of CFS is still unknown, but is presumably complex 
and multifactorial. 
There is accumulating evidence to suggest that stress is an important pathophysiological 
factor in CFS (Nater, Fischer, & Ehlert, 2011). For instance, some symptoms of CFS point to 
disturbances in stress-responsive systems such as the ANS. Bou-Holaigah et al. (1995) recognised 
similarities between post-exertional malaise, dizziness, and cognitive problems, and symptoms of 
neurally mediated hypotension (a so-called “dysautonomia”, see 1.1.1.3). At the same time, in a 
sample of CFS patients, both the amount of exposure and emotional response to an environmental 
stressor (Hurricane Andrew) were found to predict clinical relapses and exacerbation of symptoms 
(Lutgendorf et al., 1995). Taken together, these studies (and many more along these lines) give 
reason to assume that stressors elicit symptoms of CFS via ANS dysfunctions. 
The studies have spurred a variety of research looking at altered autonomic stress reactivity in 
an effort to better understand CFS. Unfortunately, the literature still has to be considered as 
inconsistent, and many studies suffer from major shortcomings. For instance, rarely have main 
effectors of the ANS (e.g., the catecholamines NA and adrenaline) been measured and rarely has 
autonomic stress reactivity been tested by means of laboratory paradigms that were able to 
concomitantly stimulate the release of NA and adrenaline. Most importantly, these paradigms often 
had little in common with the situations which patients with CFS perceive as exacerbating their 
symptoms (e.g., physical activity). 
In study I, we set out to compare autonomic responses to an exercise stressor between 
patients with CFS and healthy controls. Moreover, we aimed at contrasting the exercise stressor with a 
pharmacological stressor. This allowed us to distinguish effects of a paradigm that mimics everyday 
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stressors in the lives of patients with CFS (i.e., physical exertion) from responses to a standardised 
stimulant of the sympathetic-neural and sympatho-adrenomedullary (SAM) system. We expected to 
find attenuated autonomic responses in a comparison between patients and controls. 
 
Methods 
A German self-help organisation was contacted and informed about our study. Patients interested in 
participating were carefully screened for positive and negative criteria in accordance with the CDC 
case definition for CFS (Fukuda et al., 1994). To this end, they were admitted to the research unit of a 
general hospital and underwent a medical examination and standardised diagnostic interview 
conducted by a clinical psychologist (Wittchen & Pfister, 1997). Twenty-one patients endorsed the 
CDC case definition, and were matched with 20 healthy control participants in terms of sex and age. 
Both groups participated in two laboratory appointments with at least 48 hrs in between. Both 
stressors were preceded by a resting period of 45 min after insertion of an intravenous catheter. Cycle 
ergometry was scheduled at 2 p.m., and started with 50 W (men) and 40 W (women), respectively, 
with 40 W increments every 3 min. The stressor continued until participants terminated the procedure 
or until their presumed maximum heart rate (85% 220 bpm - age) was reached. Heart rate (Sport 
Tester Profi, Polar Instruments, Gross-Gerau, Germany) and perceived exertion (Borg scale; Borg, 
1982) were measured every 3 min, and blood was drawn immediately before, and after 10 and 30 min 
of stressor onset. For the insulin tolerance test, 0.15 U/kg of insulin (H-Insulin, Hoechst, Frankfurt, 
Germany) was injected at 9.45 a.m. to induce hypoglycaemia. Blood was drawn at baseline, and 20 
and 30 min thereafter. 
Blood plasma levels of the catecholamines NA and adrenaline were analysed by high-
pressure liquid chromatography (detection limit: 0 - 25 pg/ml) at the Laboratory for Stress Monitoring 
(Göttingen, Germany). For statistical analyses, SPSS 19 was used. Repeated measures ANOVAs 
were calculated to determine catecholaminergic responses over time. Mean increases in 
catecholaminergic responses were calculated by subtracting baseline from peak values (10 and 30 
min, respectively), and groups were compared by means of univariate ANOVAs. 
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Results 
Our results indicated no significant group differences in peak heart rate and maximum perceived 
exertion. Both stressors were successful in eliciting an increase in catecholamines. Partly confirming 
our hypotheses, cycle ergometry resulted in blunted adrenaline (but not NA) response profiles in 
patients with CFS compared to healthy control participants. Similarly, mean increases in adrenaline 
(but not NA) were lower in patients. Following the insulin tolerance test, no group differences 
whatsoever were revealed. 
 
Discussion 
Two major findings emerged from study I. First, adrenaline (but not NA) responses to cycle ergometry 
were dampened in the patient sample. This is in perfect accordance with a previous report by 
Ottenweller et al. (2001), in which a slightly different protocol was employed to test autonomic 
reactivity. Second, no differences in response patterns following the insulin injections were present 
between groups. This resonates well with the observation that the insulin tolerance test did not seem 
to be able to reveal other adrenal abnormalities (i.e., cortisol secretion) in patients with CFS (Bearn et 
al., 1995; Gaab et al., 2004).  
The exact mechanisms of how patients’ inability to mount an adequate autonomic stress 
response may translate into post-exertional malaise and other symptoms of CFS are poorly 
understood. Adrenergic receptors are well known to be expressed on numerous tissues and organs of 
the body, including the cells of the immune system, allowing for catecholamines to modulate various 
immune processes (Elenkov, Wilder, Chrousos, & Vizi, 2000). In CFS, at least one of these processes, 
inflammation, has emerged as a pivotal factor that is likely to contribute to the general “influenza-like 
state” described by patients (Irwin, 2011). It may thus be speculated that the failure of catecholamines 
to regulate inflammation under conditions of acute stress elicits symptoms of CFS. 
To conclude, study I showed attenuated autonomic responses to acute exercise stress in 
patients with CFS. It is tempting to assume that the identified dysfunction of the ANS plays a key role 
in the precipitation and exacerbation of CFS symptoms. Future studies are needed to test this 
assumption, preferably in an ecologically valid setting.  
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3.2 Study II 
Fibromyalgia syndrome is an incapacitating illness that tends to be rather intractable. A follow-up on a 
cohort of patients yielded only a small fraction of improving cases (Walitt et al., 2011). At the same 
time, there is evidence from qualitative studies and clinical practice that most patients do not perceive 
pain, the hallmark symptom of FMS (see also 1.1.2.1), as stable over the course of a day. In fact, 
there seem to be symptom flares, which make it difficult for patients to plan and go about their 
activities (Dennis, Larkin, & Derbyshire, 2013). Knowing more about pain-exacerbating factors could 
be an important first step towards interrupting the perpetuation of FMS. 
There is ever-increasing evidence that stress is an important perpetuating factor in patients 
with FMS (Nater, Fischer, & Ehlert, 2011). In cross-sectional survey studies, chronic stress levels and 
the amount of daily hassles were shown to be positively correlated with patients’ pain severity (e.g., 
Alok, Das, Agarwal, Salwahan, & Srivastava, 2011; Dailey, Bishop, Russell, & Fletcher, 1990). In 
addition, stress-responsive systems, such as the ANS and HPA axis, are well known to be involved in 
central and peripheral pain regulation (Clauw & Chrousos, 1997; Irwin, 2011), and both systems have 
been shown to be dysfunctional in patients with FMS (Fries et al., 2005; Martinez-Lavin, 2004). Taken 
together, there is therefore reason to suggest that both everyday stress and dysfunctions of stress-
responsive systems could explain pain exacerbations in patients with FMS. 
However, there are a number of reasons why previous studies offer only limited insight 
regarding this assumption. For instance, cross-sectional survey studies in general suffer from recall 
bias and a lack of ecological validity. In other words, retrospective stress and pain reports are often 
inaccurate and global measures of these constructs can barely grasp the dynamics of the assumed 
stress-pain relationship as it unfolds in patients’ daily lives. Moreover, virtually no study has 
investigated whether the ANS and HPA axis are involved in the pain exacerbation in patients with 
FMS. 
The aim of study II was to explore whether and how stress exacerbates pain in the everyday 
lives of women with FMS. We chose an ambulatory assessment approach to answer this research 
question as this enables researchers to tap into patients’ experiences in their natural habitat. We 
hypothesised that stress predicts pain and vice versa (i.e., pain itself was assumed to operate as a 
stressor), and that autonomic and HPA axis activity mediate this relationship. All analyses were run 
twice: cross-sectionally (momentary analyses), and prospectively (time-lagged analyses). 
 34 
 
 
Methods 
Thirty female patients endorsing the Fibromyalgia Research Criteria (Wolfe et al., 2011) were recruited 
via advertisement in newspapers, general practitioners’ and rheumatologists’ offices, and self-help 
organisations. Eligibility was checked on the telephone and during the initial study appointment by 
means of an interview on mental disorders and a review of the medical history. For inclusion in the 
study, patients had to be free of any major mental disorder (including a current major depressive 
episode), and not have any disease which affects autonomic or endocrine functioning. 
Patients were introduced to the ambulatory assessment during the initial study appointment. 
They were required to answer six daily queries on an iPod touch® and simultaneously collect six 
saliva samples via SaliCaps (IBL, Hamburg, Germany). The measurement time points were 
prescheduled for 11 a.m., 2 p.m., 6 p.m., and 9 p.m., except for the first assessment, which was to be 
initiated by the patients themselves directly upon awakening. Momentary stress was measured on a 
five-point Likert scale (not at all to very much). Momentary pain was measured on a visual analogue 
scale (I am in no pain to I am in the most intense pain possible). A variety of potentially confounding 
variables (e.g., physical activity, intake of medication) were additionally measured. The assessment 
period lasted for 14 consecutive days and ended with a final study appointment. Questionnaires on 
symptoms of FMS, depression, childhood trauma and chronic stress were filled in during the initial and 
final study appointments. 
The activity of sAA, an indicator of the ANS (see 1.1.1.3), was measured using a kinetic 
colorimetric test (Roche Diagnostics, Mannheim, Germany). Cortisol levels were measured using a 
commercially available enzyme-linked immunoassay (IBL, Hamburg, Germany). In terms of statistical 
analyses, descriptive statistics and testing of statistical assumptions were calculated by means of 
SPSS 21. To test our hypotheses, two-level hierarchical linear modelling (HLM) was performed by 
means of HLM 7. 
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Results 
Momentary stress predicted momentary pain, even when controlling for physical activity and intake of 
medication during the past two hours, and time since awakening on level one, and age, number of 
pain sites, regular intake of medication, childhood trauma, and chronic stress on level two. Within this 
model, stress alone explained 8% out of the 16% total variance in momentary pain. A similar model 
including stress reported at the previous measurement time point explained 19% of the variance in 
momentary pain, and 1% of this was attributable to previous stress alone. The reversed relationship 
(previous pain on stress) did not prove significant, and nor did momentary associations between sAA 
and pain. Momentary cortisol was positively linked to momentary pain. 
 
Discussion 
Study II yielded two major findings. First, the fact that stress was a meaningful predictor of pain 
supports the theoretical assumption of stress as a pain-exacerbating factor in patients with FMS. Our 
study elaborates on previous findings by showing that elevations in stress levels temporally precede 
elevations in pain levels on the same day, but not vice versa. Second, cortisol, but not sAA, was 
associated with momentary pain. 
Our findings indicate that HPA axis activity may be involved in the exacerbation of pain in 
FMS. The more cortisol was secreted, the more pain our patients experienced. One way to make 
sense of this observation is to assume that temporary elevations in individual cortisol output may 
disturb the CRH system, which is known to be involved in analgesia via descending pathways (Clauw 
& Chrousos, 1997). This assumption would fit in with the finding that patients with FMS exhibit 
enhanced negative feedback sensitivity (e.g., Wingenfeld et al., 2007), meaning that their CRH system 
is hyper-responsive to the inhibitory effects of cortisol. However, as no causality can be implied by our 
findings, this remains speculative.  
To conclude, study II confirmed that stress is an important exacerbating (and thus potentially 
perpetuating) factor of pain in patients with FMS. The mechanisms underlying this relationship remain 
to be fully elucidated. Future studies should begin to approach this question by gathering information 
about the reasons for momentary elevations in patients’ stress levels.  
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3.3 Study III 
“Functional somatic syndromes” is an umbrella term for conditions such as CFS, FMS, and IBS. The 
struggle to understand these puzzling conditions has resulted in thousands of publications on the 
subject of their aetiopathogenesis. In all three of the above-mentioned conditions, most research has 
at some point abandoned biological models, which mostly claimed that the observed symptoms were 
caused by a neurological or immunological process, and turned to psychobiological conceptualisations 
of FSS. The last decades have witnessed a particular interest in stress and its role in the development 
of FSS (Nater, Fischer, & Ehlert, 2011; Tak & Rosmalen, 2010). 
As outlined in the introduction (see 1.1.1), there is overwhelming evidence that different facets 
of stress are involved in the predisposition, precipitation, and perpetuation of FSS. Among these are 
experiences of childhood trauma, stress reactivity (emotional and biological), and chronic stress. An 
abundant literature now shows that early life stress, such as childhood trauma, is a powerful 
determinant of stress reactivity throughout life (e.g., Schlotz & Phillips, 2013). At the same time, there 
is reason to assume that it negatively affects resilience (e.g., Campbell-Sills, Forde, & Stein, 2009), a 
personality characteristic that promotes adaptation in the face of psychosocial stressors. Each of these 
factors, that is, experiencing childhood trauma, altered stress reactivity, and low resilience, is in turn 
known to foster chronic stress (Gonzalez-Ramirez, Garcia-Campayo, & Landero-Hernandez, 2011; 
Lustyk, Widman, & Becker Lde, 2007; Schlotz, Yim, Zoccola, Jansen, & Schulz, 2011). 
However, as is evident from this brief summary, studies on stress in FSS have mostly studied 
individual facets (e.g., chronic stress in IBS); some have extended this to examine connections 
between two facets (e.g., altered stress reactivity in patients with CFS as a consequence of childhood 
trauma). Unfortunately, as of yet, barely any efforts have been made to bring findings from this 
intriguing line of research together. Moreover, the role of resilience remains completely understudied. 
Our aim with study III was to empirically test whether a model integrating multiple facets of 
stress and resilience is capable of predicting the manifestation of FSS. Based on the outline of 
predisposition in the preceding paragraph, we expected chronic stress to precipitate and perpetuate 
FSS. We tested our model cross-sectionally and prospectively in order to be able to establish a 
temporal order, where stress in its various forms precedes the manifestation of FSS (rather than vice 
versa). 
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Methods 
Administrators of the major Swiss colleges and universities were contacted and asked for their 
cooperation. Those who agreed sent out an e-mail to all registered students containing a link to our 
online survey. The link was additionally posted on websites frequently visited by students. All 
participants willing to be contacted again were sent a link to an identical follow-up survey six months 
later. A total of 3054 students (73% female) provided complete data sets at T0, and 429 complete data 
sets were received at follow-up (T1). 
Childhood trauma was measured via the Childhood Trauma Questionnaire (Bernstein et al., 
2003). An example item is “I felt that someone in my family hated me” (emotional abuse). We relied on 
the Stress Reactivity Scale (Schulz, Jansen, & Schlotz, 2005) to assess emotional stress reactivity. 
This instrument refers to situations such as high workload, failure, social evaluation, and anticipation of 
a psychosocial stressor. Items such as “When I’m wrongly criticised by others…” were answered by 
choosing a statement completing the sentence. These ranged from “I am normally annoyed for a long 
time” to “In general, I am hardly annoyed at all”, reflecting different levels of stress reactivity. We 
adhered to the Resilience Scale (Schumacher, Leppert, Gunzelmann, Strauss, & Brähler, 2005) to 
measure resilience (e.g., “I usually manage one way or another”). To obtain a measure of chronic 
stress, the screening version of the Trier Inventory for the Assessment of Chronic Stress (Schulz et al., 
2004) was administered. Our items measured excessive demands at work, work and social overload, 
and chronic worrying during the past three months (e.g., “I do not have enough time to perform my 
daily tasks”). Finally, FSS were diagnosed by means of the Questionnaire on Functional Somatic 
Syndromes (Nater, Fischer, Latanzio, Ruoss, & Gaab, 2011). This hierarchical, modular instrument 
allows for the assessment of 17 different FSS. To answer our research question, we dichotomised all 
participants into non-cases (0) and cases (1). 
MPlus V7.0 was used for structural equation modelling. Childhood trauma was the latent 
exogenous variable; stress reactivity, resilience, and chronic stress were latent mediators; and the 
presence of any FSS was the manifest endogenous variable. A weighted least squares method and a 
Χ2 test, root mean square error of approximation, comparative fit index, and the Tucker-Lewis index 
were calculated to test whether the covariance matrix of our variables was consistent with our 
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expectations (Browne & Cudek, 1993; Hu & Bentler, 1999). Indirect effects were tested by the Sobel 
test (MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002; Sobel, 1982) and a bias-corrected 
bootstrapping approach by MacKinnon et al. (2004). 
 
Results 
Our model proved a good fit with the data structure at T0 and T1. Both direct and indirect effects turned 
out to be significant and coefficients were in the expected directions. However, one path (direct path 
from childhood trauma to FSS) needed to be removed in both models.  
 
Discussion 
In sum, the findings of study III offer an impression of how suffering childhood trauma may transform 
into FSS by modifying the experience of stress later on in life. Participants who grew up under 
emotionally hostile, neglectful, and unstable circumstances (childhood trauma) not only showed a 
pattern of strong stress responses in terms of difficult work and social situations (heightened stress 
reactivity), but at the same time lower beliefs in their own competence and acceptance of themselves 
(lowered resilience). As a consequence of this predisposition, they were more prone to experiencing 
stress in the work and social domain, and to engaging in chronic worrying (chronic stress). This, in 
turn, precipitated and perpetuated FSS. 
Our findings echo evidence on the biological embedding of childhood trauma, that is, its long-
term effects on stress-responsive systems that extend into adulthood. An example of this is provided 
by a study in which patients with IBS and healthy controls were matched in terms of abuse and 
subsequently underwent the same laboratory stressor (Videlock et al., 2009). In this study, the abused 
patients with IBS exhibited the most abnormal stress response. Analogous to our study, childhood 
trauma was thus associated with dysfunctional reactivity in patients when a stressor was being faced. 
In conclusion, in study III, we empirically confirmed a model illustrating how different facets of 
stress interact over the course of developing an FSS. Professionals involved in the treatment of FSS 
should pay attention to the possibility of childhood trauma. Furthermore, modules enhancing resilience 
and lowering stress reactivity and chronic stress may enhance treatment outcomes.  
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3.4 Study IV 
As briefly reviewed in the introduction, there is a conceptual debate as to whether or not CFS, FMS, 
and IBS are, in fact, all expressions of a “general FSS” (Wessely & White, 2004). Wessely et al. (1999) 
first expressed the view that it was only through medical specialisation that MUS were attributed to 
specific syndromes. They reached this conclusion by claiming that a variety of symptom 
characteristics (e.g., overlap in case definitions) and non-symptom characteristics (e.g., high 
comorbidity with depressive and anxiety disorders) are shared by all FSS. 
One of their strongest arguments, however, was that of a substantial co-occurrence of 
different syndromes (syndrome overlap); in other words, they claimed that a patient with CFS was very 
likely to suffer from FMS and IBS as well, and vice versa. The first systematic review on the overlap 
among FSS was published in rapid succession to the seminal article by Wessely et al. (1999). The 
authors revealed a great amount of overlap within the category of FSS (Aaron & Buchwald, 2001), 
thus supporting the thesis of Wessely et al. 
However, as acknowledged by Aaron and Buchwald (2001), several shortcomings undermine 
the validity of findings on the overlap among FSS. For instance, one problem is referral bias, that is, 
the recruitment of participants via specialised care centres (e.g., CFS clinics). As health care-seeking 
behaviour is known to be associated with various traits (Taylor, Marshall, Mann, & Goldberg, 2012) 
and states (Hilbert, Martin, Zech, Rauh, & Rief, 2010) in patients with MUS, it becomes clear that 
these samples cannot reflect the total patient population. Another, even more salient limitation, is the 
fact that although there are over 20 FSS, rarely have more than two been studied simultaneously. This 
precludes research from stating that FSS in general have high overlaps and can therefore be lumped 
together.  
Our aim with study IV was therefore to investigate overlap among a wide range of FSS in a 
sample of apparently healthy young adults. In line with previous studies, we assumed that FSS 
commonly co-occur. However, since a non-clinical sample allowed us to reduce referral bias, we 
expected fewer individuals to suffer from multiple syndromes at the same time, and overlap rates to be 
lower. In addition, according to the arguments outlined by Wessely et al. (1999), we hypothesised that 
the manifestation of any FSS could be predicted by symptom and non-symptom characteristics. 
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Methods 
Apparently healthy students were recruited from major Swiss colleges and universities and asked to 
participate in the exact same survey twice (six months in between). In total, our data sets 
encompassed 3054 students (73% female) at T0, and 429 at follow-up (T1). 
The number of somatic symptoms and consequent impairment in activities of participants’ 
daily lives (symptom characteristics) were measured by the screening part of the Questionnaire on 
Functional Somatic Syndromes (Nater, Fischer, Latanzio, et al., 2011). This part comprises questions 
on how frequently 52 different somatic symptoms are experienced. In addition, there are questions on 
impairment, which refer to all symptoms that are at least frequently present. To obtain a measure of 
somatisation (another symptom characteristic), that is, how bothered participants were by various 
somatic symptoms, a subscale of the revised Symptom Check List 90 (Derogatis, 1977) was 
employed. The frame of reference for all somatic symptoms contained in this instrument was seven 
days. Depression and anxiety disorders (non-symptom characteristics) were assessed by the Patient 
Health Questionnaire (Spitzer, Kroenke, & Williams, 1999), which follows DSM-IV criteria (American 
Psychiatric Association, 2000). Functional somatic syndromes were diagnosed by means of the 
Questionnaire on Functional Somatic Syndromes (Nater, Fischer, Latanzio, et al., 2011). This 
hierarchical, modular instrument allows for the assessment of 17 different FSS. 
SPSS 20 was used for all statistical analyses. To answer our first research question, the 
number of diagnoses per person and per FSS category was calculated and presented in absolute and 
relative numbers. For our second research question, FSS were dichotomised into non-cases (0) and 
cases (1), and t tests and binary logistic analysis were computed.  
 
Results 
Four concomitant FSS were reported by one person, three syndromes by 12 persons (4% of total 
cases), two syndromes by 49 persons (17%), and one syndrome was reported by 227 persons (79%). 
Overlap rates mostly did not exceed 10% when we looked at each syndrome separately. For instance, 
within the functional dyspepsia category, 2% of patients endorsed criteria for temporomandibular 
disorder, functional chest pain, chronic low back pain, and chronic pelvic pain, respectively, 4% had 
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premenstrual dysphoric disorder, 7% had hyperventilation syndrome, and 19% had IBS. All symptom 
and non-symptom characteristics, except for anxiety disorders, predicted the incidence of any FSS six 
months later. The number of somatic symptoms proved most powerful in this regard. 
 
Discussion 
In study IV, two major findings were presented. First, we found that only a minority of participants was 
affected by several FSS at the same time, and our numbers regarding overlap rates are at odds with 
other studies. For instance, roughly 40% of functional dyspepsia cases had IBS in one study 
(compared to barely 20% in our sample; Locke, Zinsmeister, Fett, Melton, & Talley, 2005). Second, we 
found that a high number of symptoms, symptom impairment, somatisation and depression predicted 
the manifestation of any FSS six months later. Our findings are in agreement with other prospective 
studies showing the same factors to be germane to the development of CFS, FMS, and IBS (Forseth, 
Husby, Gran, & Forre, 1999; Leone et al., 2006; Nicholl et al., 2008). The overall findings can therefore 
be summarised as low syndrome overlap on the one hand and common risk factors for all syndromes 
on the other hand. 
Our first finding implies that FSS are best regarded as distinct, albeit to some degree 
comorbid conditions. It points to specific aetiopathogenetic processes that operate in each FSS. Moss-
Morris and Spence (2006) found different types of infection to precipitate CFS and IBS, which gave 
rise to the notion that differential biological mechanisms are involved in each FSS. Our second finding, 
by contrast, suggests common aetiopathogenetic processes. One might speculate that the identified 
predictors are indicative of certain cognitive-behavioural mechanisms that are relevant to the 
development of FSS in general (Witthöft & Hiller, 2010). For instance, a high number of symptoms, 
and a high amount of symptom impairment and distress, may reflect attentional and interpretative bias 
regarding somatic perceptions, and a high level of depression may be paralleled by physiological 
deconditioning through avoidance behaviour.  
In conclusion, the findings of study IV point to both specific and common aetiopathogenetic 
factors in FSS. Our identified predictors provide a possibility for prevention by early detection of 
individuals at risk of developing an FSS. Futures studies are required to unravel the reasons 
underlying the apparent inconsistencies in the literature on syndrome overlap.  
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3.5 Study V 
The epidemiological data concerning FSS vary widely. For instance, in a review article on the 
epidemiology of IBS, prevalence rates ranged from as low as 1% to as high as 45% (Lovell & Ford, 
2012). However, there was substantial heterogeneity in the data, which could not be explained by 
variables such as geographical region, the use of different case definitions, data collection via 
questionnaires versus interviews, and socio-demographic characteristics. Likewise, the most important 
review on overlap among FSS revealed that, for example, in patients with FMS, 21% to 80% 
concurrently had CFS (Aaron & Buchwald, 2001). The diversity of these findings is again striking, and 
one is left wondering what the underlying causes are. 
One explanation that is rather peculiar to research on FSS is emphasised in both reviews: the 
choice of the diagnostic approach. Inherent in the case definition of any given FSS are two criteria: 
first, presence of a symptom or constellation of symptoms that is characteristic of the FSS in question 
(positive criterion), and second, absence of any medical condition that is able to fully account for these 
symptoms (negative criterion). Both criteria can be checked by asking patients about symptoms, and 
performing physical examinations and laboratory testing in terms of exclusionary conditions. This two-
step procedure is currently considered the gold standard approach. However, as epidemiological 
research is in most instances forced to rely on self-reported data, numerous ways of diagnosing FSS 
have instead been adopted. 
The repercussions of using different diagnostic strategies in research on FSS have rarely 
been assessed. Based on an empirical comparison, Warren and Clauw (2012) have argued in favour 
of symptom-based diagnoses as opposed to physician diagnoses, meaning that people should be 
asked about each symptom contained in the case definition criteria rather than whether their physician 
has diagnosed them with syndrome X. However, with the symptom-based approach, the negative 
criterion (see above) is neglected. 
We conducted STUDY V in order to compare the symptom-based approach with a symptom-
and-exclusion-based approach. The latter approach combines questions about symptoms with 
questions about exclusionary conditions as detected by a health care professional. We expected to 
find substantial decreases in prevalence and overlap rates when following this approach. 
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Methods 
Apparently healthy students were recruited from major Swiss colleges and universities and asked to 
participate in the exact same survey twice (six months in between). In total, our data set encompassed 
3054 students (73% female). 
Functional somatic syndromes were diagnosed by means of the Questionnaire on Functional 
Somatic Syndromes (Nater, Fischer, Latanzio, et al., 2011). This hierarchical, modular instrument 
allows for the assessment of 17 different FSS. It has three parts that are separated via several 
algorithms. The first part is the screening part, where 52 somatic symptoms are rated in terms of how 
often they are experienced. In addition, questions about impairment and the duration of symptoms are 
asked. The second part is only presented if participants report symptom constellations that point to a 
certain FSS (e.g., abdominal pain and digestive problems for at least six months in the case of IBS). In 
this part, case definition criteria (e.g., the Rome III criteria for IBS; Longstreth et al., 2006) are covered. 
In this study, all participants satisfying any case definition were labelled “symptom-based cases”. The 
third part only applies if health care visits were made due to symptoms. Participants were asked about 
exclusionary conditions that were named by their physician as causes for their symptoms (e.g., 
ulcerative colitis). The label “symptom-and-exclusion-based cases” was given to those stating that no 
other condition was found that would serve as an explanation for their symptoms. 
SPSS 21 was used for all statistical analyses. Prevalence rates and number of diagnoses per 
person and per FSS were calculated and presented in absolute and/or relative numbers. 
 
Results 
There was an up to seven-fold decrease in prevalence rates across all 16 measured FSS when the 
symptom-and-exclusion-based approach was used. Participants with symptom-based FSS had one 
(62% of all cases) to eight (< 1%) concomitant syndromes. Participants with symptom-and-exclusion-
based FSS had one (79%) to four (< 1%) concomitant syndromes. In the symptom-based group, nine 
other syndromes were present on average. This number was reduced to four in the symptom-and-
exclusion-based group. 
 
 44 
 
Discussion 
Taken together, in study V, the use of medical exclusionary criteria resulted in sizable decreases in the 
prevalence and overlap of FSS, mirroring data from a previous study on functional gastrointestinal 
disorders (Koloski et al., 2002). The symptom-and-exclusion-based approach seems to “mimic” the 
two-step gold standard approach adequately well, meaning that a comparable proportion of individuals 
is excluded from an FSS diagnosis due to medical explanations for their symptoms (Perrot, Vicaut, 
Servant, & Ravaud, 2011; Reyes et al., 2003). 
Our study somewhat contradicts the recommendation by Warren and Clauw (2012), who 
made a case for the symptom-based approach to diagnose FSS in epidemiological studies. Based on 
our findings, it could be argued that their approach bears the risk of mislabelling symptoms (e.g., 
abdominal pain) as part of an FSS (e.g., IBS) instead of a medical disease (e.g., ulcerative colitis), 
which ultimately inflates prevalence rates of FSS. This certainly raises the question of whether the 
common notion of high syndrome overlap is, to some degree, a methodological artefact.  
To conclude, study V found the prevalence of FSS and their overlaps to largely depend on the 
choice of diagnostic approach. Our findings raise concern about the validity of a number of earlier 
epidemiological findings in the context of FSS. The strict application of case definition criteria, that is, 
covering both the positive and negative criterion, is strongly encouraged in order to further the 
accuracy of figures in terms of the prevalence and overlaps of FSS. 
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3.6 Study VI 
As Deary (1999) pointed out, getting a grasp of medically unexplained conditions (i.e., MUS, FSS, or 
somatoform/somatic symptom disorders) requires a detailed examination of their phenomenology. In 
the context of FSS, findings so far remain equivocal as to whether the different FSS are the 
expression of a general syndrome or distinct entities (one vs. many debate; Wessely & White, 2004). 
However, research along the lines of this question may have been somewhat hampered by its a priori 
assumption that FSS do exist as described by case definition criteria. 
In recent years, another, more unbiased approach to scrutinise the phenomenology of 
medically unexplained conditions has emerged. Taking one step back, these studies have inquired 
about the latent structure of symptoms rather than describing syndromes (i.e., FSS or 
somatoform/somatic symptom disorders). Four different models have so far been assumed to best 
represent the variance in bothersome somatic symptoms (Witthöft, Hiller, Loch, & Jasper, 2013). In a 
comparison of these models, the so-labelled “bi-factor model” proved the best fit for the data. In brief, 
this model postulates that a general factor and four symptom-specific factors (labelled “fatigue”, “pain”, 
“gastrointestinal”, and “cardio-respiratory”) account for the variance in bothersome somatic symptoms. 
However, the jury is still out on how these factors might best be interpreted and how they 
relate to existing diagnostic categories such as FSS (construct validity). Other important concepts that 
are discussed in relation to bothersome somatic symptoms are depression, health anxiety (i.e., the 
unsubstantiated and disproportionate fear or conviction of suffering from a severe illness), and 
somatosensory amplification (i.e., the tendency to experience somatic reactions as more intense, and 
to evaluate them as more negative; Henningsen et al., 2003; Jones, Schettler, Olden, & Crowell, 2004; 
Schroeder et al., 2012). 
STUDY VI was conducted to replicate the bi-factor model and to provide evidence for its 
construct validity. To this end, depression, health anxiety, and somatosensory amplification were 
assessed in addition to bothersome somatic symptoms. Based on the available literature, all 
constructs were expected to strongly relate to the general factor. We also included different FSS in our 
analyses, which we assumed to be predicted by both the general factor and the symptom-specific 
factors.  
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Methods 
Two separate samples were recruited to replicate the bi-factor model and to provide evidence for its 
validity. The first sample consisted of 1604 students (60% females) who had filled in a battery of 
questionnaires in the waiting area of the office of student enrolment at the University of Muenster. The 
second sample contained 3053 students (73% women) recruited from major Swiss colleges and 
universities who had participated in an online survey. 
Depression was assessed by the Patient Health Questionnaire (Spitzer et al., 1999), which is 
in accordance with DSM-IV criteria (American Psychiatric Association, 2000). The Whiteley Index 
(Pilowsky, 1967) was used to tap into health anxiety, with items such as “Do you worry a lot about your 
health?”. A measure of somatosensory amplification was obtained by the Somatosensory Amplification 
Scale (Barsky et al., 1990). An example item is “I can sometimes hear my pulse or my heartbeat 
throbbing in my ear”. Functional somatic syndromes were diagnosed by means of the Questionnaire 
on Functional Somatic Syndromes (Nater, Fischer, Latanzio, et al., 2011). This hierarchical, modular 
instrument allows for the assessment of 17 different FSS. We additionally dichotomised all participants 
into non-cases (0) and cases (1). Finally, somatic symptom distress was measured via the Patient 
Health Questionnaire (Spitzer et al., 1999). With this scale, 13 somatic symptoms are evaluated with 
respect to how much participants were bothered by each one of them. 
MPlus V6.11 was used for confirmatory factor analyses. A weighted least squares method and 
several fit indices were used to test whether the empirical covariance matrix of our variables was 
consistent with our expectations. More specifically, a Χ2 test, root mean square error of approximation, 
comparative fit index, and the Tucker-Lewis index were calculated. 
 
Results 
The bi-factor model showed an excellent model fit to the data structure of both samples. In the first 
sample, depression and health anxiety were associated with the general factor and together explained 
67% of its variance. In the second sample, depression and somatosensory amplification were again 
associated with the general factor, explaining 65% of the variance. The general factor, in turn, was 
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linked to the overall category of FSS. The FSS functional dyspepsia and IBS were each predicted by 
the general and gastrointestinal factor. 
 
Discussion 
Two major findings emerged from study VI. First, the latent structure of bothersome somatic symptoms 
was composed of a general factor, which was related to depression and health anxiety. Beyond this 
affective component, the general factor was associated with somatosensory amplification, which may 
represent cognitive processes specifically involved in medically unexplained conditions. Second, there 
were four symptom-specific factors that showed strong affiliations with individual FSS. These factors 
may be interpreted as a sensory component that is unique to each FSS. 
The fact that FSS were predicted by both a general and symptom-specific factors has 
important conceptual implications (one vs. many debate). The finding of a general factor is in line with 
the notion of shared aetiopathogenetic mechanisms among FSS that are beyond mechanisms 
underlying depression and health anxiety. The finding of symptom-specific factors favours viewing 
them as distinct syndromes with unique aetiopathogenetic factors. Taken together, FSS may have to 
be conceptualised as one and many. 
Study VI provided evidence for a bi-factor model that best describes the latent structure of 
bothersome somatic symptoms. This model may enable the reconciliation of contradictory findings in 
the context of FSS. An important direction for future research will be to discern the aetiopathogenetic 
mechanisms that are unique to fatigue, pain, gastrointestinal, and cardio-respiratory syndromes. 
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4. Discussion 
4.1 Summary 
Studies I to III examined the role of stress as an aetiopathogenetic factor in different FSS. Study I 
showed that patients with CFS are characterised by attenuated catecholaminergic stress reactivity in 
response to exercise, which may directly relate to symptoms such as fatigue. Study II complemented 
these findings in a sample of female patients with FMS by demonstrating that stress and cortisol seem 
to act as exacerbating factors of pain in the everyday lives of these women. Study III integrated both 
findings by demonstrating that childhood trauma is associated with heightened stress reactivity and 
lower resilience, and predicts the manifestation of FSS via chronic stress. Taken together, the findings 
of studies I to III shed light on important mechanisms translating stress into FSS. 
Studies IV to VI studied phenomenological aspects of FSS. Study IV revealed that syndrome 
overlap was lower than previously shown and that the number of somatic symptoms, impairment due 
to somatic symptoms, somatisation, and depression predicted the incidence of FSS in general. The 
findings of study V suggested that a methodological artefact may account for discrepant findings 
regarding syndrome overlap in the literature: Depending on whether or not exclusionary medical 
conditions were diagnostically considered, prevalence and overlap rates of FSS were lower and 
higher, respectively. Study VI showed that the latent structure of bothersome somatic symptoms 
consisted of a general and four symptom-specific factors (“fatigue”, “pain”, “gastrointestinal”, “cardio-
respiratory”). Beyond this, the general factor was related to somatosensory amplification, depression, 
and health anxiety, while the symptom-specific factors loaded on individual FSS. Taken together, 
these studies revealed that FSS appear to be one and many. 
 
4.2 Integration 
The findings of studies I to VI are integrated in Figure 3. Based on the results summarised above, a 
certain predisposition may be suggested in individuals who later go on to develop a medically 
unexplained condition (i.e., MUS, an FSS, or a somatoform/somatic symptom disorder). According to 
Heim and Nemeroff (2001) and Heim et al. (2010), early life events, including childhood trauma, 
program stress-responsive systems (i.e., they alter stress reactivity). Furthermore, they impact on 
certain personality traits (e.g., resilience) and this predisposition in turn lowers the threshold for 
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symptoms to be precipitated when encountering psychosocial stressors (e.g., chronic stress, daily 
hassles) later on in life. This resonates well with the fact that chronic stress is an intermediary between 
the above-outlined predisposition and the development of medically unexplained conditions (study III). 
An important mechanism underlying the translation of psychosocial stressors into medically 
unexplained conditions is allostatic load. As described by McEwen (1998) and McEwen and Stellar 
(1993), inadequate biological responses towards repeated bouts of stress foster the wear and tear of 
the very same systems in the long term and ultimately result in ill health. In fact, patients with a 
medically unexplained condition show lower autonomic reactivity than healthy controls when exposed 
to acute stress (study I) and it may be hypothesised that this directly contributes to symptoms such as 
fatigue and pain (Clauw & Chrousos, 1997; Heim et al., 2000). Importantly, not only does stress seem 
to precipitate medically unexplained conditions, but it most likely perpetuates them once they become 
manifest: Both stress as experienced in everyday life (e.g., daily hassles) and HPA axis functioning 
are associated with pain exacerbation on a momentary basis (study II). 
The fact that stress is an aetiopathogenetic factor germane to medically unexplained 
conditions in general fits in well with the observation that a general factor explains a great amount of 
variance in these conditions (study VI). This factor has strong links to somatosensory amplification, 
which refers to a trait-like tendency to experience somatic reactions as overly intense and negative 
(Barsky et al., 1988; Barsky et al., 1990). Together with stress, somatosensory amplification may be 
an important factor that governs the development of medically unexplained conditions among 
predisposed individuals. Barsky and Borus (1999) emphasised two pathways via which somatic 
sensations may be amplified under conditions of stress: First, some individuals hold beliefs about 
stress being immediately harmful to health. Second, stress can cause depression or anxiety, which are 
both known to enhance the perception of somatic sensations. Indeed, depression and anxiety are 
linked to medically unexplained conditions in general (studies IV and VI). 
Despite these similarities, syndrome overlap is rather modest when case identification is not 
overly broad (studies IV and V). This points to differential factors in medically unexplained conditions, 
but current knowledge on this subject is scarce. One study found that gene expression profiles at 
baseline and after exercise stress differed depending on whether patients had CFS or FMS (Light et 
al., 2012). Moreover, different types of infections seem to trigger CFS and IBS, respectively (Moss-
Morris & Spence, 2006). Another study pointed to differences in the operant learning of pain 
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sensitisation and habituation between patients with FMS and patients with additional IBS (Becker, 
Kleinbohl, Baus, & Holzl, 2011). These findings are in accordance with the observation of distinct 
symptom complexes within the group of medically unexplained conditions (study VI). 
In conclusion, it has become clear that the phenomenon of medically unexplained conditions is 
far too complex to be reduced to a one versus many question. It is possible that both high levels of 
past or current psychosocial stress and subsequent alterations in stress-responsive systems, and 
somatosensory amplification constitute endophenotypes that are shared by all medically unexplained 
conditions (i.e., MUS, different FSS, or somatoform/somatic symptom disorders). If this holds true, the 
complexes surrounding the core symptoms of fatigue, pain, gastrointestinal problems, or cardio-
respiratory difficulties would need to be understood as additional endophenotypes that develop as a 
consequence of yet to be identified circumstances. 
 
Figure 3 A model positing that individuals who go on to develop a medically unexplained condition (i.e., medically unexplained 
symptoms, MUS, chronic fatigue syndrome, CFS, fibromyalgia syndrome, FMS, or irritable bowel syndrome, IBS) are 
characterised by childhood trauma and subsequent alterations in the stress reactivity of the autonomic nervous system (ANS) 
and hypothalamic-pituitary-adrenal (HPA) axis. Based on this predisposition, chronic stress and daily hassles precipitate and 
perpetuate these conditions via allostatic load and somatosensory amplification. The four symptom complexes are 
phenomenological variants of this process that develop as a consequences of yet to be identified circumstances. 
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4.3 Nosological implications 
The findings of the present thesis have two nosological implications. First, the fact that stress and 
somatosensory amplification are potentially relevant to the aetiopathogenesis of medically 
unexplained conditions suggests that they are best classified within the realm of mental disorders. Not 
only would such an approach encourage research to look into other potential commonalities in these 
patients, but it would help patients to receive adequate treatment. There is increasing evidence that 
cognitive-behavioural therapy is effective in the treatment of symptoms when techniques to manage 
stress and deal with somatic sensations are included (e.g., Allen, Woolfolk, Escobar, Gara, & Hamer, 
2006; White et al., 2011). Unfortunately, with the ICD-10, clinicians may choose whether to classify a 
medically unexplained condition as a mental disorder or, for instance, as a disease of the nervous, 
musculoskeletal, or digestive system. This dualistic approach clouds rather than clarifies the issues at 
hand by segregating research into completely separate domains (psychiatry/clinical psychology vs. 
other medical specialities). It is equally doubtful that the treatment of these already complex conditions 
will be helped by this. 
Second, the fact that distinct symptom complexes can be identified among patients with 
medically unexplained conditions speaks for a classificatory category that acknowledges these 
phenomenological variants. Defining subcategories within a general category of medically unexplained 
conditions may be one way to achieve this. These would reflect predominant symptoms (e.g., fatigue, 
pain, or gastrointestinal problems) and allow for research to investigate differential mechanisms across 
these variants while still allowing patients to receive adequate treatment. Unfortunately, the recent 
developments regarding the DSM are in complete disagreement with this idea. As outlined in the 
introduction, the new category of somatic symptom disorders has abolished its former subcategories 
and now even includes medically explained conditions such as multiple sclerosis, rheumatoid arthritis, 
and Crohn’s disease (if certain psychological characteristics are present). It is evident that any effort to 
identify differential aetiopathogenetic features of the identified symptom complexes is impossible when 
adhering to this new categorisation. 
Lest the nosological complexity of FSS is to give way to chaos, it is hoped that ICD-11 will 
avoid following the DSM approach of turning the somatoform disorder category into an amorphous 
conglomerate of different conditions. A glance at the beta draft that is available online 
(http://apps.who.int/classifications/icd11/browse/l-m/en) reveals that, although the general dualistic 
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approach of ICD-10 (see above) is maintained, the current proposal does seem to be more in line with 
recent research, including the studies that form this thesis. According to the website, the committee 
has so far settled on the term “bodily distress disorder”. The thus labelled category is composed of 
three subcategories indicating the degree of severity of the condition (mild, moderate, and severe). 
This is affirmative of the notion that there seems to be a minority of patients with several concomitant 
FSS. On the other hand, although fatigue, pain, gastrointestinal symptoms, and respiratory symptoms 
are listed as the most common symptoms, as yet, there is no explicit mention of different symptoms 
complexes, even though phenomenological research has found evidence for their existence. 
 
4.4 Conclusion 
The current nosology of FSS has created significant confusion by providing multiple options to label 
and categorise these conditions. This is due to the fact that the conceptualisation of FSS is still subject 
to debate (one vs. many). The aim of this thesis was to recognise similarities and differences of FSS 
by a) elucidating specific aspects of their aetiopathogenesis, and b) disclosing their phenomenology in 
greater detail. Stress was shown to be involved in the predisposition, precipitation, and perpetuation of 
FSS in different samples of patients. Despite this commonality, syndrome overlap was rather low when 
the approach to case identification excluded clear-cut medical explanations for somatic symptoms. 
This apparent discrepancy was reflected by the fact that symptoms pertaining to FSS could best be 
explained by a general and four symptom-specific factors. Based on the findings of this thesis, the 
greatest confidence may have to be placed in stating that FSS appear to be one and many. 
Nosology shapes the way in which we perceive illness. Future attempts at classifying 
medically unexplained conditions should acknowledge both common and symptom-specific factors in 
order to foster prolific research. One of the greatest challenges to be faced will be the unravelling of 
mechanisms behind the four identified symptom-specific factors. Longitudinal studies following up on 
individuals who have been exposed to early life or chronic stressors will be crucial to answer the 
question of which factors determine outcome variability. Another promising approach is to compare 
pathophysiological features across patients with either fatigue, pain, gastrointestinal, or cardio-
respiratory symptoms in the laboratory, which would help to foster our understanding of differential 
factors that are at work in these variants.  
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Chronic  fatigue  syndrome  (CFS)  is  characterized  by fatigue  lasting  6  months  or longer.  CFS  has  been
associated  with  a  disturbed  (re-)activity  of  the  autonomic  nervous  system.  However,  the  sympathetic
adrenomedulla  (SAM)  remains  under-examined  in  CFS.  To investigate  SAM  reactivity,  we implemented
a  submaximal  cycle  ergometry  (ERGO)  and  a pharmacological  test  (Insulin  Tolerance  Test,  ITT)  in  21  CFS
patients  and  20  age-,  sex-,  and BMI-matched  controls.  Plasma  norepinephrine  and  epinephrine  wereutonomic nervous system
atecholamines
hronic fatigue syndrome
xercise test
nsulin Tolerance Test
collected  once  before  and  twice  after  the  tests  (+10/+20,  and  +30  min).  Lower  baseline  levels and  atten-
uated  responses  of  epinephrine  to the  ERGO  were  found  in  CFS  patients  compared  to  controls,  while  the
groups  did  not  differ  in their  responses  to the  ITT.  To  conclude,  we found  evidence  of altered  sympathetic-
neural  and  SAM  reactivity  in CFS.  Exercise  stress  revealed  a subtle  catecholaminergic  hyporeactivity  in
CFS  patients.  It is  conceivable  that inadequate  catecholaminergic  responses  to  physical  exertion  might
ms.tress contribute  to CFS  sympto
. Introduction
Chronic fatigue syndrome (CFS) refers to fatigue of more than 6
onths duration that cannot be sufficiently explained by any med-
cal or psychiatric condition. According to the Centers for Disease
ontrol and Prevention (CDC) 1994 diagnostic criteria, a number of
ncillary symptoms, such as myalgia, memory and concentration
roblems, and postexertional malaise need to be fulfilled for a diag-
osis of CFS (Fukuda et al., 1994). The diagnosis of CFS requires a
omplete clinical evaluation to exclude any medical or psychiatric
ause of symptoms. Prevalence rates range from 0.2% to 2.5% in the
eneral population, with women being more frequently affected
han men  (Reeves et al., 2007; Reyes et al., 2003). CFS provokes sub-
tantial suffering and impairment in patients (Lowry & Pakenham,
008), leading to a considerable amount of direct (e.g., medical
are) and indirect (e.g., lost productivity) costs for society (Lin et al.,
011).
Elucidating pathophysiological mechanisms in any illness is
mportant in identifying targets for treatment. Given the hetero-
eneity and complexity of CFS, the identification of underlying
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301-0511/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.biopsycho.2013.06.002© 2013 Elsevier B.V. All rights reserved.
psychological and physiological mechanisms is still subject to
extensive research. A prominent line of research has been dedicated
to the role of stress as an etiological and perpetuating factor in CFS
(Nater, Fischer, & Ehlert, 2011). On a physiological level, stressors
might result in a deregulation of stress-responsive systems, such
as the hypothalamic–pituitary–adrenal axis (HPA), the autonomic
nervous system (ANS), and the immune system (Danese, Pariante,
Caspi, Taylor, & Poulton, 2007; Evans & English, 2002; Heim et al.,
2000). It has been suggested that this deregulation contributes
to core symptoms of CFS, such as pain and fatigue (Fries, Hesse,
Hellhammer, & Hellhammer, 2005; Irwin, 2011; Rief & Barsky,
2005). In accordance with these propositions, symptoms of CFS are
exacerbated by psychological (e.g., life events; Lutgendorf et al.,
1995) and physiological stress (e.g., exercise; Jammes, Steinberg,
Mambrini, Bregeon, & Delliaux, 2005), possibly resulting in post-
exertional malaise and avoidance behavior often found in these
patients (Nater et al., 2006; VanNess, Stevens, Bateman, Stiles, &
Snell, 2010).
Due to the observation that conditions characterized by a dys-
functional ANS, such as neurally mediated hypotension or postural
orthostatic tachycardia, share prominent clinical features with CFS
(e.g., Rowe, Bou-Holaigah, Kan, & Calkins, 1995), several studies
have investigated autonomic abnormalities in patients suffering
from CFS, yielding inconsistent results (Nater, Heim, & Raison,
2012). Most of this research focused either on the sympathetic
neural or the parasympathetic branch of the ANS using indirect
measures of autonomic activity such as heart rate or heart rate
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ariability. However, power spectrum analysis of heart rate vari-
bility as a measure of sympathetic activity is still considered
quivocal in terms of the relative contributions of the sympa-
hetic and parasympathetic nervous system (Task Force, 1996).
nly few studies have been dedicated to the examination of
he sympatho-adrenomedullary (SAM) part of the ANS (Boneva
t al., 2007; De Lorenzo, Hargreaves, & Kakkar, 1997; Ottenweller,
isto, McCarty, & Natelson, 2001; Streeten, Thomas, & Bell, 2000;
immers et al., 2002), focusing on the release of the catecholamines
pinephrine (E), and – to a lower extent (Goldstein, McCarthy,
olinsky, & Kopin, 1983) – norepinephrine (NE) from chromaffin
ells in the adrenal medulla. This is somewhat surprising, since
atecholamines are the main effectors of the sympathetic ner-
ous system and the SAM system in particular and are therefore
ntimately related to stress-related pathophysiology (Kvetnansky,
abban, & Palkovits, 2009). Studies merely assessing baseline lev-
ls of catecholamines reported no differences between adult CFS
atients and controls (Boneva et al., 2007; De Lorenzo et al., 1997).
owever, subtle differences in catecholaminergic activity as well
s the role of feedback mechanisms might only be revealed during
hallenges. Three studies employed physiological challenges with
dult CFS patients (Ottenweller et al., 2001; Streeten et al., 2000;
immers et al., 2002), of which two tested the effects of ortho-
tatic stress. Unfortunately, these tests are limited in their ability
o elicit both NE and E responses concomitantly (Robertson et al.,
979).
Exercise, on the other hand, increases both sympathetic neu-
al and adrenomedullary activity. In addition, this test bears the
dvantage of being a critical real-life stressor in CFS and might pos-
ibly be related to post-exertional malaise and avoidance behavior
n these patients (Jammes et al., 2005; VanNess et al., 2010). A num-
er of studies have used an exercise protocol to test physiological
apacity und cardiac function in CFS in the laboratory, yielding
nconsistent findings (Gibson, Carroll, Clague, & Edwards, 1993;
ontague, Marrie, Klassen, Bewick, & Horacek, 1989; Riley, O’Brien,
cCluskey, Bell, & Nicholls, 1990; Sisto et al., 1996; Wallman,
orton, Goodman, & Grove, 2004). However, exercise testing does
ot only allow for the assessment of physiological capacity but can
lso be used as a psycho-physiological stressor. This is due to the
act that exercise testing provokes intraindividual processes that
ight impact motivation and effort (Silver et al., 2002). There is only
ne published CFS study using (treadmill) exercise as a stressor to
hallenge the release of catecholamines, showing lower responses
f E in CFS compared to healthy controls (Ottenweller et al., 2001).
othing is known about catecholaminergic responses toward other
xercise protocols, such as the frequently used cycle ergometry test
ERGO), in CFS patients.
A far more common approach to study endocrine stress
esponses involves the use of highly standardized pharmacologi-
al protocols. In contrast to exercise testing, these protocols offer
n opportunity to minimize the effects of intraindividual processes.
 frequently used pharmacological stressor to study the integrity of
hypoglycemia-responsive) endocrine systems in CFS is the Insulin-
olerance-Test (ITT). The intravenous injection of insulin results in a
arked hypoglycemia that provokes a counterregulatory response
n the hypothalamic, pituitary and adrenal level, thus constitut-
ng a robust stimulus of adrenomedullary catecholamine release
Goldstein, 2010; Pacak, Baffi, Kvetnansky, Goldstein, & Palkovits,
998). This test has previously been implemented in the study of
ndocrine dysfunction in CFS, eliciting normal or diminished HPA
xis responses in these patients (Bearn et al., 1995; Gaab et al.,
004). Of note, this stimulus does not rely on cognitive-evaluative
r affective processes to elicit an adaptive response and is therefore
ecommended in the study of adrenomedullary function. Currently,
othing is known about the ITT- or hypoglycemia-induced release
f NE and E from the adrenal medulla in CFS.ology 94 (2013) 160– 166 161
In sum, deregulated stress–responsive systems seem to play
a major role in the development and perpetuation of CFS. While
there is evidence for a deregulation of the ANS in a subgroup of CFS
patients little is known about a possible stress-related deregulation
of catecholamines as direct effectors of the sympathetic-neural and
SAM system. Moreover, previously used autonomic stress protocols
did not show adequate relevance regarding CFS symptomatology.
The aims of this study are therefore to assess the responses of
NE and E (outcome variables) to both the ERGO and ITT in male
and female CFS patients compared to healthy controls (predictor
variables). Employing these two tests will allow us to disentangle
different aspects of stress-induced adaptive responses underlying
a potentially deregulated stress reactivity in CFS, i.e., its phys-
iological component (as elicited by the ITT) and intraindividual
factors, such as cognitive-evaluative and affective processes. Based
on the evidence mentioned above, we expect a relative hyporeac-
tivity of both NE and E in CFS patients to the ERGO and the ITT.
Due to cognitive-evaluative processes and the subsequent affec-
tive response to exercise, we expect that hyporeactivity is even
more pronounced in the ERGO condition. In addition, investigating
both men  and women will enable us to explore sex-related differ-
ences in physiological alterations possibly underlying higher CFS
prevalence rates in women.
2. Methods
2.1. Subjects
A total of 41 subjects participated in this study. Patients were contacted
through a German self-help organization. Interested patients received a postal
screening questionnaire, containing all symptoms required by the CDC 1994 def-
inition (Fukuda et al., 1994). Patients fulfilling the symptom requirements in this
screening questionnaire were interviewed over the phone and asked for diagnosed
medical illnesses and psychiatric disorders. Interested patients were only excluded
from participating in the study if they had received a medical or psychiatric diagno-
sis defined as exclusionary by the CDC 1994 definition (Fukuda et al., 1994). Further
selection criteria were acute onset of CFS, between 30 and 50 years of age, no cur-
rent antidepressive, anxiolytic, antibiotic, antihypertensive, or steroid medication
and no medical or psychiatric cause for chronic fatigue using routine laboratory
testing and psychiatric interviews. Thus, ten men and 13 women were selected
from a cohort of 86 subjects with chronic fatigue syndrome willing to participate
in  the study. Patients were admitted to the research unit of a general hospital for
the  duration of one week. All patients were medically examined according to CDC
recommendations (Fukuda et al., 1994), and interviewed by a trained psychologist
(J.G.) using a computer-aided standardized diagnostic interview (Wittchen & Pfister,
1997) and a semi-structured CFS interview. Two  female patients were excluded from
the study due to hormone levels indicative of thyroid hypofunction and primary
adrenal insufficiency, diagnosed by a blunted cortisol response to Synacthen (Ciba,
Wehr, Germany). Patients were matched for age and sex with a total of 20 healthy
volunteer controls. Controls were medication-free and underwent comprehensive
medical examination for past and current health problems. All subjects provided
written informed consent before participation in the study and ethical committee
approval for the study was  obtained. The study was  conducted in accordance with
the  Declaration of Helsinki. Not all CFS patients underwent both tests; three female
patients were unwilling to participate in the ITT, resulting in a sample of 18 patients
undergoing the ITT test. Further, not all control subjects were included in both tests;
seven controls (three men  and four women) did not undergo the ITT. Therefore, four
new control subjects (two men and two women) were recruited for this test, result-
ing in a sample of 17 control subjects participated in the ITT. The newly recruited
control subjects did not differ in demographic variables and underwent the same
screening and test procedures as the other control subjects while only undergoing
the  ITT. Patients and controls were not compensated for participating.
2.2. Test protocols
Each subject participated in two laboratory sessions. All subjects arrived 60 min
before each test. They were taken into a separate room and an intravenous catheter
was  inserted and kept patent with a heparin lock. All subjects had to rest for at least
45  min. A baseline blood sample was  collected immediately before the respective
test began. After the incremental ERGO, starting at 1400 h, all subjects were taken
back into their room for further sampling. Subjects who agreed to participate in the
ITT  reported to the laboratory 48 h after the ERGO. The ITT started at 0945 h. Blood
samples for determination of NE and E responses were taken 10 and 30 min  (ERGO)
and 20 and 30 min  (ITT) after the respective test.
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.3. Incremental cycle ergometry test (ERGO)
To test the integrity of catecholaminergic systems during a physiological chal-
enge, a standard cycle ergometry test was used. Notably, the ERGO primarily elicits
oradrenergic responses (Dimsdale & Moss, 1980; Robertson et al., 1979). On the day
f  the ERGO, participants were asked to abstain from caffeine, alcohol, and nicotine.
he ERGO started at 50 W for men  and 30 W for women, respectively, with 40 W
ncrements every 3 min  until the subject was  no longer able to continue or until
redicted maximum heart rate (85% of 220 bpm – subjects’ age). Patients were not
erbally encouraged during the test and their heart rate was continuously moni-
ored throughout the test. Subjects were asked to rate perceived exertion using the
org scale (Borg, 1982).
.4. Insulin Tolerance Test
The ITT is a standardized pharmacological stressor assessing the integrity of the
drenal hormonal system, thus primarily constituting a potent adrenergic stimulus
Goldstein et al., 1983). Subjects were asked to fast overnight and abstain from caf-
eine, alcohol, and nicotine. After a 45-min resting period, a baseline sample was
aken to measure catecholamines, and an intravenous bolus injection of 0.15 U/kg
oluble insulin (H-Insulin, Hoechst, Frankfurt, Germany) was given. Subjects were
old  that they could request intravenous glucose infusion or oral glucose to reduce
ymptoms of hypoglycemia. None of the tested subjects received any glucose during
he  ITT.
.5. Biochemical analyses
EDTA-treated blood samples were spun immediately at 4 ◦C and stored at −20 ◦C
ntil assayed. Plasma samples were analyzed for NE and E by high-pressure liquid
hromatography (detection limit: 0–25 pg/ml) at the Laboratory for Stress Monitor-
ng  (Goettingen, Germany).
.6. Heart rate
Heart rate (HR) was  determined every 3 min  during the incremental ERGO with
 heart rate monitor (Sport Tester Profi, Polar Instruments, Gross-Gerau, Germany).
eak HR was  defined as the maximal HR achieved during the ERGO session. In the
esults section, only peak HR will be reported since cardiovascular measures were
ot  the main focus of this report.
.7. Statistical analysis
Chi square analysis was used to test significant differences in categorical vari-
bles; continuous variables were analyzed with ANOVAs. ANOVAs for repeated
easures were computed to analyze catecholaminergic responses in the tests. Uni-
ariate ANOVAs were utilized to compare increases in catecholamines between
roups. Data were tested for normal distribution and homogeneity of variance
sing Kolmogorov–Smirnov and Levene’s test. All reported results were corrected
y  Greenhouse–Geisser procedure when assumptions of sphericity were violated.
atecholaminergic increases elicited by the stressors were calculated by subtrac-
ion  of the baseline measurement time point from the respective peak value (10
s.  30 min). The optimal total sample size of N = 40 to detect an expected effect size
f  0.35 with a power ≥0.90 and  ˛ = 0.05 was  calculated a priori with the statistical
oftware G-Power (Buchner, Faul, & Erdfelder, 1997). For all analyses, significance
evel was  ˛ = 0.05. Unless indicated, all results are presented as mean ± standard
eviation (SD).
able 1
emographic characteristics and cycle ergometry variables.
Chronic fatigue syndrome (N = 21) Co
Females (N [%]) 11 (52.4%) 9 (
Age  (years) 36.0 ± 4.6 (range: 29–47) 35
Body  mass index (kg/m2) 22.4 ± 6.8 (range: 17.6–26.3) 24
Exercise duration (min) ♀ 7.9 ± 2.5 ♀ 1♂ 13.0 ± 2.8 ♂1
Maximal workload (W) ♀ 130.0 ± 34.6 ♀ 1♂ 218.0 ± 31.6 ♂ 
Peak  heart rate (bpm) ♀ 159.7 ± 20.5 ♀ 1♂ 167.8 ± 13.7 ♂ 
BORG  (6–20) ♀ 17.4 ± 2.1 ♀ 1♂ 18.7 ± 1.4 ♂ ology 94 (2013) 160– 166
3. Results
3.1. Patients and controls characteristics
Sex ratio as well as mean age did not differ significantly between
groups while there was  a trend toward a higher body mass index
(BMI) in controls (Table 1). Sixteen CFS patients reported an infec-
tious onset of their symptoms. All patients reported an acute onset
of their CFS symptoms. Mean duration of symptoms in patients
was 63.1 ± 41.5 months, with a range from 17 to 168 months. All
patients were drug free for a minimum of one month, while four
female subjects in each group used monophasic oral contraceptives.
One patient fulfilled criteria for a current episode of major depres-
sion. Since the exclusion of these subjects did not alter results, they
were included into the following analyses. Seven patients reported
a past history of major depression and four reported a past history
of anxiety disorder. None of the controls reported any current or
lifetime psychiatric disorder.
3.2. Incremental cycle ergometry test (ERGO)
Results of all variables related to the ERGO are reported by sex in
Table 1. Groups differed in exercise duration (CFS 10.36 ± 3.66 min
vs. controls 12.47 ± 2.75 min; p = 0.014) and maximal workload
(CFS 171.91 ± 55.46 W vs. controls 199.00 ± 43.76 W;  p = 0.024), but
not regarding peak heart rate (CFS 163.57 ± 17.67 bpm vs. controls
166.75 ± 13.01 bpm; p = 0.592) and maximal perceived exertion
(Borg scale: CFS 18.00 ± 1.87 vs. controls 18.10 ± 1.17; p = 0.968).
Men  exhibited significantly higher overall levels in all parame-
ters related to the ERGO (all p < 0.017), except in peak heart rate
(p = 0.123). However, no significant group by sex interaction effects
emerged (all p > 0.412).
Before the ERGO, baseline levels of E were lower in CFS patients
(F(1/36) = 7.01, p = 0.012, 2 = 0.163) while there was  no differ-
ence with regard to baseline levels of NE (F(1/36) = 0.41, p = 0.526,
2 = 0.011). There were non-significant lower baseline E values in
women (F(1/36) = 3.48, p = 0.070). No other effects were significant
(all p > 0.20). The ERGO protocol induced significant catecholamin-
ergic responses (NE: F(1.109/41.037) = 202.89, p < 0.001, 2 = 0.846;
E: F(1.143/42.283) = 77.46, p < 0.001, 2 = 0.677). Since we  found dif-
ferences in exercise duration and maximal workload and a trend
toward a difference in BMI, these variables were included as covari-
ates in the following ANOVAs. Baseline levels of E were included as
a further covariate into the ANOVAs regarding E.
Patients with CFS showed significantly dampened response pro-
files to the exercise test with regard to E (F(1.149/37.931) = 4.85,
ntrols (N = 20) Statistics
45.0%) 2 = 0.22, p = 0.636
.7 ± 4.8 (range: 29–44) T = −0.24, p = 0.813
.7 ± 4.7 (range: 18.2–34.6) T = 1.95, p = 0.058
0.0 ± 1.6 Fgroup(1/37) = 6.60, p = 0.014, 2 = 0.151
4.5 ± 1.7 Fsex(1/37) = 47.82, p < 0.001, 2 = 0.564
Fgroup×sex(1/37) = 0.27, p = 0.609, 2 = 0.007
58.9 ± 26.7 Fgroup(1/37) = 5.54, p = 0.024, 2 = 0.130
231.8 ± 20.9 Fsex(1/37) = 78.64, p < 0.001, 2 = 0.680
Fgroup×sex(1/37) = 0.69, p = 0.412, 2 = 0.018
62.8 ± 13.5 Fgroup(1/37) = 0.29, p = 0.592, 2 = 0.008
170.0 ± 12.3 Fsex(1/37) = 2.49, p = 0.123, 2 = 0.063
Fgroup×sex(1/37) = 0.01, p = 0.931, 2 = 0.000
7.6 ± 0.9 Fgroup(1/37) = 0.002, p = 0.968, 2 = 0.000
18.5 ± 1.2 Fsex(1/37) = 6.25, p = 0.017, 2 = 0.144
Fgroup×sex(1/37) = 0.14, p = 0.712, 2 = 0.004
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eig. 1. Catecholamine levels and mean catecholaminergic response during the ERGO
ith regard to group and sex (mean ± standard error of mean).
 = 0.029, 2 = 0.128), but not to NE (F(1.106/37.603) = 2.63,
 = 0.110, 2 = 0.072) (Fig. 1). A time by sex effect was evident
or E (F(1.149/37.931) = 10.62, p = 0.002, 2 = 0.243) as well as
 trend toward a significant time by group by sex interaction
F(1.149/37.931) = 3.24, p = 0.075, 2 = 0.089), with no differences
etween females and less pronounced response profiles in male
FS patients compared to male controls. No time by sex or time by
roup by sex interaction was shown with regard to NE response
rofiles (all p > 0.183). Both individuals with CFS and healthy con-
rols returned to baseline levels of NE and E within 30 min  after the
RGO.
Mean increases of catecholaminergic responses were calcu-
ated to examine differences in the magnitude of stress reactivity
etween groups. Individuals belonging to the CFS group showed
ower increases of E (F(1/33) = 4.56, p = 0.040, 2 = 0.121), but not
f NE (F(1/34) = 3.27, p = 0.079, 2 = 0.088) compared to healthy
ontrols. Higher mean increases of E were observed in men
F(1/33) = 9.90, p = 0.003, 2 = 0.231) although no group by sex inter-
ction was found (F(1/33) = 2.35, p = 0.135, 2 = 0.066). Regarding
E, no effect of sex or group by sex interaction could be observed
all p > 0.119).
.3. Insulin Tolerance TestSince we found a trend toward a difference in BMI, this vari-
ble was included as a covariate in the following ANOVAs. Prior
o the ITT, no group difference in baseline levels of E and NE was
vident (E: F(1/31) = 2.18, p = 0.150, 2 = 0.066; NE: F(1/31) = 0.18,Fig. 2. Catecholamine levels during the ITT with regard to group and sex
(mean ± standard error of mean).
p = 0.671, 2 = 0.006). The ITT protocol induced significant changes
over time for both analytes (E: F(1.046/31.375) = 69.56, p < 0.001,
2 = 0.699; NE: F(2/60) = 41.36, p < 0.001, 2 = 0.580). Catecholamin-
ergic response profiles to the ITT did not differ between groups
(E: F(1.046/30.322) = 1.68, p = 0.206, 2 = 0.055; NE: F(2/58) = 0.32,
p = 0.727, 2 = 0.011; see Fig. 2) and no time by sex effects and no
triple interaction effects were evident (all p > 0.239). Thus, no fur-
ther analyses were conducted comparing stress reactivity scores
between groups.
4. Discussion
To address a possible stress-related deregulation of the
sympathetic-neural and SAM system in CFS, we compared cate-
cholaminergic response in CFS patients and healthy controls during
a physiological (ERGO) and a pharmacological (ITT) stress test. Both
stressors induced increased catecholaminergic activity. During the
ERGO, a relative hyporeactivity emerged in CFS patients with regard
to E, but not with regard to NE. However, both groups returned to
baseline levels of NE and E within 30 min. This indicates that CFS
patients are capable of establishing a counterregulatory response to
physical exertion, albeit to a lower degree. When exploring possible
disparities between men  and women, female CFS patients showed
non-significantly lower baseline values of E during the ERGO but
exhibited similar reactivity profiles compared to female controls.
On the other hand, male CFS patients’ resting levels were compa-
rable to those of healthy controls, while their exercise-induced E
levels were blunted. In contrast to the ERGO, groups did not differ
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n their catecholaminergic responses to the ITT. Thus, a relatively
ormal catecholaminergic secretion could be observed to a stan-
ardized pharmacological stimulus. No effect of sex was found in
esponse to this stimulus.
Exercise testing constitutes an ecologically valid stressor in CFS
nd has so far primarily been used to test physiological capacity
nd cardiac functioning in these patients. Peak HR has often been
ncluded as a dependent variable in these studies, showing atten-
ated (Gibson et al., 1993; Montague et al., 1989; Sisto et al., 1996;
allman et al., 2004) or normal (Bazelmans, Bleijenberg, Van Der
eer, & Folgering, 2001; Riley et al., 1990) levels in individuals
ith CFS. These findings are only partially in accordance with our
nding of equal peak HR values between groups. Unfortunately,
omparability between studies is severely limited by differing exer-
ise protocols (e.g., cycle ergometery vs. treadmill, submaximal
s. maximal performance testing) and prevents us from drawing
onclusions at this time.
This is the first study to assess the catecholaminergic response
o a cycle ergometry test in CFS. Our finding of a relative hypore-
ctivity of E to the ERGO in CFS patients is in line with findings
rom another study using a treadmill exercise test to examine cate-
holamines in women with CFS (Ottenweller et al., 2001). Notably,
ifferences in temporal dynamics of NE and E might account for
hese results. Importantly, in our study, response profiles were
ttenuated in male CFS patients compared to male controls, while
emales did not differ. As mentioned above, this difference might
e attributed to the differing stress protocols. Moreover, our sub-
ects performed a submaximal test in a sitting posture instead
f a maximal exercise test in upright posture, as opposed to the
tudy by Ottenweller et al. (2001), thus enhancing comparability
etween CFS and healthy control subjects by controlling for the
ffects of orthostasis and physiological deconditioning. Our finding
f a relative catecholaminergic hyporeactivity is not in accordance
ith other studies implementing protocols testing the effects of
rthostatic stress inducing catecholaminergic stress responses in
atients with CFS and controls. In contrast to our findings, these
ests elicited comparable (Timmers et al., 2002) and excessive cat-
cholaminergic responses (Streeten et al., 2000) in CFS patients.
his might be explained by the different physiological processes
nvolved in orthostatic and exercise stress, respectively (blood vol-
me  shift vs. energy mobilization), and their ability to stimulate
atecholamine release (Goldstein, 1981).
Catecholaminergic responses to the ITT have not been reported
n CFS so far. The lack of a difference between CFS patients and
ontrols in responses of NE and E is, however, in line with studies
nvestigating responses of other adrenal hormones (i.e., cortisol)
o this stressor (Bearn et al., 1995; Gaab et al., 2004). There-
ore, when contrasting both stressors, our results do not support
 general dysfunction of the adrenomedullary hormonal system
n CFS. Instead, our finding of differential response profiles dur-
ng the ERGO compared to the ITT points to the role of specific
ntraindividual processes in patients with CFS regarding physi-
al exertion. Interestingly, psychological stress seems to primarily
licit adrenomedullary responses while physiological stressors
avor the release of NE from sympathetic nerve endings (Dimsdale &
oss, 1980). However, since our assessment did not include meas-
res directly addressing both of these putative aspects of the ERGO,
his remains purely speculative.
Our result of similar peak HR values in CFS patients and
ealthy controls despite attenuated stress levels of circulating
atecholamines might point to compensatory changes in beta-
drenergic receptor function at the cardiac level. Interestingly,
ecent research on exercise induced gene expression patterns
ound elevated amounts of alpha- and beta-adrenergic receptors
n peripheral blood mononuclear cells in CFS patients compared to
ontrols (Light, White, Hughen, & Light, 2009; White, Light, Hughen,ology 94 (2013) 160– 166
Vanhaitsma, & Light, 2012), which can be considered reflective of
changes in other tissues such as the heart (Mills & Dimsdale, 1993).
However, this was not evident during resting conditions (Light
et al., 2012; White et al., 2012). This indicates that, during acute
stress, lower levels of circulating catecholamines might bind to
more sensitive adrenergic receptors resulting in unchanged auto-
nomic reactivity on the cardiac level. Again, this assumption needs
to be verified in future studies.
One possibility of how a relative hyporeactivity of cate-
cholamines might be linked to symptoms of CFS is via the immune
system. Adrenergic receptors are expressed on various immune
cells and organs enabling circulating catecholamines to exert their
immunomodulatory effects (Elenkov, Wilder, Chrousos, & Vizi,
2000). During acute stress (e.g., exercise), NE and E favor a shift
from a Th1 to a Th2 mediated immune response (Elenkov et al.,
2000). It is therefore conceivable that deficiencies in reaching a
sufficient catecholaminergic response to re-occurring acute stress-
ors may  enhance inflammation, ultimately leading to symptoms of
pain and fatigue (Irwin, 2011). When examining the exact mech-
anisms underlying the interaction between catecholamines and
inflammatory processes, the sensitivity of immune cells needs to
be taken into account. In a previous study, the capacity of a beta2-
adrenergic agonist to inhibit the production of tumor necrosis
factor-alpha and to enhance the release of the anti-inflammatory
cytokine interleukin-10 was reduced in adolescents suffering from
CFS during baseline conditions (Kavelaars, Kuis, Knook, Sinnema,
& Heijnen, 2000). Thus, in addition to lower circulating levels of
catecholamines, adrenergic receptors on immune cells seem to be
less responsive to these signals. However, no study so far has exam-
ined the effect of acute stress on the sensitivity of immune cells to
adrenergic signaling in CFS. The exact mechanisms that translate
acute stress into fatigue are largely unknown and clearly warrant
further research.
In our study, limited evidence was found for sex-specific phys-
iological alterations in CFS. Male patients suffering from CFS
demonstrated attenuated response profiles of E to the ERGO com-
pared to their female counterparts. However, the lack of significant
differences in females could be due to a floor effect. All other anal-
yses failed to show any significant group by sex interaction. To the
best of our knowledge, this is the first study examining sex-specific
alterations in catecholamines in CFS. Our finding of comparable
response profiles in women in both groups on the one hand and
attenuated response profiles of E in male CFS patients compared
to male controls on the other hand does not explain epidemiologi-
cal reports of higher CFS prevalence rates in women (Reeves et al.,
2007; Reyes et al., 2003). Future studies with larger samples are
needed to investigate sex-specific mechanisms in CFS.
This study had several limitations. First, generalization of our
results is limited by the fact that we  recruited individuals with
CFS via self-help organizations, as opposed to identifying repre-
sentative cases from the general population. Second, as mentioned
above, the small sample size does not allow us to draw defi-
nite conclusions on sex as a moderator of the catecholaminergic
stress response in CFS. Furthermore, it prevented us from deter-
mining whether only a subgroup of patients might be affected
by catecholaminergic deregulation. Third, we  did not assess lev-
els of physical fitness in our sample. Thus, possible differences
in physiological capacity might have contributed to the differ-
ential catecholaminergic responses observed. By implementing a
submaximal as opposed to a maximal exercise protocol, we did
however account for these confounding effects to some extent.
Also, no information on hormonal status (i.e., menstrual cycle
phase, menopause) was available, except for the use of oral contra-
ceptives. However, women  using hormonal contraceptives were
equally distributed among groups, thus minimizing a possible
impact on our findings. Fourth, our limited number of measurement
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ime points after the ITT prevents us from detecting possible group
ifferences during the recovery period. Fifth, we  are not able to
etermine whether our result of a relative hyporeactivity is due
o a diminished release of catecholamines into the circulation or
hether metabolism and clearance rate is accelerated. Finally,
ntraindividual (cognitive-evaluative and affective) processes were
ot directly measured in this study while clearly deserving more
ttention.
In sum, our results do not support the notion of altered
atecholaminergic reactivity in CFS. Using a highly potent phar-
acological stressor of the adrenomedullary system (i.e., the ITT),
o differences were apparent between healthy controls and indi-
iduals suffering from CFS, indicating the lack of a stress-related
ndocrine disturbance in this disorder. In contrast, exercise seems
o be a highly relevant and potent stressor in CFS, leading to subtle
atecholaminergic deregulation in these patients. It is conceivable
hat inadequate catecholaminergic responses induced by physi-
al exertion might contribute to symptoms (e.g., post-exertional
alaise) in CFS patients. Replication of our findings in larger sam-
les is required, especially in shedding light on possible sex-specific
hysiological alterations in CFS. Further, research on stressor-
pecific effects (e.g., physical activity vs. psychosocial stress) in the
ifferent branches of the ANS in CFS is warranted to examine cog-
itive and affective contributions to deregulated stress responses.
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Stress and pain in fibromyalgia 
Abstract 
Objective 
Although fibromyalgia syndrome (FMS) is a chronic condition, its cardinal symptom pain is known to 
fluctuate over the day. Stress has often been claimed to exacerbate pain. However, there is hardly any 
evidence about whether this is true on a day-to-day basis (or whether it is the other way around). We 
tested whether and how stress and pain are intertwined in participants with FMS, using an ecologically 
valid measurement design. We additionally looked into the role of the two major stress-responsive 
systems, the hypothalamic-pituitary-adrenal axis and autonomic nervous system, as potential 
mediators of this relationship.  
Methods 
We conducted an ambulatory assessment study over the course of 14 days. Each day, 32 females 
with FMS provided six diary entries on momentary stress and pain levels. Saliva samples were 
collected at the same time points to determine cortisol and alpha-amylase as indicators of stress-
responsive systems. 
Results 
Higher stress at a given measurement time point was associated with higher reported pain levels at 
the next time point (UC = 1.62, p = .002), but not vice versa (UC < 0.01, p = .083). The stress - pain 
relationship was neither mediated by momentary cortisol nor by alpha-amylase; however, momentary 
cortisol was independently associated with momentary pain (UC = 0.28, p = .008). 
Conclusion 
Stress seems to be a powerful exacerbating factor for pain as experienced by patients with FMS in 
their everyday lives. Cortisol may be involved in the diurnal fluctuation of pain levels in patients with 
FMS. Future studies should identify relevant daily stressors in persons with FMS and scrutinize the 
mechanisms underlying the cortisol – pain relationship. 
 
Stress and pain in fibromyalgia syndrome 3 
Fibromyalgia syndrome (FMS) refers to widespread pain of more than three months duration that 
cannot be sufficiently explained by any medical condition. According to the American College of 
Rheumatology (ACR) 2010 diagnostic criteria, a number of ancillary symptoms, such as fatigue, 
waking unrefreshed, and cognitive symptoms often occur in patients (1). Prevalence rates range from 
2.1% to 5.3% in the general population, with a female preponderance regarding symptom severity (2, 
3). The course of FMS is mostly chronic, with a minority of patients reporting symptom improvements 
over time (4, 5). 
Given the typically chronic course of FMS, the identification of mechanisms underlying its 
perpetuation is imperative. Although generally stable, symptoms of FMS are known to show diurnal 
variation (6). In a subgroup of patients with high pain sensitivity, on average, a decline in pain levels 
was observed from 11 a.m. until the end of each day (7). However, symptom fluctuations are mostly 
perceived as unpredictable by the individual patient, leaving him/her in emotional distress and 
incapable of engaging in his/her daily routine (8). Moreover, the planning of daily activities is severely 
hampered by the fact that the triggers for symptom flares often remain obscure (9).The question thus 
arises what factors underlie the experience of symptom exacerbation in patients with FMS. 
In the past, a case has been made that stress may be an important perpetuating factor in FMS 
(10). As far as empirical evidence is concerned, a plethora of cross-sectional studies have used 
questionnaires measuring chronic stress or daily hassles in patients with FMS. In these studies, the 
magnitude of self-reported stress was linked to pain severity and/or functional impairment (11-14). 
These findings suggest that stress can indeed exacerbate symptoms in patients with FMS. However, 
the validity of these findings may be questioned, since a peak- and end-bias in the retrospective 
reporting of symptoms has been discussed in the pain literature (15), meaning that the most intense 
and recent pain experience influences reports. Moreover, the generalizability of single occasion 
measurements in a survey or in the laboratory to real-life processes is limited. 
Answering the question on whether stress exacerbates symptoms of FMS demands 
measuring pain close to the actual experience in a repeated, ecologically valid manner. Ambulatory 
assessment approaches offer the possibility of addressing all these issues simultaneously (16). 
Regarding FMS, only one study has approached the named question using such a design (17), finding 
no association between stress and pain experience. However, this study used aggregated stress and 
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pain scores. Thus, one could argue that a potential relationship was missed due to information loss as 
a consequence of data aggregation. In other words, the question on how stress possibly translates 
into the experience of more intense pain over the day in patients with FMS remains unanswered. 
The two major stress-responsive systems might be involved in this process i.e. the 
hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). Dysregulations 
of both systems have been hypothesized to contribute to core symptoms of FMS. At the central level, 
blunted corticotropin-releasing hormone and locus coeruleus/norepinephrine-sympathetic systems are 
known to interact and enhance pain via descending analgesic pathways (18). Evidence has 
accumulated for patients with FMS to be characterized by hypocortisolism (19). In terms of the SNS, 
findings generally point to elevated sympathetic activity and attenuated reactivity in patients with FMS 
(20). Importantly, both cortisol and catecholamines regulate central and peripheral processes involved 
in pain sensation, including inflammation (21).  
However, although widely assumed in theory, there is hardly any empirical evidence for both 
systems to operate as exacerbating factors of pain in FMS, at least not on a momentary basis. In fact, 
only one ambulatory assessment study has examined the relationship between concurrent cortisol 
activity and pain intensity (22), reporting a positive association within the first hour of awakening, but 
not later during the day. However, although valuable insight was gained from this study, the 
measurement period was rather short (two days). 
Taken together, research lacks a detailed characterization of the proposed role of stress as an 
exacerbating factor of pain in real life. Also, while there is ample evidence for a general dysregulation 
of the HPA axis and SNS in FMS, almost nothing is known about the role of these systems in the daily 
fluctuations of pain levels. 
Therefore, the first aim of the presented study was to examine the relationship between stress 
and pain in the everyday lives of persons’ with FMS. More specifically, we assumed increases in 
stress to predict increases of pain. However, since high pain levels may themselves act as a stressor 
in persons with FMS, we additionally tested whether increases in pain preceded increases in stress 
levels. Secondly, we were interested in examining the role of biological stress markers as mediators of 
these prospective associations. Based on the evidence mentioned above, we expected 1a) 
momentary stress to predict momentary pain, 1b) stress reported at the previous measurement time 
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point to predict momentary pain, and vice versa, 1c), previous-day mean stress levels to predict mean 
daily pain levels, and vice versa, and 2) momentary and daily activity of the HPA axis and SNS to 
mediate these assumed associations. Although a female preponderance regarding FMS is not 
substantiated by more recent epidemiological studies, the severity of symptoms seems to be more 
pronounced in women, which is why we decided to only include women into our study. As it is hardly 
feasible to assess central parts of the HPA axis and SNS in an ambulatory assessment study, we 
decided to measure salivary cortisol and alpha-amylase (sAA) as easily accessible end products of 
these systems. 
 
Participants and methods 
Participants 
Interested persons were recruited via advertisements in newspapers, through flyers posted in offices 
of general physicians and rheumatologists, and via self-help groups. Persons were included if they 
were female, fluent in German, and between 18 and 65 years of age. In addition, all participants 
needed to satisfy the Fibromyalgia Research Criteria (23), a modified version of the ACR 2010 
diagnostic criteria (1; see below). Exclusion criteria were body mass index (BMI) above 30 kg/m²; 
pregnancy, breast feeding, or irregular menstruation cycles, current episode of major depression, any 
major psychiatric disorder (substance abuse within the past two years, lifetime psychotic or bipolar 
disorder, eating disorder within the past five years), and any non-medicated medical condition known 
to affect endocrine or autonomic functioning. The total sample consisted of 32 women. All women 
received 80 Euro for participation. The study was carried out in accordance with the Declaration of 
Helsinki and was approved by the local ethics committee (Department of Psychology, University of 
Marburg, Germany). All participants provided written informed consent. 
 
Study protocol 
We used an ambulatory assessment design. Participants were pre-screened for eligibility via 
telephone and informed about the study aims and procedures. Eligibility was confirmed during an 
initial study appointment and several questionnaires were administered. Participants were then 
instructed on how to handle an electronic diary device (iPod touch®) to answer several questions at 
six prompts throughout the day (upon awakening, +30 min, 11 a.m., 2 p.m., 6 p.m., 9 p.m.). Similarly, 
they were trained in the collection of saliva samples, which had to be collected immediately after 
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answering the electronic diary questions. Importantly, participants were asked to complete the first 
entries and provide the first saliva sample immediately upon awakening (before doing anything else). 
All participants completed a test run in front of the research assistant to ensure that they understood 
the procedures. They received a manual on how to handle the devices, also including a detail 
explanation of all items and a telephone number they could call in case of technical problems. The 
assessments took place over a period of 14 consecutive days. The follow-up appointment consisted of 
a post-monitoring interview and filling in another set of questionnaires.  
 
Questionnaires on patient characteristics 
Detailed medical and gynecological histories were obtained. Participants brought a list of their current 
medication to the initial study appointment. These documents were checked for compatibility with 
eligibility criteria. 
For FMS diagnosis and assessment of FMS severity, participants were asked in how many of 
19 areas they had experienced pain for the last three months (Widespread Pain Index; WPI). The 
German version of the Regional Pain Scale (24) was utilized to measure pain in each area on a scale 
from 0 (“no pain”) to 4 (“severe pain”). Furthermore, participants were asked to indicate the level of 
severity of fatigue, waking unrefreshed, and cognitive symptoms on a scale from 0 (“no problems”) to 
3 (“severe problems”) during the past week and the presence (“no” vs. “yes”) of headaches, pain or 
cramps in the lower abdomen, and depression in the past six months (Symptom Severity Score; SSS). 
The symptoms had to be present at a similar level for at least three months and the Fibromyalgia 
Research Criteria were satisfied if the WPI was higher than or equal to 7 and the SSS higher than or 
equal to 5, or if the WPI was between 3 and 6 and the SSS higher or equal to 9 (23). 
The German version of the Patient Health Questionnaire 9 (PHQ-9; 25) was used to screen for 
major depression and as a measure of depression. We excluded any potential participants reporting 
depressed mood or anhedonia on “several days” over the past two weeks.  
As evidence suggests that childhood abuse and neglect have stress-sensitizing effects (26), 
the German version of the short Childhood Trauma Questionnaire (CTQ; 27) was administered to all 
participants. The total score of childhood trauma was calculated by adding up all items. For similar 
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reasons, chronic stress was measured via the screening version of the Trier Inventory for the 
Assessment of Chronic Stress (SSCS; 28), and a sum score was computed. 
 
Momentary stress and pain (ambulatory assessment)All items were presented using the application 
iDialogPad (G. Mutz, University of Cologne, Germany). Momentary stress (“At the moment, I feel 
stressed”) was scored on a five point Likert scale ranging from 0 (“not at all”) to 4 (“very much”). 
Momentary pain was rated on a visual analogue scale (VAS) from 0 to 100 (“At the moment, I am in 
no pain” vs. “At the moment, I am in the most intense pain possible”). Control questions concerned the 
amount of physical activity within the last two hours (VAS from 0 to 100; “not at all active” vs. “active a 
lot”), the participants’ eating, drinking, and smoking behavior, and intake of medication (dichotomous 
variables; 0 “no” vs. 1 “yes”). 
 
Momentary cortisol and alpha-amylase (ambulatory assessment) 
Saliva samples were collected using the SaliCap® system (IBL, Hamburg, Germany). In brief, 
participants were asked to collect saliva for two minutes in their mouths and subsequently salivate into 
a pre-labeled polypropylene tube via a straw. They were told to store saliva samples in their freezers 
or refrigerators and return them to our laboratory at the follow-up appointment. 
All analyses were conducted at our laboratory (Biochemical Laboratory of the Department of 
Clinical Biopsychology, University of Marburg). Samples were kept frozen at -20°C. Cortisol levels 
were measured using a commercially available enzyme-linked immunoassay (IBL, Hamburg, 
Germany). Salivary alpha-amylase activity was measured using a kinetic colorimetric test and 
reagents from Roche (Roche Diagnostics, Mannheim, Germany). Inter- and intra-assay variance for 
both assays was below 10%. 
We calculated the cortisol (CAR) and alpha-amylase awakening response (AAR) by 
subtracting the first from the second measurement time point. The CAR refers to a rise in cortisol 
within 30 to 45 minutes after awakening, while the AAR represents a decline within the same time 
frame. Both the CAR and AAR have been associated with clinical conditions such as post-traumatic 
stress disorder and chronic fatigue syndrome (29, 30). In addition, slopes and areas under the curves 
(AUCs) were computed to measure total daily cortisol output and diurnal dynamics, respectively (31). 
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Statistical analysis 
We used two-level hierarchical linear modeling (HLM 7, Scientific Software International Inc., 
Lincolnwood, USA) in terms of statistical analyses. Stress, cortisol, sAA, and pain (i.e., all momentary 
assessments) were considered level one variables. Intake of food and drink, smoking, the amount of 
physical activity (all within the last two hours), salivary flow rate and time since awakening  were 
treated as potentially confounding variables on level one. On level two, age, BMI, duration of FMS, 
number of pain sites (WPI), depression (PHQ-9), childhood trauma (CTQ), and chronic stress (SSCS) 
were included into the analyses (i.e., all participant characteristics). Each analysis was conducted 
twice: within days (84 momentary assessments per participant) and between days (14 aggregated 
assessments per participant). For each analysis, a different set of covariates and level two variables 
was considered relevant; these are reported in the tables of the results section. 
Two participants had completely missing iPod touch® data sets due to technical problems and 
were thus excluded from all analyses. One participant had a slightly higher BMI (31.2) than indicated 
during the telephone interview, and a review of the medical histories revealed that two participants had 
inflammatory respiratory diseases and one person had Hashimoto’s thyroiditis. However, since this 
had no impact on our results, we included these participants into all following analyses. All cortisol and 
sAA data were checked for incompliance with the protocol by the use of electronic time stamps. 
Incompliance was considered present if the second saliva sample was collected later than 45 minutes 
after the first sample; for the remaining samples (11 a.m., 2 p.m., 6 p.m., and 9 p.m.), collection later 
than 60 minutes after the scheduled time point was considered incompliant behavior (32). 
Consequently, 229 values out of 2’520 were eliminated and treated as missing values. 
For the within-day analyses, we omitted the second measurement time point (30 min after 
awakening) as we intended to test the effects of the CAR and AAR in separate analyses (see below). 
Calculations of the HLM 7 software were based on 1’885 to 1’966 out of 2’100 data points depending 
on the model that was being tested (listwise deletion of missing values). For our prospective analyses, 
we time-lagged the predictor variables stress and pain, respectively. As result of this, the data set was 
again reduced (deletion of the first entry on each day). In these analyses, 1’541 out of 1’980 possible 
data points were used by the HLM 7 software. 
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For the between-day analyses, all missing values regarding salivary cortisol and amylase were 
replaced before running HLM analysis. This was in order to have enough data for HLM analysis after 
the calculation of the CAR, AAR, the AUCs, and slopes. A total of 219 (cortisol) and 226 (alpha-
amylase) out of 2’520 possible values were replaced by the mean of the respective participant at that 
time of day. Mean daily stress and pain were only calculated if at least two entries had been made on 
the respective day. HLM 7 used 413 out of 420 (383 out of 390 in time-lagged analyses) data points 
for calculations. On level two, five values were replaced with the mean value of the sample. 
The Kolmogorov-Smirnov test revealed that a few of the measurement time points of the 
outcome variables were not normally distributed. We thus relied on coefficients with robust standard 
errors whenever they differed from unstandardized coefficients (33). Our testing of hypotheses 
consisted of several steps in accordance with Woltman et al. (33). Pseudo-R² was determined as a 
means of variance estimation for each predictor in question (34). The following equation was used: 
Pseudo-R² = (σ²reference model – σ²final model)/σ²reference model, with the reference model being the final model 
excluding the specified predictor. Mediation analyses were based on the steps suggested by Kenny 
and Korchmaros (35, 36). We were specifically interested in testing whether previous stress predicted 
momentary pain via momentary cortisol and sAA. In addition, we aimed at testing whether previous-
day stress predicted daily pain via daily activity of the HPA axis and SNS. Data are presented as 
mean ± standard deviation (SD). For descriptive purposes, figures are provided using mean and 
standard error values. Overall level of significance was defined as p < .05. 
 
Results 
Descriptive data 
Participants’ mean age was 50.7 years (± 9.9) and their average BMI was 25.2 kg/m
2 
(± 2.9). Eight 
(26.7%) participants were on antidepressants, six (20.0%) on thyroid medication, three (10.0%) took 
antihypertensives, two (6.7%) took analgesics, and ten (33.3%) took other medication (e.g., 
omeprazole). They had suffered from widespread pain for 10.2 (± 7.2) years on average, had pain in 
11.6 (± 4.0) out of 19 possible sites, and rated their symptoms severity as 8.2 (± 2.0) out of a 
maximum score of 12. In accordance with our eligibility criteria, participants were only mildly 
depressed (PHQ-9 score of 8.7 ± 3.8). They had a score of 63.3 (± 24.1 out of a 155 maximum score) 
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on the CTQ and slightly elevated levels of chronic stress (25.3 ± 7.4) when compared to the general 
population. 
Over the day, momentary stress ranged from 1.1 (± 0.9) to 1.7 (± 1.1) on a scale from 0 to 4, 
indicating low to medium levels of stress (see Figure 1). The lowest levels were observed at 
awakening and the highest levels at 2 p.m. In contrast, momentary pain, measured on a scale from 0 
to 100, was highest upon awakening (50.1 ± 24.7) and lowest at 2 p.m. (46.3 ± 26.3; see Figure 2).. 
As can be seen in Figure 3, overall, characteristic daily salivary cortisol and sAA profiles including a 
CAR and AAR were present in our sample of females with FMS. 
 
Effects of stress on pain 
The final models of the stress on pain analyses are reported in Table 1. In line with our expectations, 
we found a positive association between momentary stress and momentary pain, even when physical 
activity, the intake of medication, and time since awakening were controlled for (UC = 4.60, p < .001). 
This means that the more stress a participant experienced, the higher her concurrent pain ratings. The 
final intercept as outcome model explained 16% of variance in momentary pain levels (8% was 
explained by stress alone). 
We then explored whether stress reported at the previous measurement time point predicted 
momentary pain. This association was again positive and statistically significant, even when 
controlling for the effects of momentary stress, physical activity, intake of medication, and time since 
awakening (UC = 1.62, p = .002). This means that the higher a participant’s stress level at one time 
point the more pain she experienced three to four hours later. The final model explained 19% of total 
momentary pain variance (1% was explained by stress at the previous measurement time point). 
Finally, we evaluated whether previous-day mean stress levels were predictive of mean daily 
pain levels. This association was not significant when mean daily stress levels were controlled for (UC 
= 0.59, p = .581), indicating that stress levels on one day had no implications on the pain levels of the 
following day. 
 
Effects of pain on stress 
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The final models regarding the effects of pain on stress are reported in Table 2. As we had already 
found a concurrent relationship between momentary pain and stress (reported above), we directly 
tested whether pain reported at the previous measurement time point was able to predict momentary 
stress. This association was not significant when controlling for momentary pain, physical activity, and 
time since awakening (UC < 0.01, p = .083). This means that pain at one time point failed to predict 
stress levels three to four hours later. 
Finally, we evaluated whether previous-day mean pain levels predicted mean daily stress 
levels. The association was non-significant when considering mean daily pain levels (UC < 0.01, p = 
.707), indicating that pain levels on one day were independent of stress levels on the next day. 
 
Salivary cortisol as a mediator of the stress on pain association 
All models including cortisol are shown in Table 3. Momentary cortisol and momentary pain were 
correlated when physical activity, intake of medication, and time since awakening were considered 
(UC = 0.28, p = .008). This means that the higher a participant’s cortisol level, the more intense her 
concurrent pain experience. Interestingly, a negative interaction term combining cortisol and time 
since awakening (UC < -.01, p = .006) indicated that this relationship was reversed with increasing 
hours. The final model explained 11% of variance in momentary pain levels (2% by cortisol alone). 
However, as stress was not related to momentary cortisol, no mediation analyses were computed. 
Next, we tested whether the CAR, AUC, and slope were predictive of mean daily pain levels. 
No significant relationships whatsoever became apparent between the CAR (UC = - 0.06, p = .225), 
the AUC (UC < 0.01, p = .101), the slope (UC = -82.17, p = .152), and mean daily pain levels. This 
indicates that neither cortisol output nor its diurnal dynamic were associated with same-day pain 
levels. 
 
Salivary alpha-amylase as a mediator of the effect of stress on pain 
We used the same procedures as with cortisol to explore whether alpha-amylase mediated the stress 
- pain relationship. Momentary sAA was not related to pain when controlling for physical activity, the 
intake of medication, and time of day (UC = -0.01, p = .199; Table 4).  
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Next, we tested whether the same-day AAR, AUC, and slope were predictive of mean pain 
levels. Again the AAR had no significant impact on mean pain levels (UC = < -0.01, p = .980), and 
neither did the AUC (UC = < 0.01, p = .692) or slope (UC = 1.78, p = .557). This means that neither 
sAA output nor its diurnal dynamic were related to same-day pain levels. 
 
Discussion 
Three findings emerge from our study: first, we identified stress as a powerful precursor of momentary 
pain in the everyday lives of participants with FMS. Second, there was no evidence for pain to be 
similarly predictive of momentary stress. Third, cortisol but not and alpha-amylase impacted on pain 
on a momentary basis. None of our positive results was mirrored on a more aggregated level 
(between-day analyses). 
Our results replicate and extend the results of various survey studies which suggest that 
stress may be a perpetuating factor in FMS. However, none of these studies examined stress and 
pain as they interact over the day. Using an ecologically valid momentary assessment design, we 
were able to show that stress is in fact an important exacerbating (and thus potentially perpetuating) 
factor of pain levels in the everyday lives of persons with FMS. Pain, on the other hand, was 
concurrently linked to stress, but failed to predict it up to several hours later. One explanation for the 
fact that pain was not equally powerful in eliciting stress is that some of our participants may have 
been so called ‘adaptive copers’ (37). This subgroup of patients with FMS is characterized by low pain 
intensity, low impairment, and little comorbidity with mental disorders (38). Our exclusion of major 
mental disorders including current episodes of major depression may therefore have enhanced the 
proportion of adaptive copers in our sample. Another explanation is that, instead of stress, pain 
caused emotional distress (e.g., feeling depressed or anxious), which is conceptually distinct and has 
been shown in a similar study in patients with FMS (39).  
As the corticotropin-releasing hormone and locus coeruleus/norepinephrine-sympathetic 
systems are involved in regulating pain via descending pathways, and as both systems interact with 
the immune system, we were interested in whether momentary cortisol and alpha-amylase levels were 
associated with momentary pain levels. Our findings are in line with McLean et al. (22), who found a 
positive correlation between cortisol levels within one hour of awakening and pain. One of the most 
robust findings regarding HPA axis activity in FMS is an altered negative feedback sensitivity, which 
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seems increased in these patients (40). It is tempting to assume that the corticotropin-releasing 
hormone system is hyper-responsive to the central effects of cortisol, which, in concert with a 
hypoactive locus coeruleus/norepinephrine-sympathetic systems system, results in a loss of pain 
inhibitory effects via descending pathways (19) However, as no causality can be implied by our 
findings, this remains speculative. Another pathway via which cortisol can affect pain levels is through 
glucocorticoid receptors on numerous cells of the immune system. In fact, a recent report suggests 
that monocytes of patients with FMS exhibit reduced glucocorticoid sensitivity (41), meaning that they 
are not responsive enough to the immune-suppressive effects of circulating cortisol. 
Our study offers a number of strengths. First, the ambulatory assessment approach allowed 
us to explore potential mechanisms underlying FMS as they operate in real life. Second, our two week 
assessment period with six daily assessments enabled us to study the exacerbation of pain in FMS in 
great detail and in a repeated fashion. Both ecological validity and reliability of our findings are thus 
likely to be high. Third, we controlled for a variety of potential confounders of momentary assessments 
(e.g., intake of medication). Still, several limitations need to be acknowledged. First, male persons 
were excluded; our findings are therefore not representative for the general population of persons with 
FMS. Second, we excluded subjects with a current episode of major depression. Although this was 
necessary to control for effects of depression on cortisol levels, it limits the ecological validity of our 
findings as the comorbidity of FMS with major depression is rather high (42). Third, an obvious 
limitation inherent in any ambulatory assessment design is the lack of internal validity. Investigations 
into the stress - pain relationship under highly controlled conditions are thus an important addition to 
the findings we present here. 
Although our sample size is comparable to or even bigger than similar ambulatory assessment 
studies in persons with FMS, a replication of our findings is warranted. Furthermore, it would be 
interesting to identify the exact reasons responsible for elevations in momentary stress levels. Our 
findings highlight the general importance of stress management interventions in patients with FMS. 
However, knowing what kind of stressors operate as pain exacerbating factors in these patients would 
allow for cognitive-behavior therapy to specifically target these stressors and potentially increase its 
efficacy. Moreover, it is of great importance to further explore the mechanisms responsible for the pain 
exacerbating effect of stress. To this end, it may be informative to additionally perform event-based 
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measurements in future ambulatory assessment studies, as this would allow looking into possible 
alterations in patients’ responses as stressors occur.  
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Table 1 Final hierarchical linear models predicting pain by stress, using restricted maximum likelihood; residuals were set free whenever there were significant 
random effects 
 Fixed effects Random effects 
 UC SE t-ratio p SD Variance 
component 
χ² p 
Momentary stress on pain         
Intercept 47.08 3.27 14.38 < .001 15.57 242.26 1941.13 < .001 
Age 0.84 0.26 3.31 .003     
Regular intake of antidepressants -6.21 4.81 -1.29 .210     
Regular intake of antihypertensives 13.10 5.60 2.34 .029     
Regular intake of analgesics 6.99 5.29 1.32 .200     
Number of pain sites (WPI) 2.12 0.70 3.04 .006     
Childhood trauma (CTQ) -0.02 0.08 -0.21 .833     
Chronic stress (SSCS) 0.65 0.31 2.07 .051     
Momentary stress 4.60 0.64 7.20 < .001 2.84 8.05 79.59 < .001 
Time since awakening < 0.01 < 0.01 0.58 .569 0.01 < 0.01 104.05 < .001 
Physical activity -0.05 0.02 -2.25 .032 0.10 0.01 91.87 < .001 
Intake of medication 5.68 2.81 2.02 .044     
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Preceding stress on pain         
Intercept 46.30 3.49 13.28 < .001 16.38 268.34 1743.90 < .001 
Age 0.60 0.29 2.07 .050     
Regular intake of antidepressants -5.13 6.42 -0.80 .433     
Regular intake of antihypertensives 7.45 4.51 1.65 .113     
Regular intake of analgesics 12.62 6.06 2.08 .049     
Number of pain sites (WPI) 1.92 0.74 2.58 .017     
Childhood trauma (CTQ) -0.05 0.10 -0.55 .591     
Chronic stress (SSCS) 0.94 0.32 2.89 .008     
Momentary stress 4.66 0.67 6.99 < .001 3.14 9.85 77.92 < .001 
Preceding stress 1.62 0.53 3.03 .002     
Time since awakening 0.01 < 0.01 3.63 .001 < 0.01 < 0.01 51.52 .006 
Physical activity 0.01 0.03 0.45 .657 0.13 0.02 95.80 < .001 
Intake of medication 6.70 2.77 2.42 .016     
         
Previous-day stress on pain         
Intercept 46.94 3.28 14.33 < .001 15.14 229.37 841.02 < .001 
Age 0.93 0.28 3.32 .003     
Regular intake of antidepressants -4.15 7.09 -0.59 .565     
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Regular intake of antihypertensives 10.82 7.36 1.47 .156     
Regular intake of analgesics 14.42 8.92 1.62 .120     
Number of pain sites (WPI) 1.78 0.80 2.22 .037     
Childhood trauma (CTQ) -0.04 0.12 -0.32 .752     
Chronic stress (SSCS) 0.94 0.35 2.68 .014     
Previous-day stress 0.59 1.07 0.55 .581     
Same-day stress 7.34 1.39 5.30 < .001     
CTQ = Childhood Trauma Questionnaire, SD = standard deviation, SE = standard error, SSCS = Screening version of the Trier Inventory for the Assessment of 
Chronic Stress, UC = unstandardized coefficient, WPI = Widespread Pain Index; for all variables, higher values imply a higher level of the respective construct 
  
Stress and pain in fibromyalgia syndrome 21 
Table 2 Final hierarchical linear models predicting stress by pain, using restricted maximum likelihood; residuals were set free whenever there were significant 
random effects 
 Fixed effects Random effects 
 UC SE t-ratio p SD Variance 
component 
χ² p 
Preceding pain on stress         
Intercept 1.52 0.10 14.63 < .001 0.59 0.34 810.05 < .001 
Childhood trauma (CTQ) -0.01 < 0.01 -1.75 .092     
Chronic stress (SSCS) 0.04 0.02 2.54 .017     
Momentary pain 0.02 < 0.01 7.10 < .001 0.01 < 0.01 75.87 < .001 
Preceding pain < 0.01 < 0.01 1.73 .083     
Physical activity 0.01 < 0.01 4.48 < .001 0.01 < 0.01 83.62 < .001 
Time since awakening < -0.01 < 0.01 - 5.70 < .001     
         
Previous-day pain on stress         
Intercept 1.41 0.10 14.75 < .001 0.54 0.29 529.41 < .001 
Childhood trauma (CTQ) -0.01 < 0.01 -1.90 .068     
Chronic stress (SSCS) 0.04 0.01 2.80 .009     
Previous-day pain < 0.01 < 0.01 0.38 .707     
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Same-day pain 0.02 < 0.01 6.52 < .001     
CTQ = Childhood Trauma Questionnaire, SD = standard deviation, SE = standard error, SSCS = Screening version of the Trier Inventory for the Assessment of 
Chronic Stress, UC = unstandardized coefficient; for all variables, higher values imply a higher level of the respective construct 
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Table 3 Final hierarchical linear models in terms of cortisol, using restricted maximum likelihood; residuals were set free whenever there were significant random 
effects 
 Fixed effects Random effects 
 UC SE t-ratio p SD Variance 
component 
χ² p 
Momentary cortisol on pain         
Intercept 47.23 3.44 13.73 < .001 16.18 261.93 1909.29 < .001 
Age 1.15 0.27 4.35 < .001     
Regular intake of antidepressants -7.26 5.22 -1.4 .179     
Regular intake of antihypertensives 14.59 4.65 3.14 .005     
Regular intake of analgesics 4.44 4.12 1.08 .293     
Number of pain sites (WPI) 2.47 0.67 3.67 .001     
Childhood trauma (CTQ) 0.06 0.08 0.84 .411     
Chronic stress (SSCS) 0.88 0.27 3.22 .004     
Momentary cortisol 0.28 0.10 2.87 .008 0.29 0.08 51.44 .006 
Time since awakening 0.01 < 0.01 2.92 .007 0.01 < 0.01 76.77 < .001 
Momentary cortisol*time since awakening < -0.01 < 0.01 -2.74 .006     
Physical activity 0.01 0.03 0.32 .749 0.11 0.01 92.94 < .001 
Intake of medication 7.52 3.13 2.40 .017     
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CAR on pain         
Intercept 46.92 3.24 14.46 < .001 15.01 225.33 743.51 < .001 
Age 0.89 0.28 3.16 .005     
Regular intake of antidepressants -3.68 7.17 -0.51 .613     
Regular intake of antihypertensives 10.47 7.10 1.47 .155     
Regular intake of analgesics 13.76 8.49 1.62 .119     
Number of pain sites (WPI) 1.78 0.80 2.23 .036     
Childhood trauma (CTQ) -0.04 0.11 -0.40 .694     
Chronic stress (SSCS) 0.96 0.34 2.78 .011     
CAR -0.06 0.05 -1.22 .225     
         
AUC (cortisol) on pain         
Intercept 46.93 3.25 14.46 < .001 15.01 225.38 748.82 < .001 
Age 0.89 0.28 3.16 .005     
Regular intake of antidepressants -3.68 7.17 -0.51 .613     
Regular intake of antihypertensives 10.47 7.10 1.47 .155     
Regular intake of analgesics 13.76 8.49 1.62 .119     
Number of pain sites (WPI) 1.78 0.80 2.23 .036     
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Childhood trauma (CTQ) -0.04 0.11 -0.40 .694     
Chronic stress (SSCS) 0.96 0.34 2.78 .011     
AUC < 0.01 < 0.01 1.64 .101     
         
Slope (cortisol) on pain         
Intercept 46.93 3.25 14.46 < .001 15.01 225.34 745.25 < .001 
Age 0.89 0.28 3.16 .005     
Regular intake of antidepressants -3.68 7.17 -0.51 .613     
Regular intake of antihypertensives 10.47 7.10 1.57 .155     
Regular intake of analgesics 13.76 8.49 1.62 .119     
Number of pain sites (WPI) 1.78 0.80 2.23 .036     
Childhood trauma (CTQ) -0.04 0.11 -0.40 .694     
Chronic stress (SSCS) 0.96 0.34 2.78 .011     
Slope -82.17 57.29 -1.43 .152     
AUC = area under the curve, CAR = cortisol awakening response, CTQ = Childhood Trauma Questionnaire, SD = standard deviation, SE = standard error, SSCS 
= Screening version of the Trier Inventory for the Assessment of Chronic Stress, UC = unstandardized coefficient, WPI = Widespread Pain Index; for all variables, 
higher values imply a higher level of the respective construct 
  
Stress and pain in fibromyalgia syndrome 26 
Table 4 Final hierarchical linear models in terms of alpha-amylase, using restricted maximum likelihood; residuals were set free whenever there were significant 
random effects 
 Fixed effects Random effects 
 UC SE t-ratio p SD Variance 
component 
χ² p 
Momentary alpha-amylase on pain         
Intercept 47.10 3.33 14.14 < .001 16.00 255.98 1771.68 < .001 
Age 1.10 0.26 4.17 < .001     
Regular intake of antidepressants - 7.90 5.52 -1.43 .166     
Regular intake of antihypertensives 17.74 6.90 2.57 .017     
Regular intake of analgesics 4.94 6.41 0.77 .449     
Number of pain sites (WPI) 2.14 0.73 2.92 .008     
Childhood trauma (CTQ) 0.04 0.09 0.52 .610     
Chronic stress (SSCS) 0.88 0.30 2.94 .008     
Momentary alpha-amylase -0.01 0.01 -1.29 .199     
Time since awakening < -0.01 < 0.01 -0.29 .773 0.01 < 0.01 106.49 < .001 
Momentary amylase*time since awakening 0.01 0.01 0.82 .412     
Physical activity -0.01 0.02 -0.54 .597 0.11 0.01 102.10 < .001 
Intake of medication 7.01 3.26 2.15 .032     
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AAR on pain         
Intercept 46.93 3.25 14.46 < .001 15.01 225.30 740.09 < .001 
Age 0.89 0.28 3.16 .005     
Regular intake of antidepressants -3.68 7.17 -0.51 .613     
Regular intake of antihypertensives 10.47 7.10 1.47 .155     
Regular intake of analgesics 13.76 8.49 1.62 .119     
Number of pain sites (WPI) 1.78 0.80 2.23 .036     
Childhood trauma (CTQ) -0.04 0.11 -0.40 .694     
Chronic stress (SSCS) 0.96 0.34 2.78 .011     
AAR < 0.01 < 0.01 0.03 .980     
         
AUC (alpha-amylase) on pain         
Intercept 46.93 3.25 14.46 < .001 15.01 225.30 740.25 < .001 
Age 0.89 0.28 3.16 .005     
Regular intake of antidepressants -3.68 7.17 -0.51 .613     
Regular intake of antihypertensives 10.47 7.10 1.47 .155     
Regular intake of analgesics 13.76 8.49 1.62 .119     
Number of pain sites (WPI) 1.78 0.80 2.23 .036     
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Childhood trauma (CTQ) -0.04 0.11 -0.40 .694     
Chronic stress (SSCS) 0.96 0.34 2.78 .011     
AUC < 0.01 < 0.01 0.40 .692     
         
Slope (alpha-amylase) on pain         
Intercept 46.93 3.25 14.46 < .001 15.01 225.30 740.71 < .001 
Age 0.89 0.28 3.16 .005     
Regular intake of antidepressants -3.68 7.17 -0.51 .613     
Regular intake of antihypertensives 10.47 7.10 1.47 .155     
Regular intake of analgesics 13.76 8.49 1.62 .119     
Number of pain sites (WPI) 1.78 0.80 2.23 .036     
Childhood trauma (CTQ) -0.04 0.11 -0.40 .694     
Chronic stress (SSCS) 0.96 0.34 2.78 .011     
Slope 1.78 3.04 0.59 .557     
AAR = alpha-amylase awakening response, AUC = area under the curve, CTQ = Childhood Trauma Questionnaire, SD = standard deviation, SE = standard 
error, SSCS = Screening version of the Trier Inventory for the Assessment of Chronic Stress, UC = unstandardized coefficient, WPI = Widespread Pain Index; for 
all variables, higher values imply a higher level of the respective construct 
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Figure legends 
Figure 1 Daily stress profile, averaged across 14 days of measurement (mean ± standard error of 
mean) 
Figure 2 Daily pain profile, averaged across 14 days of measurement (mean ± standard error of 
mean) 
Figure 3 Daily cortisol and alpha-amylase profiles, averaged across 14 days of measurement (mean ± 
standard error of mean) 
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Figure 1 Daily stress profile, averaged across 14 days of measurement (mean ± standard error of 
mean) 
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Figure 2 Daily pain profile, averaged across 14 days of measurement (mean ± standard error of 
mean) 
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Abstract
Background: Stress has been suggested to play a role in the development and perpetuation of functional somatic
syndromes. The mechanisms of how this might occur are not clear.
Purpose: We propose a multi-dimensional stress model which posits that childhood trauma increases adult stress reactivity
(i.e., an individual’s tendency to respond strongly to stressors) and reduces resilience (e.g., the belief in one’s competence).
This in turn facilitates the manifestation of functional somatic syndromes via chronic stress. We tested this model cross-
sectionally and prospectively.
Methods: Young adults participated in a web survey at two time points. Structural equation modeling was used to test our
model. The final sample consisted of 39054 participants, and 429 of these participated in the follow-up survey.
Results: Our proposed model fit the data in the cross-sectional (x2(21) = 48.808, p,.001, CFI = .995, TLI = .992, RMSEA = .021,
90% CI [.013.029]) and prospective analyses (x2(21) = 32.675, p,.05, CFI = .982, TLI = .969, RMSEA = .036, 90% CI [.001.059]).
Discussion: Our findings have several clinical implications, suggesting a role for stress management training in the
prevention and treatment of functional somatic syndromes.
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Introduction
The term ‘functional somatic syndrome’ (FSS) refers to various
clusters of somatic symptoms (e.g., fatigue, abdominal or
musculoskeletal pain) that cannot be adequately explained by
means of modern medicine (‘medically unexplained symptoms’).
Conditions such as chronic fatigue syndrome, fibromyalgia
syndrome, or irritable bowel syndrome represent frequently
occurring disorders that fall into this broad category. Functional
somatic syndromes as well as medically unexplained symptoms are
prevalent in the general population [1–3] and account for a large
proportion of health care visits both in primary [4–6] and
secondary care [7]. They cause substantial suffering in patients
and lead to a considerable amount of direct (e.g., medical care)
and indirect (e.g., lost productivity) costs [8–10].
Despite remarkable efforts in attempting to elucidate patho-
physiological mechanisms in FSS, the exact determinants and
processes underlying these debilitating disorders are still unknown.
Current knowledge points to a number of predisposing, precip-
itating, and perpetuating factors, such as genetic factors [11–13],
viral infections [14,15], and alterations of visceral and central
sensitivity [16,17]. A prominent line of research has been
dedicated to the role of stress in FSS [18], thus conceptualizing
FSS as ‘stress-related disorders’. The transactional stress theory by
Lazarus and Folkman [19] provides a framework encompassing
several aspects of the stress concept. According to these authors,
stress is understood as a person-environment interaction, involving
a potentially threatening stimulus (i.e., a stressor), and a biological
and psychological stress response [19]. Importantly, this interac-
tion is mediated by complex appraisal processes within the
individual, encompassing an assessment of individual resources to
deal with potentially stressful events [19]. As will be outlined in the
following paragraphs, there is empirical evidence for all of these
theoretical aspects to play a role in FSS.
Events during childhood that are perceived as traumatic (i.e.,
childhood traumas), such as emotional, physical, or sexual abuse
[20], are among the most severe stressors and have been reported
in a substantial number of FSS patients [21]. Unlike mild to
moderate stress, severe early life stress including childhood trauma
is well-known to permanently alter the reactivity of biological
stress-responsive systems in a negative manner [22]. Simliar to its
biological analogue, psychological stress reactivity, which is defined
as an individual’s personal capacity or tendency to respond to
stressors [23], seems to be heightened as a consequence of early life
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stress. For instance, abnormal birth weight reflecting an adverse
prenatal environment was linked to higher levels of psychological
stress reactivity as an older adult [24]. In FSS, it has been reported
that patients feel more tense or stressed after a laboratory stress
test, that is, they show higher levels of psychological stress
reactivity [25,26]. Decades of (mostly biological) research have
documented the effects of childhood trauma on heightened stress
reactivity and subsequent adverse health outcomes [22]. However,
no study has ever tested whether a trauma-induced elevation of
psychological stress reactivity perpetuates or even favors the
development of full-blown FSS. The present study fills this gap.
Apart from the detrimental effects of childhood trauma on stress
reactivity, the impact of early life stress unfolds in another fashion:
in affecting resilience. Initial evidence for a negative association
between levels of childhood trauma and resilience exists in healthy
individuals [27,28]. Resilience can be defined as a positive
personality characteristic that enhances individual adaptation,
including the facets of believing in one’s personal competence and
accepting oneself and one’s life [29]. According to the transac-
tional stress theory [19], personality characteristics, such as
resilience, largely influence appraisal processes that in turn
mediate the stressor-stress response relationship. From this follows
that stressors and resilience are intertwined in predicting stress
reactivity: an individual with high levels of acceptance of him-/
herself is unlikely to lose confidence when being faced with
criticsm, and vice versa. Indeed, in an experimental study using a
laboratory paradigm to induce pain, healthy individuals scoring
high on a resilience scale experienced less stress and even pain
after being exposed to a tourniquet procedure [30]. Regarding
FSS, research demonstrates comparably low overall scores in
associated personality characteristics such as sense of coherence
[31] and self-efficacy [32] in these patients. So far, evidence
indicates that resilience mediates the effect of childhood trauma on
psychological distress in apparenly healthy individuals [33] and
Holocaust survivors [34]. However, we are not aware of any
studies examining these relationships in FSS patients.
At this point, it remains unclear how experiences of childhood
trauma, and (subsequent) alterations in stress reactivity and
resilience influence the development of FSS. One possible
mediating factor is the occurrence of chronic stress. Chronic stress
is characterized by recurring episodes of stress that are often
related to unsatisfied personal needs [35]. In Lazarus and
Folkman’s terms [19], experiencing chronic stress may be the
result of a negative bias in the appraisal of stimuli, that is, to
perceive ambiguous stimuli as a threat [36]. Recent data
demonstrating a linkage between early abusive experiences,
heightened levels of chronic stress, and premenstrual symptoms
suggest a possible origin of these threat appraisals [37]. Similarly, a
cross-sectional survey in a non-clinical sample found evidence for a
positive relationship between stress reactivity with a measure of
chronic stress [38]. Finally, another study conducted in fibromy-
algia patients showed that 53% of the variance in chronic stress
levels could be explained by self-esteem, self-efficacy, and social
support, all of which are known to be associated with resilience
[39].
Elevated levels of chronic stress have repeatedly been reported
in patients suffering from FSS [40,41]. Several mechanisms by
which both traumatic and chronic stress foster the development of
FSS are conceivable. At the biological level, traumatic [42] and
chronic stress [43] result in the epigenetic modification of genes
related to stress-responsive systems. In the long run, this causes
dysregulation of the hypothalamic-pituitary axis, the autonomic
nervous system, and the immune system [22,44]. Notably, all of
these physiological systems seem to be dysregulated in patients
suffering from FSS [18] and might exacerbate symptoms like
fatigue and pain [45]. From a psychological point of view,
medically unexplained symptoms can be regarded as mispercep-
tions and -interpretations of bodily sensations that are generated
by stored memory representations [46]. According to Brown [46],
these representations can have varied origin. For instance,
sensorimotor and emotional concomitants of trauma exposure
are an important source for their development [46]. For this
reason, experiences of childhood trauma might directly be related
to the occurrence of FSS (that are characterized by medically
unexplained symptoms). In addition, a recent study found the
interaction of stress and the perception of stress as ‘dangerous’ or
‘harmful’ to increase reportings of poor health [47]. It is thus likely
that chronic stress leads to emotional arousal and accompanying
bodily sensations that can be subject to misinterpretation [48].
In sum, FSS seem to be associated with the occurrence of
childhood trauma as well as alterations in stress reactivity at the
biological and psychological level. Furthermore, chronic stress
seems to play an important mediating role in translating these
vulnerabilities into FSS. No study has so far targeted multiple
aspects of stress (i.e., childhood trauma, stress reactivity, and
chronic stress) in a large sample. Thus, the interactions between
these variables remain to be specified, and we do not know of any
studies that have included measures of resilience in a comprehen-
sive model describing the role of stress in FSS. In the current
study, we set out to examine the associations between childhood
trauma, stress reactivity, resilience, and chronic stress in FSS in a
sample of young adults. Our conceptual model depicting the
hypothesized associations is illustrated in Figure 1. In brief, our
model posits that the occurrence of childhood trauma takes its toll
on stress reactivity and resilience, which in turn facilitate the
manifestation of FSS via chronic stress. In addition, we assume
that childhood trauma itself is indirectly (via chronic stress) and
directly linked to FSS. Importantly, since a temporal order of
events and changes in personality characteristics is implied in our
model, we wanted to rule out the possibility that stress reactivity,
resilience, and chronic stress were merely elevated as a
consequence of having an FSS. We thus tested our model not
only cross-sectionally, but also prospectively, including its evalu-
ation in new FSS cases. We tested these hypotheses as part of a
bigger study [49].
Methods
Sample and procedures
We have previously described how participants for this study
were recruited [49]. In brief, German speaking students of Swiss
colleges and universities were asked to participate in a web survey
on physical and mental well-being (T0). In addition, the
participants were asked if they wished to participate in a follow-
up survey, and those who agreed were asked to complete the exact
same survey six months later (T1). This enabled us to evaluate
whether experiences of childhood trauma, heightened stress
reactivity, and lower resilience were prospectively related to the
occurrence of chronic stress six months later and whether this in
turn predicted the development (of new) and perpetuation (of
existing) FSS.
Ethics statement
The study was conducted in accordance with the Declaration of
Helsinki. The web survey design was approved by the ethics
committee of the University of Zurich. Written (online) informed
consent was obtained from all participants.
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Measures
We decided to shorten each scale in order to reduce the
complexity of measurement models of the constructs in terms of
the number of parameters to be estimated.
Childhood trauma. To measure childhood abuse and
neglect, we used eight items from the German short version of
the Childhood Trauma Questionnaire [50] that had the highest
factor loadings on the general factor in this sample. The
questionnaire consists of six different domains of childhood
trauma: emotional abuse, physical abuse, sexual abuse, emotional
neglect, physical neglect, and experiences of inconsistency. Of
these, only emotional abuse, neglect, and experiences of inconsis-
tency were represented in our eight selected items. An example
item is: ‘I felt that someone in my family hated me’. Participants
rated items on a five point Likert scale from 1 (never) through 5
(very often). A factor analysis (Principal Axis Analysis; PAA) with
the eight items signaled a one factor solution (eigen value: 3.91;
explained variance: 48.93%). Cronbach’s alpha for these items
was.88. In addition, participants were classified as having
experienced childhood trauma according to recently reported
cut-off scores for Germany [51].
Stress reactivity. We selected eight items from the Stress
Reactivity Scale [52] to measure stress reactivity that had the
highest factor loadings on the general factor. The Stress Reactivity
Scale measures general stress reactivity as well as stress reactivity in
specific domains (social evaluation, social conflicts, failure, work
overload). Moreover, anticipatory stress reactivity, that is, feeling
nervous before a previously announced stressor, and prolonged
stress reactivity, that is, difficulty relaxing after occurrence of a
stressful situation, can be measured with this instrument. Of these,
stress reactivity concerning social conflicts and prolonged stress
reactivity were the only domains that were not reflected by our
choice of items. An exemplary item is: ‘When I9m wrongly
criticized by others I am normally annoyed for a long time’. Items
are rated by marking one out of three statements, leading to a scale
ranging from 0 to 2. According to a PAA, a one-factorial structure
(eigen value: 3.09; explained variance: 38.65%) underlies the items
used in the current study. Internal consistency for these eight items
was.83.
Resilience. To obtain a global measure of resilience, we used
eight items from the German version of the Resilience Scale [53]
with the highest factor loadings. This instrument encompasses
aspects of personal competence (e.g., self-esteem) and acceptance
of self and life (e.g., flexibility). Items are rated on a seven point
Likert scale. An example for an item is: ‘I usually manage one way
or another’. A PAA with our eight selected items indicated a one
factor solution (eigen value: 3.10; explained variance: 38.80%).
Internal consistency was.83.
Chronic stress. To measure chronic stress, we used eight
items from the screening version of the Trier Inventory for the
Assessment of Chronic Stress [35] that had the highest factor
loadings. The Trier Inventory for the Assessment of Chronic
Stress refers to the past three months, measuring different facets of
chronic stress, namely chronic worrying, work and social overload,
excessive demands at work, and lack of social recognition on a five
point Likert scale. An example item is: ‘I do not have enough time
to perform my daily tasks’. The eight items used were based on a
common factor (eigen value: 4.57; explained variance: 57.09%).
Cronbach’s alpha was.91.
Functional somatic syndromes. Details on how FSS were
diagnosed are reported elsewhere [49]. In brief, we administered a
previously developed questionnaire, the Questionnaire on Func-
tional Somatic Syndromes [54]. The German version of this scale
is freely available as a Web supplement to the original article
(http://content.karger.com/ProdukteDB/miscArchiv/000/333/
298/000333298_sm_supplemental_material.pdf). The Question-
naire on Functional Somatic Syndromes consists of three different
parts which are connected via several algorithms. First, a screening
part encompassing various somatic symptoms was presented.
These items represent cardinal symptoms of 17 different FSS.
Symptoms were rated according to frequency of occurrence
(‘never/rarely’, ‘frequently’, ‘almost always/always’). Second, if
participants reported cardinal symptoms that were characteristic
of one FSS (e.g., abdominal pain), additional questions based on
diagnostic criteria, e.g., Rome III [55], were presented. Third,
those who fulfilled the diagnostic criteria of a specific FSS were
surveyed about health care visits (e.g., ‘Did you ever visit a doctor
about your abdominal pain/changes in bowel movement?’).
Participants who responded with ‘no’ were counted as non-cases.
Participants who responded with ‘yes’ were ultimately directed to a
list of items addressing frequent medical exclusionary diagnoses
(‘What diagnosis did your doctor give you?’). Participants were
labeled as having an FSS if they reported that no abnormalities
which might account for their symptoms (e.g., an inflammatory
bowel disease) had been detected by their physician.
Mental disorders. Details on how the presence of mental
disorders was assessed can be found in our previous report [49]. In
Figure 1. Conceptual model for FSS.
doi:10.1371/journal.pone.0111214.g001
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brief, we used the German version of the Patient Health
Questionnaire [56] to screen for the most common mental
disorders, including somatoform syndrome, major depressive
syndrome, anxiety syndrome, alcohol syndrome, and bulimia
nervosa. All questions and algorithms of the PHQ are guided by
DSM-IV criteria [57].
Statistical analyses
We tested our conceptual model (see Figure 1) using a structural
equation modeling (SEM) approach. This approach allowed us to
evaluate how well our hypothesized relationships between a latent
exogeneous variable (childhood trauma), latent mediators (stress
reactivity, resilience, and chronic stress), and a manifest dichot-
omous endogeneous variable (FSS) fit our data. We used item
parceling to form our latent variables [58-61]. More specifically,
we created two parcels for childhood trauma, stress reactivity,
resilience, and chronic stress, with each parcel being based on four
items using an item-to-construct balance approach [58–61]. In
case of unidimensional constructs (see the results of the PAA) the
parceling approach is recommended as a method to reduce the
number of variables and to improve the stability of the parameter
estimates [58–61]. As in our study FSS was a dichotomous
endogenous variable, we used the modified weighted least squares
method (WLSMV) for our analysis [62]. To estimate to what
extent the empirical covariance matrix of the involved variables
could be reproduced by the model, we conducted a x2-Test and
referred to several fit indices: Comparative fit index (CFI), Tucker-
Lewis index (TLI), and root mean square error of approximation
(RMSEA). A CFI $.95, a TLI $.95 as well as an RMSEA #.05
signals a good model fit [63,64]. To test the indirect effects for
statistical significance, we used the conventional Sobel test [65,66].
Since the Sobel test does, however, rest on the often implausible
assumption that both the sampling distribution and indirect effect
is normally distributed, we additionally applied the bias-corrected
bootstrapping approach as recommended by MacKinnon et al.
[67]. The standard errors of the indirect effects and their 95%
confidence intervals were estimated based on 19000 re-samples. In
the results section, we report standard errors and p-values based
on the Sobel Test (see also Table 1 and 2) and confidence intervals
stemming from the bootstrapping approach. All analyses were
conducted using MPlus V7.
Results
Sample characteristics
A total number of N = 69206 participants visited the website and
about 51% of them finished the survey. After the exclusion of
implausible (e.g., survey response duration below 15 minutes) and
incomplete datasets, N = 39054 datasets remained for further
analyses. Of these, 29042 (73.4%) were women and 812 (26.6%)
were men and mean age 24.665.6 (SD) years. The majority
(92.6%) of the participants was not married, and parental
household income was almost uniformly distributed across nine
predefined categories ranging from less than 39000 to more than
109000 Swiss Francs per month (equal intervals across categories).
In our sample, physical neglect (24.7%) and emotional abuse
(19.4%) were the most prevalent forms of trauma. The prevalence
rates of each FSS are reported elsewhere [49]. The most
frequently reported FSS were premenstrual syndrome (112 cases
or 5%), functional dyspepsia (57 cases or 1.9%), premenstrual
dysphoric disorder (34 cases or 1.5%), hyperventilation syndrome
(40 cases or 1.3%), and irritable bowel syndrome (39 cases or
1.3%). In our sample, 15.1% had an alcohol syndrome, 9.0% an
anxiety syndrome, 8.1% a major depressive syndrome, 6.5% had a
somatoform syndrome, and 1.4% had a preliminary diagnosis of
bulimia nervosa. Four hundred twenty-nine participants took part
in the follow-up survey at T1, and these participants did not differ
from those who chose not to participate with regard to gender,
marital status, household income, childhood trauma, stress
reactivity, resilience, and chronic stress (data not shown).
However, this sub-sample was slightly older (25.667.0 vs.
24.465.3 years; t(512.25) =23.36, p= .001). Of the participants
at follow-up, 21 out of 429 (4.9%) had at least one newly
developed FSS (incident cases) and 10 out of 48 (20.8%) were
stable cases reporting at least one FSS.
Model fit
The first cross-sectional model analyzed included all variables as
hypothesized in Figure 1. The model demonstrated good fit
statistics (x2(20) = 50.546, p,.001, CFI = .995, TLI = .991,
RMSEA = .022, 90% CI [.015.030]). The x2-test was significant
for this and the following models, but needs to be interpreted in
the context of the large sample size. No significant direct effect of
childhood trauma on FSS emerged (Beta = .083, SE(Beta) = .050,
p= .101). We thus removed this path and repeated our analysis.
Our second and final cross-sectional model as depicted in Figure 2
fit our data well (x2(21) = 48.808, p,.001, CFI = .995, TLI = .992,
RMSEA = .021, 90% CI [.013.029]) and did not have a significantly
worse fit than the more complex initial model (Dx2 = 1.74, Ddf = 1,
p= .19).
In order to evaluate whether our variables were in fact
predisposing/precipitating and/or perpetuating factors for FSS,
we analyzed our sub-sample of 429 participants that had
participated in the follow-up survey. Again, the direct effect of
childhood trauma on FSS was non-significant (Beta = .052,
SE(Beta) = .064, p= .410) and therefore restricted to zero (see
Figure 3). As it was the case for the cross-sectional version, this
more parsimonious model fitted the data well (x2(21) = 32.676,
p,.05, CFI = .982, TLI = .969, RMSEA = .036, 90% CI
[.001.059]).
Model parameters
All parameter estimates for our cross-sectional and longitudinal
analyses are shown in Tables 1 and 2, respectively. In accordance
with our proposed conceptual model, childhood trauma had a
positive effect on stress reactivity and a negative effect on
resilience. Unsurprisingly, the parts of stress reactivity and
resilience that could not be accounted for by childhood trauma
were negatively related (correlation).
As shown in Tables 1 and 2, our results regarding the direct
effects of childhood trauma, stress reactivity, and resilience on
chronic stress were also in accordance with our assumptions.
Exposure to childhood trauma resulted in more chronic stress at
both time points. The same was true regarding stress reactivity,
whereas being resilient had an opposite effect. Having suffered
from chronic stress during the past three months, in turn,
significantly enhanced the probability of having an FSS.
In line with our mediation hypotheses, stress reactivity (Beta
= .156, p ,.001, 95% CI: 0.115, 0.197) had a positive indirect
effect on FSS via elevated levels of chronic stress, whereas
resilience indirectly lowered the probability of FSS (Beta =2.050,
p,.001, 95% CI: 20.067.20.034) via reduced amount of chronic
stress (indirect effects; see Table 1). As can be seen in Table 2, this
was also true when chronic stress and FSS were measured at T1
(indirect effect of stress reactivity: Beta = .147, p ,.001, 95% CI:
0.065, 0.229; indirect effect of resilience: Beta =2.057, p,.01,
95% CI: 20.113. 20.001). Moreover, the hypothesized indirect
effects of childhood trauma on FSS via chronic stress (Beta = .031,
Stress and Resilience in Functional Somatic Syndromes
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p ,.001, 95% CI:.019,.043), reactivity and chronic stress (Beta
= .041, p,.001, 95% CI:.028,.054), as well as via resilience and
chronic stress (Beta = .012, p,.001, 95% CI:.008,.017) were
significant and in the expected direction. Thus, childhood trauma
increased the probability of having an FSS via three indirect
routes. The indirect effects of childhood trauma on FSS via
chronic stress (Beta = .040, p,.05, 95% CI:.001,.079) and via
reactivity and chronic stress (Beta = .029, p,.01, 95%
CI:.004,.049) could be replicated in the prospective model (Sobel
test and bootstrapping approach). However, the indirect connec-
tion via resilience and chronic stress (Beta = .10, p,.05, 95% CI:
2.003,.023) was only significant when applying the Sobel test.
Discussion
We set out to examine the role of stress in FSS both cross-
sectionally and prospectively. In accordance with our conceptual
model, our data show the occurrence of childhood trauma to be
significantly related to elevated stress reactivity and attenuated
resilience, which in turn predicted the manifestation of FSS via
chronic stress. While we observed an indirect effect of childhood
trauma on the development and perpetuation of FSS via chronic
Table 1. Cross-sectional model direct and indirect effects (standardized coefficients) of variables on chronic stress and FSS (T0).
Beta (SE) p value
Measurement Model
Childhood trauma
Parcel I .904 (.014) ,.001
Parcel II .926 (.014) ,.001
Stress reactivity
Parcel I .873 (.009) ,.001
Parcel II .823 (.009) ,.001
Resilience
Parcel I .865 (.008) ,.001
Parcel II .894 (.008) ,.001
Chronic stress
Parcel I .925 (.006) ,.001
Parcel II .938 (.006) ,.001
Structural Model
Effect on stress reactivity
Childhood trauma .261 (.019) ,.001
Effect on resilience
Childhood trauma 2.246 (.016) ,.001
Correlation between stress reactivity and resilience 2.489 (0.16) ,.001
Effects on chronic stress
Direct effects
Childhood trauma .116 (.014) ,.001
Stress reactivity .582 (.016) ,.001
Resilience 2.188 (.016) ,.001
Indirect effects
Childhood trauma via stress reactivity .152 (.012) ,.001
Childhood trauma via resilience .046 (.005) ,.001
Effects on FSS at T0
Direct effect
Chronic stress .268 (.032) ,.001
Indirect effects
Childhood trauma via chronic stress .031 (.005) ,.001
Childhood trauma via reactivity and chronic stress .041 (.006) ,.001
Childhood trauma via resilience and chronic stress .012 (.002) ,.001
Stress reactivity via chronic stress .156 (.019) ,.001
Resilience via chronic stress 2.050 (.007) ,.001
FSS = functional somatic syndromes.
Beta = standardized coefficient.
SE = standard error.
doi:10.1371/journal.pone.0111214.t001
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stress, we were not able to show a direct link between traumatic
experiences and FSS.
Emotional neglect and abuse were the particluar types of
trauma that were indirectly associated with FSS in our sample.
These types of childhood trauma resulted from an environment
that was perceived as unstable, with caregivers not only failing to
meet the child’s emotional needs but also showing demeaning and
humiliating behavior towards the child [20]. We observed that
such experiences were associated with higher stress reactivity and
lower resilience in adulthood. More specifically, affected individ-
uals reported elevated habitual levels of stress before important
tasks, in response to high workload, social evaluation, and
experiences of failure [52]. In addition, they had weaker beliefs
in their personal competence and lower levels of acceptance of
themselves and their lives [29]. Of note, although stress reactivity
and resilience were highly correlated in our sample, they cannot be
considered as two sides of the same coin. Rather, they seem to
exhibit both overlapping and unique aspects in the stress response
context, a finding that is mirrored by recent research suggesting
specific neurocircuits to underlie resilience [68]. Interestingly, a
recent study showed specific regional patterns of cortical thinning
depending on whether participants reported childhood experienc-
Table 2. Longitudinal model direct and indirect effects (standardized coefficients) of variables on chronic stress and FSS (T1).
Beta (SE) p value
Measurement Model
Childhood trauma
Parcel I .915 (.039) ,.001
Parcel II .969 (.041) ,.001
Stress reactivity
Parcel I .869 (.026) ,.001
Parcel II .853 (.026) ,.001
Resilience
Parcel I .794 (.028) ,.001
Parcel II .910 (.031) ,.001
Chronic stress
Parcel I .913 (.023) ,.001
Parcel II .897 (.023) ,.001
Structural Model
Effect on stress reactivity
Childhood trauma .196 (.050) ,.001
Effect on resilience
Childhood trauma 2.173 (.048) ,.001
Correlation between stress reactivity and resilience 2.545 (0.44) ,.001
Effects on chronic stress
Direct effects
Childhood trauma .117 (.047) ,.05
Stress reactivity .433 (.053) ,.001
Resilience 2.169 (.053) ,.01
Indirect effects
Childhood trauma via stress reactivity .085 (.025) ,.01
Childhood trauma via resilience .029 (.012) ,.05
Effects on FSS at T1
Direct effect
Chronic stress .339 (.065) ,.001
Indirect effects
Childhood trauma via chronic stress .040 (.018) ,.05
Childhood trauma via reactivity and chronic stress .029 (.011) ,.01
Childhood trauma via resilience and chronic stress .010 (.005) ,.05
Stress reactivity via chronic stress .147 (.036) ,.001
Resilience via chronic stress 2.057 (.021) ,.01
FSS = functional somatic syndromes.
Beta = standardized coefficient.
SE = standard error.
doi:10.1371/journal.pone.0111214.t002
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es of sexual or emotional abuse [69]. Unlike sexual abuse, cortical
thinning was present in regions commonly associated with self-
awarness and -evaluation in participants reporting emotional
abuse [69]. It is thus conceivable that early adverse stimulation of
these brain areas contributes to a vulnerable concept of the self,
ultimately resulting in altered stress responses when meeting
important tasks or when being subject to social evaluation [69].
These findings fit well with the observation that social-
evaluative stressors (like public speaking tasks) are highly effective
in eliciting a stress response in FSS patients in the laboratory
[25,26]. According to the Lazarus and Folkman framework [19],
Figure 2. Cross-sectional path analysis model: FSS on chronic stress including standardized path coefficients. ctqx = Childhood
Trauma Questionnaire, indicator x. srsx = Stress Reactivity Scale, indicator x. rsx = Resilience Scale, indicator x. ticsx = Trier Inventory for the
Assessment of Chronic Stress, indicator x.
doi:10.1371/journal.pone.0111214.g002
Figure 3. Longitudinal path analysis model: FSS on chronic stress including standardized path coefficients. ctqx = Childhood Trauma
Questionnaire (T0), indicator x. srsx = Stress Reactivity Scale (T0), indicator x. rsx = Resilience Scale (T0), indicator x. ticsx = Trier Inventory for the
Assessment of Chronic Stress (T1), indicator x.
doi:10.1371/journal.pone.0111214.g003
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the reason for higher psychological stress responses lies in the
appraisal of one’s resources as insufficient when encountering a
stressor (‘secondary appraisal’). Moreover, emotional abuse and
neglect and a personality profile that is characterized by high stress
reactivity and low resilience seem to render individuals vulnerable
to the appraisal of future ambiguous stimuli as a threat [19]. In our
sample, these persons were in fact characterized by a high amount
of chronic stress at a later timepoint, including worrying and
feeling overwhelmed with various kinds of demands. In line with
this finding, a study among college students found elevated levels
of worry and co-morbidity with generalized anxiety disorder to be
characteristic of individuals suffering from irritable bowel
syndrome [70]. In our sample, chronic stress was accompanied
by the development and perpetuation of FSS. Contrary to our
expectations, we did not find a direct effect of experiences of
childhood trauma on FSS when all other variables were controlled
for. Based on our results, one could thus speculate that for the
sensorimotor and emotional concomitants of trauma exposure
[46] to translate into FSS, the occurrence of chronic stress as a
trigger later on in life is a necessary prerequisite. Regarding the
perpetuation of FSS, a recent electronic diary study found stress to
predict an increase in functional symptoms in 30% of their
participants, thus mirroring our findings in a setting with high
ecological validity [71].
Our findings regarding a linkage between childhood trauma
and altered stress reactivity in FSS can be discussed in the context
of biological findings [72]. For instance, Videlock et al. found
traumatic childhood experiences to be related to altered neuro-
endocrine stress reactivity to a visceral stressor in a sample of
irritable bowel syndrome patients [73]. This raises the possibility
that our results mirror disturbances at a neuroendocrine level.
Importantly, this study utilized an acute stressor in the laboratory
as a means of eliciting stress reactivity. However, whether chronic
stress outside of the laboratory may serve as an ‘opportunity’ to
translate dysfunctional stress reactivity into FSS has received little
attention so far. A recent study conducted in women with
fibromyalgia revealed a shorter gestational length (another
indicator of early life stress) to be related to altered neuroendocrine
stress reactivity, while at the same time 70% of the sample
reported severe stress as a triggering event for their symptoms [74].
Unfortunately, the authors did not report to what extent these
events were only present in the early life stress/altered stress
reactivity group.
This is the first study examining the association between
childhood trauma and resilience in FSS patients. It is only in
recent years that the neurobiological basis of resilience in humans
has begun to be explored [75] and a mere handful of studies have
made an effort to approach the subject of resilience integratively,
that is, considering both biological and psychological aspects. For
instance, a study in patients suffering from posttraumatic stress
disorder demonstrated blunted increases in neuropeptide Y (a
stress modulating neuropeptide) in response to a pharmacological
stimulant of the stress hormone norepinephrine [76]. These
findings are intriguing in light of the fact that neuropeptide Y is
discussed as a protective factor in stress regulation [75] and high
comorbidities with PTSD are present in many patients suffering
from FSS [77,78]. However, to what extent this finding applies to
patients with FSS remains purely speculative at this point, and
both psychological and biological aspects of resilience clearly need
to be further scrutinized.
Several limitations need to be taken into account when
interpreting our study results. First, the present survey was
conducted in a student sample that cannot be considered
representative of the general population. Second, our approach
of establishing diagnoses of FSS was dependent on the reporting of
health care visits, which could potentially lead to an underesti-
mation of prevalence rates. Also, due to the nature of a web-based
data collection approach, we were not able to confirm these
diagnoses through a physical examination or laboratory assess-
ment in our participants. Third, we relied on retrospective self-
reported data to measure childhood trauma. Although the CTQ is
a well-validated questionnaire that has been used extensively in
research on childhood trauma, we are not able to provide external
corroboration of our findings (e.g., by simultaneously asking a
family member about childhood trauma occurrence).
In conclusion, we provide a comprehensive view on the role of
stress and resilience in the development and perpetuation of
various FSS. Large-scale epidemiological studies are warranted to
replicate our prospective findings in the general population. Also,
while our data suggest stress to be a risk factor that is common to
several different FSS, further work is required to confirm our
model in samples of specific FSS. Finally, there is an urgent need
for integrative research acknowledging both biological and
psychological aspects of stress reactivity and resilience in the
search for the pathophysiology of FSS.
Our findings have important clinical implications. First, we
advocate that attention be paid to the possibility of childhood
trauma in FSS patients and affected individuals be offered
adequate treatment. Second, given our results, patients with FSS
are likely to benefit from interventions reducing stress reactivity
(e.g., by learning relaxation techniques) and/or enhancing
resilience (e.g., by strengthening individual resources). Finally,
due to the observation that the incidence and maintenance of FSS
is dependent on chronic stress, a case can be made for
psychological therapy as a means of improving stress management
strategies.
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Abstract
Background Although at least 20 different functional somatic
syndromes (FSS) have been described, and overlaps between
individual FSS and a high comorbidity with depressive and
anxiety disorders have been suggested, barely any studies
have examined a broad array of FSS within one study.
Moreover, information on psychosocial risk factors gained
from prospective studies is scarce.
Purpose This study aimed to determine prevalence rates,
overlap, and comorbidity in 17 FSS and to estimate the influ-
ence of psychosocial risk factors on the development of FSS.
Methods In total, 3,054 students (73.4 % women) completed
a Web survey containing questions on FSS, comorbidity, and
psychosocial risk factors at baseline. Of these, 429 completed
the survey again 6 months later.
Results The prevalence of any FSS was 9.5 %, with 227
(78.6 %) subjects fulfilling criteria for only one FSS, 49
(17.0 %) reporting two, and 12 (4.2 %) reporting three
syndromes simultaneously. Only one person suffered from
four FSS at the same time. “Major depressive syndrome”
(15.6 %), “panic syndrome” (4.8 %), and “other anxiety
syndromes” (19.7 %) frequently occurred among persons
with FSS. Significant predictors of FSS were number of
somatic symptoms (OR01.15), impairment in daily activi-
ties (OR03.17), depression (OR01.13), and somatization
(OR01.15).
Conclusions Our findings indicate that FSS are common in
nonclinical samples. The frequency of overlap and comor-
bidity in FSS was lower compared with previous research. A
consideration of psychosocial risk factors is warranted in the
prevention and management of FSS.
Keywords Functional somatic syndromes . Prevalence .
Symptom overlap . Comorbidity . Predictors
Introduction
The term “functional somatic syndrome” (FSS) refers to the
clinical picture of a particular constellation of somatic symp-
toms that cannot be adequately explained by any structural or
functional abnormality. Syndromes fulfilling this criterion are
abundantly prevalent in the general population, accounting for
a large proportion of health care visits both in primary [1, 2]
and secondary care [3, 4], causing substantial suffering and
impairment in patients [5] and leading to a considerable
amount of direct (e.g., medical care) and indirect (e.g., lost
productivity) costs [6]. Conditions such as chronic fatigue
syndrome, fibromyalgia syndrome, or irritable bowel syn-
drome represent, among many others, frequently occurring
examples of FSS. Despite extensive research on FSS, few
effective treatment options are available to date.
A critical prerequisite for identifying target populations for
treatment programs is the collection of epidemiological data
which accurately describe individuals affected by the condition
under examination. Prevalence rates from population-based
studies for the abovementioned FSS range from 0.2 to 9.4 %
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[7–12]. A characteristic thought to be associated with FSS is
gender, with a female preponderance having been consistently
reported [7, 8, 10–12], and biological (e.g., endocrine), psy-
chosocial (e.g., traumatic experiences), and sociocultural fac-
tors (e.g., health care-seeking behavior) proposed to be
responsible for this finding [13, 14]. Furthermore, a low socio-
economic status (SES) seems to be predominant among people
suffering from FSS [8, 10, 11]. However, despite growing
evidence on such predisposing and precipitating factors in
FSS, as yet, no final conclusions can be drawn regarding the
exact determinants and processes underlying these debilitating
disorders.
Identifying the amount of overlap and comorbidity of FSS
might further facilitate our understanding of relevant etiolog-
ical factors common to all of these syndromes. A considerable
overlap has frequently been reported between different FSS on
both the symptom and syndrome level [15, 16]. Thus, com-
mon pathophysiological mechanisms have been proposed as
underlying these syndromes [17–19]. This observation has
also led some researchers to question the validity of separate
diagnostic entities, interpreting them as mere artifacts of med-
ical specialization [20]. However, samples in these studies
were mostly drawn from clinical settings, such as primary,
secondary, or tertiary health care, thus rendering them subject
to referral bias. Clearly, studies from nonclinical populations
are needed in order to generalize findings to all groups of
affected individuals. Furthermore, despite considerable evi-
dence on the co-occurrence of FSS, only a small number of
studies have looked at more than two syndromes simulta-
neously (e.g., [21–23]), meaning that the broad spectrum of
these disorders is largely neglected.
Similar to studies on overlaps in FSS, investigations of
comorbidity have shown a high co-occurrence of depressive
and anxiety disorders [24, 25]. However, as mentioned above,
further studies recruiting nonclinical populations are needed.
In addition, one of the major limitations of previous research
in FSS was that only very few studies adopted a prospective
study design. Initial attempts to elucidate the temporal order
between FSS and comorbid mental disorders have been un-
dertaken, supporting the suggestion of a predisposing role of
depression and anxiety in the development of FSS [26–29].
For purposes of etiological research and in order to develop
effective prevention strategies, it is essential to identify risk
factors in illnesses. Clinical studies in populations at risk (e.g.,
after an infection) have revealed several psychosocial factors
to precede FSS (e.g., number of somatic symptoms, somatiza-
tion, mental disorders, and illness behavior [30–32]). Similar
factors emerged in population-based studies, thus corroborat-
ing these findings further [26, 28, 33]. When comparing
research on individual FSS, the number of somatic symptoms,
the severity of cardinal symptoms, somatization, depression,
and anxiety were, apart from gender and age, among the most
significant predictors. However, samples recruited from the
general population are diverse regarding various variables that
have frequently been associated with health (e.g., age, SES, or
lifestyle factors). Therefore, an examination of more homoge-
neous samples might further add to explaining the relationship
between psychosocial aspects and FSS.
In sum, research on FSS is in need of epidemiological
data on the co-occurrence of more than two FSS. Moreover,
nonclinical samples should be investigated in studies on
comorbidity in order to prevent selection bias. In addition,
more prospective evidence on risk factors in the develop-
ment of FSS is required. To address these issues, we con-
ducted the current study, which aimed to (1) determine
prevalence rates and associated characteristics of FSS in a
sample of apparently healthy students, (2) examine the
overlap between multiple FSS and comorbidity in a non-
clinical sample, and (3) evaluate the impact of relevant
psychosocial risk factors on the development of FSS at a
later time point. We expected prevalence rates to be compa-
rable to similar studies conducted in student populations.
Additionally, we assumed that the overlap and comorbidity
would be less extensive in our nonclinical sample. Finally,
based on the literature, we hypothesized that the number and
severity of somatic symptoms, somatization, as well as
depression and anxiety disorders would predict the inci-
dence of any FSS.
Methods
Participants and Procedure
School administrators from public colleges and universities
in the German-speaking part of Switzerland were contacted
and asked for their assistance in conducting the current
study. Potential participants were contacted through cooper-
ating institutions via e-mail and asked to participate in a
Web survey on physical and mental well-being (T0). In
addition, a link to the Website was posted on several internet
platforms known to be frequently visited by students.
Participation was voluntary and all subjects provided elec-
tronic informed consent. All procedures were in accordance
with the ethical standards laid down in the 1964 Declaration
of Helsinki, and the Web survey study design was approved
by the local ethics committee. Participants had the chance to
win luncheon vouchers and cinema tickets as compensation
for their efforts. All subjects were asked if they wished to
participate in a follow-up survey and those who agreed were
asked to complete the same survey 6 months later (T1).
Measurements
To assess prevalence rates of FSS, we administered a previ-
ously developed questionnaire (Questionnaire on Functional
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Somatic Syndromes (FFSS) [34]). The German version of
the FFSS is freely available as a Web supplement to the
original article (http://content.karger.com/ProdukteDB/
miscArchiv/000/333/298/000333298_sm_supplemental_
material.pdf). The FFSS consists of three different parts
which are connected via several algorithms. First, a screening
tool encompassing 52 items on various somatic symptoms was
presented. These items represent cardinal symptoms (e.g., ab-
dominal pain) of the most common FSS. Importantly, symp-
toms are rated according to current frequency of occurrence
(“never/rarely,” “frequently,” and “almost always/always”). A
symptom count was calculated by adding up symptoms that
were at least frequently present. In addition, the screening tool
contains dichotomous questions on functional impairment due
to symptoms in different areas (e.g., in daily routine activities),
which served as an indicator of symptom severity in this study.
Finally, a categorical item on the duration of symptoms (e.g.,
for at least 3 months) is part of the questionnaire. Second, if
participants reported cardinal symptoms that were characteris-
tic of one of 17 FSS (e.g., abdominal pain for at least 3months),
additional questions based on international research diagnostic
criteria were presented. These questions allow for a detailed
understanding of cardinal and associated complaints, symptom
course and fluctuation, functional impairment, and symptom
onset regarding each FSS. The following FSS are represented
in the questionnaire (either publication on diagnostic criteria or,
if no such publication is available, operationalization of the
syndrome is mentioned in brackets): tension-type headache and
persistent idiopathic facial pain [35], whiplash-associated dis-
orders (pain of at least 6 months’ duration that is related to an
accident), temporomandibular disorders [36], globus and func-
tional chest pain of presumed esophageal origin [37], function-
al dyspepsia [38], irritable bowel syndrome [39], chronic low
back pain (lower back pain of at least 6 months’ duration
causing impairment), fibromyalgia syndrome [40], chronic
fatigue syndrome [41], multiple chemical sensitivity [42],
chronic pelvic pain in men [43] and in women (lower abdom-
inal pain of at least 6 months’ duration), premenstrual syn-
drome [44] and premenstrual dysphoric disorder [45], and
hyperventilation syndrome [46]. Third, subjects meeting the
minimum of required diagnostic criteria (e.g., recurrent abdom-
inal pain or discomfort on at least 3 days/month in the last
3 months including changes in bowel movement, with symp-
tom onset 6 months previously) were subsequently surveyed
about health care visits (“Did you ever see a doctor about your
abdominal pain/changes in bowel movement?”). Participants
who answered “yes” to this question were ultimately directed to
a list of items addressing frequent differential diagnoses (“What
diagnosis did your doctor give you?”). Participants were
labeled as having FSS (e.g., irritable bowel syndrome) if they
reported that no abnormalities had been detected by their
doctor which might account for their symptoms (e.g., an
inflammatory bowel disease). The FFSS screening tool has
good psychometric properties regarding both internal consis-
tency (Cronbach’s alpha00.94) and retest reliability (r00.80
−0.94). No information on external validity is available to
date.
Information on comorbidity was obtained by administering
the German version of the Patient Health Questionnaire (PHQ
[47, 48]). This scale screens for general psychopathology on a
symptom and syndrome level. A “somatoform syndrome”was
considered to be present if a person reported at least 3 out of 13
somatic symptoms leading to severe impairment during the
past 4 weeks. These somatic symptoms (e.g., back pain) are
frequently experienced by patients suffering from both somato-
form disorders and FSS. Depression was measured along a
continuum by adding up nine depression-relevant items. On
the other hand, an algorithm allowed for a preliminary diag-
nosis of a current episode of major depression, labeled “major
depressive syndrome.” In order to receive this preliminary
diagnosis, individuals needed to report at least five out of nine
symptoms characteristic of a major depressive episode accord-
ing to DSM-IV [45], including depressed mood and/or dimin-
ished interest or pleasure in activities. Similarly, if between two
and four of these symptoms were present, including depressed
mood and/or diminished interest or pleasure in activities, cri-
teria for “other depressive syndromes” were seen as fulfilled.
Moreover, both syndromes needed to have been present for
2 weeks and the symptoms needed to be present for most of the
time. “Panic syndrome” was defined by recurring unexpected
panic attacks causing suffering/and or impairment. The defini-
tion of a panic attack was in accordance with DSM-IV [45].
“Other anxiety syndromes” were considered as present in an
individual if he/she reported feeling nervous, anxious, tense, or
worried during the past 4 weeks. Additionally, three out of six
symptoms relevant for a diagnosis of a generalized anxiety
disorder as described in DSM-IV [45] had to be met. A
preliminary diagnosis of “bulimia nervosa” and “binge eating
disorder” were present in cases of recurrent episodes of binge
eating occurring at least twice a week during the past 3 months.
The definition of an episode of binge eating was in accordance
with DSM-IV [45]. Furthermore, recurrent compensatory be-
havior in order to prevent weight gain differentiated a prelim-
inary diagnosis of “bulimia nervosa” from a preliminary
diagnosis of “binge eating disorder.” Finally, participants were
classified as having “alcohol syndrome” if they reported at
least one out of five maladaptive alcohol-related behaviors
within the last 6 months. As with the remaining syndromes,
these questions were guided by the DSM-IV [45] criteria for
substance abuse [45].
In addition, all 12 items of the somatization subscale of the
German version of the revised Symptom Checklist 90 (SCL-
90-R [49, 50]) were administered. Somatization refers to a
person’s tendency to both frequently experience and report
somatic distress [51]. The items in this scale represent somatic
symptoms commonly experienced in patients suffering from
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somatization disorder (e.g., dizziness and fainting spells), but
are rather untypical of common FSS such as premenstrual
syndrome, functional dyspepsia, or irritable bowel syndrome.
Importantly, symptoms are rated according to the extent
to which an individual was bothered by somatic symptoms
in the previous 7 days (“not at all” to “extremely”). Therefore,
the somatization score calculated based on these items
reflected the amount of somatic distress experienced by study
participants.
Statistical Analyses
Descriptive statistics (mean, standard deviation, and range)
were used to describe participants. Prevalence rates for diag-
noses according to well-established criteria and for overlap
between FSS, as well as for comorbidity, were calculated in
percentages. Student’s t tests and Chi-square tests were com-
puted for comparisons between FSS noncases and cases at T0
(cross-sectional analyses), as well as for comparisons between
subjects without any diagnosis of FSS at T0 or T1 and subjects
reporting a newly developed FSS at T1 (prospective analyses).
Odds ratios were calculated for variables that differed signif-
icantly between the latter two groups through the use of
univariate binary logistic regression analysis. In addition,
multivariate binary logistic regression analysis was applied
in order to identify the most significant risk factors for newly
developed FSS at T1. The software SPSS 20.0 (SPSS,
Chicago, IL) was used and the significance level was set at
α05 % (two tailed).
Results
Sample Characteristics
In total, 6,206 participants visited the survey Website at T0.
A total of 3,054 (49.3 %) students provided full information
on gender and age and completed the Web survey, taking a
minimum of 15 min (36 min completion time on average).
These subjects were considered to have provided reliable
data and were thus included in the statistical analyses. Two
thousand and forty-two (73.4 %) were women and 812
(26.6 %) were men, and the mean age was 24.6±5.6 (SD)
years. The majority (92.6 %) of the subjects was single, and
parental household income was almost uniformly distribut-
ed across nine predefined categories ranging from less than
3,000 to more than 10,000 Swiss Francs/month (equal inter-
vals across categories). At T1, 429 students participated in
the follow-up survey, and these participants did not differ
from those who chose not to participate with regard to
gender, marital status, household income, number of somatic
symptoms, functional impairment due to symptoms, as well as
number of FSS, comorbidity, and somatization according to
the SCL-90-R at T0 (data not shown). However, the subsample
was slightly older (25.6±7.0 vs. 24.4±5.3 years; T (512.25)0
−3.36, p<0.01) and indicated having suffered from somatic
symptoms for longer (52.1 % vs. 44.8 % for more than 1 year;
χ2 (6, N02,724)015.78, p<0.05).
Prevalence and Characteristics of FSS
Point prevalence rates of FSS are reported in Table 1. No
subjects reported suffering from persistent idiopathic facial
pain and no male subjects suffered from chronic pelvic pain;
these FSS were therefore excluded from all further analyses.
Premenstrual syndrome (5.0 %), functional dyspepsia
(1.9 %), and premenstrual dysphoric disorder (1.5 %) were
the most frequently reported syndromes.
At least one FSS was reported by 289 (9.5 %) subjects.
Within this group, women were significantly over-represented,
with prevalence rates of any FSS of 11.6 % (vs. 3.7 % among
men;χ2 (1,N03,054)042.96, p<0.001). Subjects belonging to
the FSS group reported 12.8±6.8 (vs. 6.5±5.5 in noncases)
symptoms on the FFSS. They experienced impairment due to
symptoms in various domains such as in their daily routine
(31.1 vs. 16.1 % in noncases), in their movements (20.1 vs.
11.2 % in noncases), in educational and/or occupational activ-
ities (34.9 vs. 25.2 % in noncases), and 26.3 % (vs. 15.5 % in
noncases) felt that their symptoms negatively affected their
social lives. More than three quarters (88.9 vs. 27.1 % in
noncases) of FSS cases had been suffering from somatic symp-
toms as measured by the FFSS for more than 1 year. These
Table 1 Prevalence rates of FSS
Total
(n03,054)
Men
(n0812)
Women
(n02,242)
Frequencies of FSS (FFSS; %)
Tension-type headache 26 (0.9) 6 (0.7) 20 (0.9)
Whiplash associated disorder 11 (0.4) 0 (0.0) 11 (0.5)
Temporomandibular disorder 19 (0.6) 4 (0.5) 15 (0.7)
Chronic low back pain 2 (0.1) 0 (0.0) 2 (0.1)
Fibromyalgia syndrome 2 (0.1) 0 (0.0) 2 (0.1)
Chronic fatigue syndrome 1 (<0.1) 0 (0.0) 1 (<0.1)
Multiple chemical sensitivity 1 (<0.1) 0 (0.0) 1 (<0.1)
Hyperventilation syndrome 40 (1.3) 7 (0.9) 33 (1.5)
Globus 2 (0.1) 1 (0.1) 1 (<0.1)
Functional chest pain 14 (0.5) 6 (0.7) 8 (0.4)
Functional dyspepsia 57 (1.9) 8 (1.0) 49 (2.2)
Irritable bowel syndrome 39 (1.3) 5 (0.6) 34 (1.5)
Chronic pelvic pain 5 (0.2) n.a. 5 (0.2)
Premenstrual syndrome 112 (5.0) n.a. 112 (5.0)
Premenstrual dysphoric disorder 34 (1.5) n.a. 34 (1.5)
FFSS questionnaire on functional somatic syndromes, FSS functional
somatic syndromes
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subjects had an average somatization score of 7.1±5.5
(vs. 3.9±3.9 in noncases) on the SCL-90-R. Cases with FSS
differed from noncases in terms of number of symptoms
(T (327.62)0−15.19, p<0.001), functional impairment in
daily routine activities (χ2 (1, N02,735)039.83, p<0.001),
movement (χ2 (1, N02,735)019.28, p<0.001), at school or
work (χ2 (1, N02,735)011.93, p<0.001), and regarding rela-
tionships with others (χ2 (1, N02,735)021.95, p<0.001),
duration of symptoms (χ2 (6, N02,724)036.90, p<0.001),
and somatization scores (T (328.67)0−13.46, p<0.001).
Overlap
The relative overlap of FSS is reported in Table 2. The number
of FSS ranged from one to four, with 227 (78.6 %) subjects
fulfilling criteria for only one FSS, 49 (17.0 %) reporting
two, and 12 (4.2 %) reporting three syndromes simulta-
neously. Only one person suffered from four FSS at the
same time. The overlap ranged from 0 to 100 %/syndrome,
with 3.7±3.0 (out of 15, excluding idiopathic facial pain and
chronic pelvic pain in men) co-occurring syndromes on
average.
Comorbidity
Comorbidity is reported in Table 3. Cases with any FSS
were more frequently affected by mental disorders as
assessed by the PHQ. They reported higher prevalence rates
of somatoform syndrome (χ2 (1, N03,054)087.53, p<
0.001), major depressive syndrome (χ2 (1, N03,054)0
24.35, p<0.001), panic syndrome (χ2 (1, N03,054)0
18.82, p<0.001), and other anxiety syndromes (χ2 (1, N0
3,054)045.18, p<0.001), but not of other depressive syn-
dromes (χ2 (1, N03,054)00.001, p00.970), bulimia nervosa
(χ2 (1, N03,054)00.24, p00.625), binge eating disorder
(χ2 (1, N03,054)03.00, p00.083), or alcohol syndrome
(χ2 (1, N03,054)00.02, p00.901).
Table 2 Relative overlap of FSS
TTH WAD TMD CLBP FMS CFS MCS HVS GH FCP FD IBS CPP PMS PMDD
Diagnosis (FFSS)
TTH 100 0 0 0 0 0 0 0 0 0 0 0 0 3.8 0
WAD 0 100 0 0 0 0 0 0 0 0 0 9.1 0 0 0
TMD 0 0 100 0 0 0 0 5.3 0 5.3 5.3 0 5.3 5.3 5.3
CLBP 0 0 0 100 0 0 0 0 0 0 50.0 0 0 0 0
FMS 0 0 0 0 100 0 0 0 0 0 0 0 0 50.0 50.0
CFS 0 0 0 0 0 100 0 0 0 0 0 0 0 0 0
MCS 0 0 0 0 0 0 100 100 0 0 0 0 0 100 100
HVS 0 0 2.5 0 0 0 2.5 100 0 2.5 10.0 5.0 0 15.0 10.0
GH 0 0 0 0 0 0 0 0 100 0 0 0 0 0 0
FCP 0 0 7.1 0 0 0 0 7.1 0 100 7.1 0 0 0 0
FD 0 0 1.8 1.8 0 0 0 7.0 0 1.8 100 19.3 1.8 7.0 3.5
IBS 0 2.6 0 0 0 0 0 5.1 0 0 28.2 100 5.1 10.3 2.6
CPP 0 0 20.0 0 0 0 0 0 0 0 20.0 40.0 100 0 0
PMS 0.9 0 0.9 0 0.9 0 0.9 5.4 0 0 3.6 3.6 0 100 30.4
PMDD 0 0 2.9 0 2.9 0 2.9 11.8 0 0 5.9 2.9 0 100 100
FFSS questionnaire on functional somatic syndromes, FSS functional somatic syndromes, TTH tension-type headache, WAD whiplash-associated
disorders, TMD temporomandibular disorders, CLBP chronic low back pain, FMS fibromyalgia syndrome, CFS chronic fatigue syndrome, MCS
multiple chemical sensitivity, HVS hyperventilation syndrome, GH globus, FCP functional chest pain, FD functional dyspepsia, IBS irritable bowel
syndrome, CPP chronic pelvic pain, PMS premenstrual syndrome, PMDD premenstrual dysphoric disorder
Table 3 Comorbidity in FSS
Non-cases
(n02,765)
Cases
(n0289)
Psychopathology (PHQ; %)
Somatoform syndromea 142 (5.1) 56 (19.4)
Major depressive syndromea 201 (7.3) 45 (15.6)
Other depressive syndromes 241 (8.7) 25 (8.7)
Panic syndromea 38 (1.4) 14 (4.8)
Other anxiety syndromesa 217 (7.8) 57 (19.7)
Bulimia nervosa 38 (1.4) 5 (1.7)
Binge eating disorder 15 (0.5) 4 (1.4)
Alcohol syndrome 419 (15.2) 43 (14.9)
FSS functional somatic syndromes, PHQ patient health questionnaire
a Significant differences between noncases and cases
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Predictors of FSS Incidence
Findings referring to predictors of newly developed FSS are
reported in Table 4. Out of 429 participants, 10 (20.8 %) were
stable cases reporting at least one FSS and 21 (4.9 %)
had a newly developed FSS after 6 months (i.e., incidence
cases). The somatic symptom count according to the
FFSS (T (21.04)0−3.20, p<0.01), impairment in daily
activities (χ2 (1, N0337)05.96, p<0.05), depression as mea-
sured by the PHQ (T (21.13)0−2.06, p<.05), and somatiza-
tion (T (20.74)0−2.38, p<0.05) were higher in new cases with
FSS at T1 than in subjects without any diagnosis of FSS at
either of the two time points. However, multivariate binary
logistic regression calculations revealed the number of somatic
syndromes to be the only significant predictor of new FSS
occurrence at T1 (OR01.1, CI01.0−1.2, p<0.05).
Discussion
The prevalence rate of any FSS was found to lie at nearly
one in ten participants (9.5 %), with the majority of subjects
(78.6 %) reporting only one syndrome occurring at a time.
The mean number of overlapping syndromes was 3.7 out of
15 syndromes. Only somatoform syndrome, major depres-
sive syndrome, panic syndrome, and other anxiety syn-
dromes were more prevalent among cases with any FSS.
Finally, significant predictors of FSS incidence at T1 were
number of somatic symptoms, functional impairment in
daily activities (as an indicator of symptom severity), as
well as depression and somatization at T0.
In previous studies, frequencies of individual syndromes
in the general population were almost consistently higher
than in our study [8–12]. However, since we studied a
student population, our findings should only be compared
with similar samples. When looking at similar samples, the
same picture emerges: our results regarding tension-type
headache were around 30 times lower compared with prev-
alence rates of 9.5 to 32.9 % obtained in students in Brazil
[52–54], Greece [55], Turkey [56], Oman [57], and
Singapore [58]. Premenstrual syndrome in a Nigerian [59],
Saudi Arabian [60], Iranian [61], and Pakistani [62] sample,
and premenstrual dysphoric disorder in a Brazilian sample
[63], two Nigerian samples [64, 65], a Kuwait-based sample
[66], and a Pakistani [62] sample were found to be more
common in comparison to our study. By contrast, similar
patterns of relatively low prevalence rates emerged in stu-
dent populations regarding other pain conditions, such as
temporomandibular disorder in a Swedish sample [67] and
fibromyalgia syndrome in a Turkish sample [68], with the
latter study additionally reporting relatively few cases with
CFS [68]. Comparisons regarding functional gastrointestinal
disorders were somewhat mixed, with a German study
showing relatively high prevalence rates of irritable bowel
syndrome [69], and a Swiss study finding prevalence rates
matching our results [70]. Overall, prevalence rates of FSS
in Swiss students seem to be relatively low compared with
similar study populations in other countries. Our finding of
lower prevalence rates compared with studies conducted in
the general population might be explained by sample char-
acteristics, such as SES, which is generally very high in
Switzerland. Moreover, the present study employed a rather
rigorous approach in diagnosing FSS, and this might have
contributed to the differing frequencies observed in other
student samples. For example, the majority of population-
based studies relied on mere self-report of symptoms re-
quired for a diagnosis of one specific FSS, while at the same
time neglecting to request information on medical illnesses
that may account for the reported symptoms.
In this nonclinical study, only a small number of individu-
als suffered from several FSS simultaneously and rather low
levels of overlap among FSS were observed. To our knowl-
edge, no study has yet examined 17 FSS simultaneously. Our
finding of only a small proportion of cases reporting several
FSS at the same time echoes previous studies on the overlap
between four and six different FSS, respectively [21, 22]. Our
results regarding the level of overlap, on the other hand, are
not entirely in agreement with earlier population-based stud-
ies. For example, Jason et al. reported levels of overlap be-
tween chronic fatigue syndrome, fibromyalgia syndrome, and
multiple chemical sensitivity ranging from 8.9 to 40.6 % [71],
and White et al. found 59.5 % of subjects with a fibromyalgia
syndrome to be affected by chronic fatigue syndrome [72].
With regard to irritable bowel syndrome, a study by
Zondervan et al. showed a substantial overlap with chronic
pelvic pain (38.5 % [73]). Sample selection bias might ac-
count for these diverging results, as two of the above-cited
studies preselected their subjects regarding symptoms of
Table 4 Predictors at T0 of FSS
incidence at T1
FFSS questionnaire on function-
al somatic syndromes, FSS
functional somatic syndromes,
PHQ patient health question-
naire, SCL symptom checklist
Non-cases (n0361) New cases (n021) OR (95 % CI)
Mean values and frequencies (SD; %)
Number of somatic symptoms (FFSS) 6.20 (5.18) 11.71 (7.80) 1.15 (1.04–1.23)
Impairment in daily routine (FFSS) 46 (14.5) 7 (35.0) 3.17 (1.20–8.37)
Depression (PHQ-9) 5.67 (3.94) 8.29 (5.73) 1.13 (1.04–1.24)
Somatization (SCL-90-R) 3.88 (3.76) 7.38 (6.70) 1.15 (1.06–1.24)
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fatigue and pain. Our findings on the overlap of FSS generally
point to specific etiological factors in individual FSS.
Nevertheless, a small group of our participants was affected
by several FSS at the same time. Interestingly, a recent study
confirmed earlier findings of distinct clusters of somatic
symptoms by employing latent class analysis in a large sample
of twins [74]. However, these authors also found one cluster
consisting of individuals reporting multiple symptoms at the
same time, which is in line with our results. Another study on
FSS in adolescents provided evidence on differential cortisol
response patterns in a cluster of gastrointestinal symptoms and
headache and one of musculoskeletal pain, dizziness, and
overtiredness, respectively, pointing to specific pathophysio-
logical correlates in FSS [75]. In conclusion, further research
investigating differential pathophysiological mechanisms in
FSS is warranted at this point.
Our findings regarding comorbidity are in line with high
levels of depressive and anxiety disorders usually experi-
enced by affected populations [24, 25]. However, as with
prevalence rates and levels of overlap, we mostly observed
slightly lower proportions of subjects with any comorbid
depressive or anxiety disorder compared with previous
population-based research [76–78]. Again, this discrepancy
might be explained by sample characteristics and/or differ-
ent diagnostic approaches. Only 19.4 % of our FSS cases
concomitantly fulfilled criteria for a somatoform syndrome,
which is often considered equivalent to a diagnosis of FSS.
This might imply that the current definition of somatoform
disorders does not capture the whole spectrum of FSS and is
thus in need of a substantial revision (for a comparison of
new proposals, see [79]). However, this finding needs to be
interpreted with caution since we did not utilize a clinical
interview to assess mental disorders. High levels of comor-
bidity with depressive and anxiety disorders often observed
in FSS patients might in part reflect mere symptom overlap
(e.g., lack of energy, problems with concentration [80]). On
the other hand, a recent population-based study on FSS,
major depression, and generalized anxiety disorder identified
two latent traits labeled “sensory component” and “affective
component”which are common to all of these conditions [81].
Interestingly, these two components seemed to load differen-
tially on FSS and mental disorders, respectively, indicating
shared as well as specific pathophysiological mechanisms
underlying these conditions.
By employing a prospective study design, the present
study showed a predictive quality for the number of somatic
symptoms, functional impairment in daily activities (as an
indicator of symptom severity), depression, and somatiza-
tion in FSS. Recruiting a rather homogeneous sample of
well-educated young adults automatically limits the influ-
ence of some confounders relevant to health (e.g., SES and
lifestyle factors). Our first finding is in accordance with an
earlier study conducted among women reporting pain, which
identified the number of associated symptoms as a major
risk factor for later development of chronic widespread pain,
which is a typical feature of fibromyalgia syndrome [32].
Moreover, a recent study in patients with glandular fever
found an association between number of nonspecific com-
plaints, among other factors, and new onset of chronic fatigue
syndrome [30]. Similar to our finding of impairment in
daily routine activities being a risk factor for incidence
of any FSS at a later time point, Leone et al. [82] found
lower levels of physical functioning to precede CFS-like
illness among sick-listed employees. Our results are compat-
ible with several prospective studies showing an association
between depression and FSS [26–28, 30, 32, 83]. Hallmark
symptoms of depression (e.g., social withdrawal, and
avoidance behavior) might be associated with aggravation
of somatic symptoms due to reducing general fitness levels
through physiological deconditioning processes. Similarly,
population-based studies showed higher levels of somatiza-
tion in individuals with later development of chronic wide-
spread pain and irritable bowel syndrome, respectively
[28, 29, 33]. Somatization reflects the individual amount
of suffering on account of somatic complaints and might thus
constitute a “cognitive vulnerability” towards the develop-
ment of FSS. Notably, our findings on predictors of FSS
suggest at least some common psychosocial risk factors in
all FSS.
Several limitations need to be taken into account when
interpreting our study results. First, the present survey was
conducted in a student sample that cannot be considered
representative of the general Swiss population, thus limiting
the generalizability of our findings. In addition, people with a
special interest in health might have been more likely to
participate in our study, therefore adding further to the selec-
tion bias. Second, our approach of establishing diagnoses of
FSS was dependent on the reporting of health care visits,
which could potentially lead to an underestimation of preva-
lence rates. Also, due to the nature of a Web-based data
collection approach, we were not able to confirm these diag-
noses through a physical examination or laboratory assess-
ment in our subjects. Third, our finding of a somatic symptom
count predicting the incidence of any FSS 6 months later
might seem trivial at first, as reporting at least one somatic
symptom (e.g., abdominal pain) is inherent to any FSS diag-
nosis (e.g., irritable bowel syndrome). This suggests at least
some conceptual overlap in these analyses. However, the fact
that subjects experiencing 12 (instead of only six) different
somatic symptoms on average had a higher probability of
suffering from any FSS 6 months later suggests that nonspe-
cific symptoms (e.g., headaches) were in fact major risk
factors for the development of specific syndromes. Also, the
somatic symptom count consisted of both medically unex-
plained and explained symptoms, which further highlights the
conceptual difference to FSS diagnoses.
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To summarize, our data on 17 FSS in Swiss students
represent an important addition to previous epidemiological
data. Furthermore, this study complements previous research
examining only a small number of FSS simultaneously. In our
prospective study, we identified the number of somatic symp-
toms and functional impairment as valid indicators of clinical
relevance in somatic complaints. Most interestingly, while our
results on overlap in FSS point to differential etiological
factors in the development of individual FSS, a number of
psychosocial factors seem to be relevant to all FSS. Thus,
future research needs to investigate differential pathophysio-
logical mechanisms and possibly specific psychosocial risk
factors by comparing multiple FSS at the same time.
Our findings point to the relevance of a somatic symptom
count as a possible red flag for FSS, which could be easily
assessed in a primary care setting by, for example, adminis-
tering a checklist to patients. Furthermore, treatment of FSS
should aim at reducing functional impairment due to somatic
symptoms. Moreover, the presence of depression might con-
tribute to motivational difficulties with regard to seeking
adequate treatment and compliance during therapy. Finally,
information on attentional bias and alternative explanations
for somatic sensations might be addressed in individuals at
risk of FSS. Thus, careful consideration of these variables in
the current diagnostic assessment of FSS is warranted and
comorbidity with depressive disorders as well as somatization
needs to find adequate consideration in the management of
FSS.
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http://www.biomedcentral.com/1471-2458/14/1034RESEARCH ARTICLE Open AccessFunctional somatic syndromes: asking about
exclusionary medical conditions results in
decreased prevalence and overlap rates
Susanne Fischer* and Urs M NaterAbstract
Background: The diagnosis of functional somatic syndromes (FSS) requires 1) presence of somatic symptoms, and 2)
absence of medical conditions potentially accounting for these symptoms. Due to the limited feasibility of medical
examinations, epidemiological research on FSS has neglected to assess the second criterion. Our objective was
therefore to evaluate the implications of considering information on exclusionary medical conditions in
epidemiological research on FSS.
Methods: A survey among 3’054 students was conducted. We compared prevalence rates and overlap of 17 FSS
obtained by: 1) a symptom-based strategy and 2) a symptom-and-exclusion-based strategy including information on
exclusionary medical conditions.
Results: The symptom-and-exclusion-based strategy led to a marked decrease in prevalence rates compared to the
symptom-based strategy. Furthermore, it resulted in fewer individuals who were affected by multiple FSS.
Conclusions: Adding self-reported information on exclusionary medical conditions leads to a significant decrease in
the prevalence and overlap of FSS. More rigorous approaches to studying FSS should be adopted.
Keywords: Diagnostic criteria, Epidemiology, Functional somatic syndromes, Overlap, Population-based, PrevalenceBackground
The term ‘functional somatic syndrome’ (FSS) refers to a
certain constellation of somatic symptoms that cannot be
adequately explained in the context of a known medical
condition. Case definitions of the numerous existing FSS
therefore each require 1) the presence of at least one char-
acteristic symptom (positive criterion), and 2) the absence
of any medical condition that can account for these symp-
toms (negative criterion). There is a long list of FSS, but
among the most prevalent are chronic fatigue syndrome,
fibromyalgia syndrome, and irritable bowel syndrome.
The diagnostic criteria for FSS are commonly formulated
by expert committees; examples are the 1994 Centers for
Disease Control and Prevention criteria for chronic fatigue
syndrome [1], the Rome III criteria for irritable bowel
syndrome (and other functional gastrointestinal disorders)* Correspondence: susanne.fischer@uni-marburg.de
Clinical Biopsychology, Department of Psychology, University of Marburg,
Gutenbergstrasse 18, 35032 Marburg, Germany
© 2014 Fischer and Nater; licensee BioMed Ce
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article, unless otherwise stated.[2], and the 1990 and 2010 American College of Rheuma-
tology criteria for fibromyalgia [3,4].
These diagnostic criteria are used in clinical practice and
research settings, where patients are asked about symptoms
(positive criterion), medical records are reviewed, and
physical examinations and laboratory tests are performed
in order to identify medical conditions considered ex-
clusionary for FSS (negative criterion). This two-step
approach, which covers the assessment of both criteria
inherent in the definition of FSS, is considered the gold
standard for diagnosing an FSS. However, epidemiological
research is challenged by the limited feasibility of review-
ing medical records and/or conducting comprehensive
medical examinations, and thus often exclusively relies on
self-reported information. Several ways of diagnosing
FSS have been adopted to deal with this problem: a)
asking patients whether they suffer from a (specific)
FSS (self-reported diagnosis), b) asking patients whether
they have ever received an FSS diagnosis by a physician
(physician diagnosis), or c) providing patients with a list ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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criteria, but without an assessment of exclusionary factors
(symptom-based diagnosis). Naturally, the approaches
leading to these outcomes differ in their ability to cover
both the positive and negative criterion of FSS.
It is conceivable from this comparison that the choice
of diagnostic strategy may contribute to diverging study
findings. In fact, reviews on the epidemiology of each FSS
show a broad range of prevalence rates across studies (e.g.,
[5-7]). Another epidemiological estimate rather specific to
research on FSS is the amount of comorbidity among FSS,
i.e., the so-called ‘overlap’. With regard to prevalence
rates, overlap between FSS has been found to vary sub-
stantially [8,9]. Importantly, studies showing high levels
of overlap have led some researchers to propose the
existence of only one FSS [10]. These so-called ‘lumpers’
are opposed by other authors, who insist that there are
several specific syndromes, and these authors are usually
referred to as ‘splitters’ [11]. Thus, the overlap rates can be
considered a key parameter in the so-called ‘one vs. many
debate’. However, direct evidence on the repercussions of
using different diagnostic strategies as a possible reason
for the observed discrepancies in prevalence rates and
overlap is extremely scarce.
To the best of our knowledge, so far, only one study has
directly examined the consequences of using different
diagnostic strategies for FSS. In a recent study conducted
among female FSS patients and matched controls, Warren
and Clauw [12] reported a lack of sensitivity and specifi-
city of physician diagnoses (the above-mentioned option
b) when compared to symptom-based diagnoses (option
c). While we fully agree with the authors’ conclusion that
‘queries of symptoms, not diagnoses, are necessary’ (p. 894
in the same article), we believe that merely asking about
characteristic symptoms (positive criterion) may result in
an overestimation of FSS prevalence (and possibly overlap)
rates. In cases in which a thorough medical examination is
not feasible (such as in the above-mentioned study designs),
we believe it preferable to also obtain self-reported infor-
mation on medical illnesses considered exclusionary for
FSS (negative criterion). In essence, we would argue in
favor of a combination of options b) and c) in determining
FSS diagnoses in epidemiological studies (symptom-and-
exclusion-based strategy).
However, the potential impact of this strategy needs to
be examined. We aimed to extend the findings reported
by Warren and Clauw [12] by comparing two different
diagnostic strategies in 17 different FSS in a large, non-
clinical sample of young adults. The two strategies
were as follows: 1) identifying cases of FSS by means of
presenting a list of symptoms that are based on the
diagnostic criteria (symptom-based strategy), and 2)
additionally asking about medical exclusionary criteria
(symptom-and-exclusion-based strategy). We expectedto find 1) a significant decrease in prevalence rates of
FSS, and 2) a marked decrease in the extent of overlap
between FSS when using the symptom-and-exclusion-
based strategy. We tested these hypotheses as part of a
larger study on the prevalence, overlap, and predictors
of FSS [13].
Methods
Participants
The recruitment procedure for participants in this study
has been described previously elsewhere [13]. In brief,
German-speaking students from 23 Swiss colleges and
universities were contacted via e-mail through cooperating
school administrators, and asked to participate in a web
survey on physical and mental well-being. All procedures
were in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki, and the web survey
study design was approved by the ethics committee of the
Canton of Zurich. Written informed consent was obtained
from all participants.
Measurement
We administered a previously developed questionnaire
(Questionnaire on Functional Somatic Syndromes; FFSS;
[14]). The German version of the FFSS is freely available
as a Web supplement to the original article (http://con-
tent.karger.com/ProdukteDB/miscArchiv/000/333/298/
000333298_sm_supplemental_material.pdf ). The FFSS
consists of three different parts which are connected via
several algorithms. In the first part, a screening section
encompassing 52 items on various somatic symptoms
was presented. These items represent cardinal symptoms
of 17 FSS: Tension-type headache and persistent idiopathic
facial pain [15], whiplash-associated disorders (pain of at
least 6 months’ duration that is related to an accident),
temporomandibular disorders [16], globus and functional
chest pain of presumed esophageal origin [17], functional
dyspepsia [18], irritable bowel syndrome [2], chronic low
back pain (lower back pain of at least 6 months’ duration
causing impairment), fibromyalgia syndrome [3], chronic
fatigue syndrome [1], multiple chemical sensitivity [19],
chronic pelvic pain in men [20] and in women (lower ab-
dominal pain of at least 6 months’ duration), premenstrual
syndrome [21] and premenstrual dysphoric disorder
[22], and hyperventilation syndrome [23]. The instruc-
tion was to rate all current symptoms (‘I suffer from the
following complaints:’) according to frequency of occur-
rence (‘never/rarely’, ‘frequently’, ‘almost always/always’).
In addition, the screening part contains dichotomous
questions on functional impairment due to symptoms in
different areas and a categorical item on the duration of
symptoms.
In the second part, if participants reported cardinal
symptoms that were at least ‘frequently’ present and
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case of irritable bowel syndrome), additional questions
based on diagnostic criteria (e.g., Rome III) were pre-
sented. Our questions were based on the most commonly
used diagnostic criteria (all publications containing these
criteria can be found in the previous section for each FSS).
These questions allowed for a detailed understanding of
both cardinal and associated symptoms, symptom course
and fluctuation, functional impairment, and symptom
onset for each FSS. Participants were labelled as having
a ‘symptom-based FSS’ if they met the minimum of re-
quired positive criteria (e.g., recurrent abdominal pain
or discomfort on at least 3 days per month in the last
3 months including changes in bowel movement, with
symptom onset at least 6 months previously).
In the third part, those who fulfilled the positive criteria
of a specific FSS were subsequently surveyed about health
care visits. Importantly, visits related to the previously
diagnosed FSS (but not health care visits in general) were
of interest at this point (e.g., ‘Have you ever visited a
doctor about your abdominal pain/changes in bowel
movement?’). Participants who responded with ‘yes’
were ultimately directed to a list of items addressing
frequent differential diagnoses (‘What diagnosis did
your doctor give you regarding your abdominal pain/
changes in bowel movement?’). These lists were again
based on the diagnostic criteria for each FSS as cited
above. If they reported that no abnormalities had
been detected by their doctor that might account for
their symptoms (e.g., an inflammatory bowel disease),
participants were labelled as having a ‘symptom-and-
exclusion-based FSS’. The FFSS screening part has
good psychometric properties regarding both internal
consistency (Cronbach’s alpha = 0.94) and retest reli-
ability (r = 0.80 – 0.94).
Prevalence rates and overlap estimations of symptom-
and-exclusion-based FSS have already been described in
our previous report [13].
Results
Participants’ characteristics
Our recruitment and data preparation process is visu-
alized in Figure 1. A total number of N = 6’206 partici-
pants visited the website and about 51% of them
finished the survey. After the exclusion of implausible
and incomplete datasets (regarding survey response
duration, gender, and age), N = 3’054 datasets remained
for further analyses. Out of these 3’054 participants,
2’242 (73.4%) were women and 812 (26.6%) were men.
The mean age was 24.6 ± 5.6 (SD) years. Parental
household income was almost uniformly distributed
across nine predefined categories ranging from less than
3’000 to more than 10’000 Swiss Francs per month (equal
intervals across categories).Prevalence of FSS
As illustrated in Figure 1, about one third of our sam-
ple endorsed an FSS when using the symptom-based
strategy. Half of these participants had embarked upon
health care visits because of their symptoms. More
than half of the health care visitors were not offered a
medical explanation for their symptoms and those
were thus labelled symptom-and-exclusion-based FSS
cases. To compare the impact of our two diagnostic
strategies on epidemiological data, we calculated the
prevalence rates of 17 FSS according to both strategies.
We additionally included the health care visitor data
for descriptive purposes. No male participant reported
suffering from chronic pelvic pain and thus this FSS
was excluded from all analyses. The results are illus-
trated in Figure 2. The prevalence rates of the premen-
strual syndrome, premenstrual dysphoric disorder, and
chronic pelvic pain all refer to the female population
only. In accordance with our first hypothesis, we
observed marked decreases in prevalence rates when
using a symptom-and-exclusion-based approach to diag-
nosing FSS.
Overlap between FSS
To evaluate the potential impact of our two diagnostic
strategies on the extent of overlap between FSS, we
counted the number of FSS per person according to
each strategy. The number of symptom-based FSS per
person ranged from one to eight, with 631 (62.2%) par-
ticipants reporting only one, 239 (23.6%) reporting
two, 92 (9.1%) reporting three, 35 (3.5%) reporting
four, 13 (1.3%) reporting five, three (0.2%) reporting
six, and one person (0.1%) reporting eight symptom-
based FSS occurring at the same time. The number of
symptom-and-exclusion-based FSS ranged from one to
four: 227 (78.5%) participants fulfilled criteria for only
one, 49 (17.0%) reported two, 12 (4.2%) reported three,
and one person (0.3%) reported four symptom-and-exclu-
sion-based FSS simultaneously.
We then calculated the number of co-occurring FSS
for each strategy separately. Since premenstrual syn-
drome represents a less severe form of premenstrual
dysphoric disorder, the extent of overlap between these
syndromes was not evaluated. We first looked at each
FSS separately. For instance, within the irritable bowel
syndrome group, most people had one additional FSS,
but some had up to seven additional syndromes. We did
this with every syndrome and computed an average
index. Within the symptom-based FSS group, 9.2 ± 3.6
different co-occurring syndromes (out of 16) were present
on average, whereas individuals with symptom-and-exclu-
sion-based FSS fulfilled criteria for an average amount of
3.7 ± 3.0 co-occurring syndromes (out of 15, excluding
idiopathic facial pain).
E-mailing 
sample
Website visitors
n = 6‘206
Survey completers
n = 3‘165 (51.0%)
Complete, plausible datasets
n = 3‘054
Symptom-based FSS
n = 1‘014 (33.2%)
Symptom-and-exclusion based FSS
n = 289 (56.9%)
Health care visitors
n = 508 (50.1%)
Lack of time/interest
n = 3‘041 (49.0%)Survey response
duration < 15 
minutes, 
implausible/no
information on 
gender, age
n = 111 (3.5%)
Absence of
characteristic
symptoms
(positive criterion)
n = 2‘040 (66.8%)
No health care visits
n = 506 (49.9%)
Presence of a 
medical condition
explaining
symptoms
(negative criterion)
n = 219 (43.1%)
Figure 1 Recruitment and diagnostic process.
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Summary of study results
In this study, we aimed to evaluate the implications of
considering self-reported information on exclusionary
medical conditions in epidemiological research on FSS.
We compared prevalence rates and overlap of 17 FSS
diagnoses obtained by two different diagnostic strategies: a
symptom-based strategy and a symptom-and-exclusion-
based strategy. We report two findings that are in accord-
ance with our initial hypotheses: First, the use of medical
exclusionary criteria (symptom-and-exclusion-based strat-
egy) led to a marked decrease in prevalence rates of FSS
when compared to the symptom-based strategy. Second,
the use of the symptom-and-exclusion-based strategy
resulted in fewer numbers of individuals who were
affected by multiple FSS at the same time. Moreover, it
also resulted in fewer overlapping syndromes.
Integration and interpretation of study results
This is the first study to directly examine the impact of
adding information on exclusionary medical conditionson the prevalence of FSS. In a recent report, Warren
and Clauw [12] found symptom-based diagnoses to be
superior to physician diagnoses of FSS in terms of sensi-
tivity and specificity. While this is an important finding,
with both diagnostic and clinical implications, the results
of the present study indicate that a symptom-based strategy
might, in turn, overestimate prevalence rates of FSS. This is
most likely due to a participant’s incorrect attribution of a
somatic symptom (e.g., abdominal pain) to a specific FSS
(e.g., irritable bowel syndrome), when, in fact, it is part of
a medical illness (e.g., Crohn’s disease).
Our finding of a marked decrease in prevalence rates of
FSS when considering exclusionary medical conditions is
mirrored by other population-based research adopting the
gold standard procedure, in which patients are first asked
about symptoms (positive criterion), followed by physical
examinations and laboratory testing (negative criterion).
None of these studies explicitly assessed the ramifications
of using different diagnostic strategies; however, their
detailed reporting of patient screening procedures (e.g.,
using flow charts) allows the reader to compare the
Point prevalence in % (n)
0 2 4 6 8 10 22 24
Persistent idiopathic facial pain
Multiple chemical sensitivity
Chronic fatigue syndrome
Fibromyalgia syndrome
Chronic low back pain
Globus
Chronic pelvic pain
Whiplash associated disorders
Functional chest pain
Temporomandibular disorders
Tension-type headache
Irritable bowel syndrome
Hyperventilation syndrome
Premenstrual dysphoric disorder
Functional dyspepsia
Premenstrual syndrome
Symptom-and-exclusion-based FSS
Health care visitors
Symptom-based FSS
21.8 (489)
5.0 (112) 
7.8 (237)
1.9 (57)
5.0 (112)
3.2 (71)
9.2 (282)
1.3 (40)
3.3 (100)
1.3 (39)
3.8 (116)
0.9 (26)
4.2 (129)
0.6 (19)
2.3 (70)
0.5 (14)
0.7 (22)
0.4 (11)
1.0 (23)
0.2 (5)
0.3 (10)
0.1 (2)
0.2 (5)
0.1 (2)
0.1 (2)
0.2 (7)
< 0.1 (1)
0.1 (3)
< 0.1 (1)
< 0.1 (1)
9.5 (212)
5.5 (168)
1.5 (34)
5.8 (176)
2.6 (78)
2.0 (61)
2.4 (74)
1.5 (45)
0.7 (21)
< 0.1 (1)
0.3 (9)
0.3 (10)
0.0 (0)
0.2 (7)
0.2 (5)
0.1 (4)
0.8 (17)
0.1 (3)
Figure 2 Prevalence rates of symptom-based FSS, health care visitors, and symptom-and-exclusion-based FSS.
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example, before vs. after medical examination by the
study investigators, chronic fatigue syndrome was present
in 555 vs. 43 individuals in a US-based study [24], and
7.5% vs. 1.6% in a French sample were estimated to have
fibromyalgia [25]. Similarly, an in-depth look at the study
by Koloski et al. [26], in which an approach comparable to
our symptom-and-exclusion-based strategy was used in
functional gastrointestinal disorders, reveals a more than
doubled decrease in prevalence rates before vs. after the
exclusion of medical illnesses. This suggests that the useof our symptom-and-exclusion-based strategy ‘mimics’ the
diagnostic pathway of epidemiological gold standard
studies adequately well. For absolute comparisons of
prevalence rates obtained by this strategy with findings
of other studies, the interested reader is referred to a
previously published article by our group [13].
Based on our findings, we further argue that potential
misattribution of somatic symptoms to a specific FSS
(instead of a medical illness) artificially inflates the extent
of overlap between syndromes. Only a small number of
population-based studies have examined overlap between
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hand, two of these studies relied either on physician-based
[27] or on symptom-based [28] diagnoses. Their finding of
a substantial co-occurrence of FSS is in accordance with
our finding of more than nine concomitant syndromes in
our symptom-based FSS group. Interestingly, in one of
these studies, the authors argue that their ‘results support
theories suggesting that medically unexplained conditions
share a common etiology’ [[27]; p. 818]. This study, as well
as our finding of a considerable overlap between symp-
tom-based diagnoses, are therefore in favor of the single
syndrome hypothesis [lumpers’ position; [10]]. On the
other hand, in another study, a symptom-and-exclusion-
based strategy was used for the diagnosis of FSS [30].
After re-analyzing their Swedish Twin Registry data, Kato
et al. reported that only 2.8% of their participants were
characterized by multiple FSS [30]. This percentage is in
line with our finding of 4.5% of participants having at least
three symptom-and-exclusion-based FSS. Based on their
findings, the authors conclude that ‘taken together, over-
laps among the three functional somatic syndromes were
not substantial’ (p. 451). This study, as well as our data
obtained by using the symptom-and-exclusion-based
strategy, thus both lend support to the notion of the
existence of multiple specific FSS instead of one single
syndrome [splitters’ position; [11]]. Taken together, study
findings regarding the overlap between FSS seem to
depend heavily on the selected diagnostic strategy, a
finding which has important conceptual ramifications
(one vs. many debate). Importantly, to answer the ques-
tion of overlap, and whether FSS are all expressions of the
same underlying phenomenon or discrete diagnoses, a
different analysis strategy should be employed [see e.g.,
[31,32]]. This strategy would ideally combine a factor
analysis with latent class analysis. Unfortunately, the
hierarchical, modular structure of the herein used FFSS
prevented the use of this approach in the current data set.
Study strengths and limitations
A strength of our study lies in our access to a large, non-
clinical sample that was free of any healthcare-seeking
bias. Nevertheless, a number of limitations need to be
taken into account when interpreting our results. First,
the present survey was conducted in a student sample,
which cannot be considered representative of the general
population. However, as outlined above, our findings are
in accordance with general population-based studies, indi-
cating potential generalizability at least to some extent.
Second, our strategy of establishing diagnoses of FSS was
dependent on health care visits. This led to a reduction of
our sample size, and could have potentially resulted in an
underestimation of ‘true’ prevalence rates in symptom-
and-exclusion-based FSS. However, accounting for med-
ical exclusionary conditions is very likely to explain a largeproportion of the decrease in prevalence rates, as mirrored
by the fact that in 43.1% of cases, a medical explanation
for patients’ symptoms was provided by a health care
professional. Third, due to the nature of a web-based
data collection approach, we were unable to confirm
our diagnoses through a physical examination or labora-
tory assessment in our participants (gold standard proced-
ure). This might again have led to an underestimation of
‘true’ prevalence rates in symptom-and-exclusion-based
FSS, since patients whose symptoms were caused both by
an FSS and a medical condition were not counted as FSS
cases in this study. In other words, we considered those
individuals having a medical condition that explained their
symptoms on part as non-cases. Also, some of the exclu-
sionary medical conditions might have been incidental,
with the FSS actually causing the symptoms. As illustrated
above, our diagnostic strategy does, however, lead to simi-
lar decreases in prevalence rates compared to those epi-
demiological studies using the gold standard approach.Conclusions
To summarize, we were able to show that including in-
formation on exclusionary medical conditions leads to a
significant decrease in prevalence and overlap rates of
FSS. This may call into question the validity of the findings
of a number of epidemiological studies on FSS. In a next
step, the validity of our symptom-and-exclusion-based
strategy should be checked in FSS patients that were diag-
nosed by the gold standard procedure. Also, comparisons
of prevalence rates as obtained by our approach with
prevalence rates of self-reported and physician diagnoses
would be of interest. Future studies should adopt more
rigorous approaches to the study of FSS, and combine
both the positive and negative criterion inherent in their
definition. This is likely to enhance the clinical benefit
from epidemiological findings on FSS, with the potential
to guide diagnostic and, ultimately, treatment decisions.
Abbreviation
FSS: Functional somatic syndromes.
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Abstract 
Distressing somatic symptoms are ubiquitous both in psychopathology and medical conditions. 
Yet, from a psychometric perspective, the structure and dimensionality of somatic symptom 
distress is unclear, and little is known about the strengths of associations to other constructs, such 
as health anxiety or the trait of somatosensory amplification. In order to clarify the latent 
structure of somatic symptom distress and to explore associations to health anxiety, 
somatosensory amplification, and functional somatic syndromes, data sets of two samples of 
college students from Germany (N = 1,520; Study 1) and Switzerland (N = 3,053; Study 2) were 
investigated with non-parametric confirmatory factor analysis. In Study 1, a bifactor model (with 
one general and four orthogonal specific symptom factors—gastrointestinal, fatigue, cardio-
pulmonary, and pain symptoms) revealed the best model fit. Medium-sized associations were 
found among latent factors of general somatic symptom distress, health anxiety, and depression. 
Study 2 demonstrated first evidence for the construct validity of the latent variables within the 
proposed bifactor structure by observing (a) strong associations between the general somatic 
symptom distress factor and somatosensory amplification, and (b) significant associations 
between both the general somatic symptom factor as well as the symptom-specific factors with 
functional somatic syndromes. The results offer a theoretically and psychometrically plausible 
model for the latent structure of somatic symptom distress and suggest a distinction between 
cognitive-affective and sensory aspects of symptom perception. The findings imply that somatic 
symptom distress is both strongly linked to but also clearly separable from psychopathological 
constructs (i.e., depression, health anxiety). 
Keywords: somatic symptoms; somatic symptom disorder; medically unexplained symptoms 
(MUS); somatoform disorders; functional somatic syndromes; irritable bowel syndrome (IBS); 
fibromyalgia syndrome (FMS); bifactor model.  
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Between two thirds and three quarters of distressing somatic symptoms presented in 
primary medical care are not fully explainable by current medical knowledge and consequently 
represent medically unexplained symptoms (MUS; Körber, Frieser, Steinbrecher, & Hiller, 
2011). A considerable amount of people with MUS (10-30%) develop chronic and distressing 
symptom patterns which fulfill the diagnostic criteria of functional somatic syndromes (e.g., 
fibromyalgia syndrome; Fischer, Gaab, Ehlert, & Nater, 2013) and/or a somatoform disorder 
according to DSM-IV. For the sake of clarity, we apply the term somatic symptom distress in this 
article. It remains largely unknown which factors contribute to a chronic development of somatic 
symptom distress. Importantly, the fundamental question of the latent structure of somatic 
symptom distress remains unanswered. According to Deary (1999), solving this question 
represents one of the crucial prerequisites for explaining aversive somatic symptom experiences 
which are the core feature of somatoform disorders and functional somatic syndromes. Without 
exact knowledge regarding the type of latent structure and an adequate measurement model, 
somatic symptom distress remains poorly specified and research into causes and correlates is 
hampered. Recent evidence from taxometric analyses suggests that somatic symptom distress 
should be considered as a continuous construct (e.g., Jasper, Hiller, Bailer, Rist, & Witthöft, 
2012). This finding implies that the etiology of chronic somatic symptom distress is indeed most 
likely a complex and multi-causal process and that the mechanisms are not qualitatively different 
from the mechanisms of milder variants of transient somatic symptom experiences. Thus, more 
detailed analyses on the dimensionality of somatic symptom distress are justified. Further 
knowledge of the factor analytic structure is directly related to the question whether it is 
reasonable to distinguish among different kinds of somatic symptom distress, in terms of separate 
diagnoses or different functional somatic syndromes (e.g., fibromyalgia or chronic fatigue 
syndrome), or whether the similarities among different somatic symptom distress patterns 
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outweigh their differences (e.g., Wessely, Nimnuan, & Sharpe, 1999). In this latter case, more 
general and comparatively broad diagnostic terms, as recently proposed with the novel diagnosis 
of somatic symptom disorder in DSM-5, would be empirically justified. 
Previous studies on the structure of somatic symptom distress (e.g., Deary, 1999) mostly 
relied on three kinds of models: (a) a general factor model, in which the variability of every 
single item is explained by one latent (general) factor; (b) a correlated factor model consisting of 
correlated symptom-specific factors; and (c) a hierarchical model in which the variability of 
symptoms is explained by lower-order symptom-specific factors, and the associations among 
these latent symptom-specific factors are accounted for by a higher order general factor. 
Recently, a fourth type of model has been proposed which can be considered as a mixture of the 
general model and the correlated subfactor approach. In this so called “bifactor” model (Brunner, 
Nagy, & Wilhelm, 2012), every single symptom is explained by two latent factors: a general 
factor that is related to every symptom, and a second symptom-specific factor that is related to 
specific groups of symptoms (e.g., pain symptoms or gastrointestinal symptoms). The different 
latent factors are orthogonal in this model, i.e., each latent factor explains the unique variability 
of a given symptom distress level. A bifactor approach was recently proposed to represent the 
best-fitting measurement model in the realm of somatic symptom distress (Thomas & Locke, 
2010; Witthöft, Hiller, Loch, & Jasper, 2013).  
Although evidence of the superiority of the bifactor model is growing, data on the 
construct validity of the proposed latent (general and specific) somatic symptom-distress factors 
is still missing and it remains unclear, how strongly the different factors relate to other relevant 
constructs. Health anxiety (i.e., the unsubstantiated and disproportionate fear or conviction to 
suffer from a severe illness) represents one of the most important related constructs. The relation 
between health anxiety and somatic symptom distress has long been debated. Currently, two 
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positions seem to prevail on this issue: The first position considers health anxiety and 
hypochondriasis as a byproduct of somatic symptom distress (APA, 2013). The second position 
considers health anxiety as a distinct construct (e.g., Leibbrand, Hiller, & Fichter, 2000), which 
might even be more strongly related to the realm of anxiety disorders than to somatic symptom 
distress and related conditions. Beyond health anxiety, the construct of somatosensory 
amplification has been proposed as an explanatory construct to account for the development and 
maintenance of both chronic somatic symptom distress and health anxiety (Barsky, Wyshak, & 
Klerman, 1990). Somatosensory amplification is defined as a trait-like disposition involving the 
tendency to experience somatic reactions as more intense and to habitually evaluate them as more 
negative, noxious, and as evidence of a physical disease. Somatosensory amplification as a rather 
general construct regarding symptom perception, should be strongly related with the general 
factor of somatic symptom distress within the bifactor model. Finally, little is known about how 
the different general and specific somatic symptom factors in the bifactor model relate to 
different functional somatic syndromes. 
We will present two studies that aim at testing and validating the latent structure of 
somatic symptom distress. In the first study, the recently proposed bifactor model will be tested 
and compared to alternative models (the general factor model, correlated factor model, and the 
hierarchical model)1. In Study 2, we aim at replicating the findings of Study 1 in an independent 
sample. Furthermore, evidence for the construct validity of the proposed latent variables will be 
tested by exploring associations to somatosensory amplification and functional somatic 
syndromes. Specifically, we hypothesize (a) that the general factor reflects the affective 
component of somatic symptom distress and should therefore reveal the strongest associations to 
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health anxiety and somatosensory amplification; and (b) that functional somatic syndromes are 
equally well predicted by the general somatic distress factor and the symptom-specific factors. 
Study 1: Method 
Participants and Measures 
A total of N = 1,604 participants completed a set of questionnaires in the years 2004 to 
2005 in the waiting area of the Office of Student Enrollment at a German University. They were 
asked to take part in a study on environment and well-being. Of the participants, 60.1 percent 
were female and the mean age was M = 21.8 (SD = 5.81). Most of the participants were 
university students (83.5%), with chemistry (17.2 %) and economics (11.7%) reported as the 
most frequent academic majors. The study was approved by the local ethics committee. 
Patient Health Questionnaire-15 (PHQ-15; Kroenke, Spitzer, & Williams, 2002). The 
PHQ represents a continuous self-report measure of somatic symptom distress over the previous 
four weeks. The PHQ-15 consists of 15 somatic symptoms (e.g., headaches, back pain, dizziness) 
with three response categories (not bothered at all, bothered a little, or bothered a lot). 
The Whitely Index (WI). The WI represents the most prominent self-report measure for 
a dimensional assessment of health anxiety. It consists of 14 dichotomous items (“yes” or “no”) 
and a two dimensional structure (factor 1: health anxiety; factor 2: symptoms and illness 
convictions; Schwarz et al., 2007). 
The Patient Health Questionnaire 9 (PHQ-9). The PHQ-9 (Kroenke, Spitzer, & 
Williams, 2001) comprises nine four-point items that are based on the criteria for depressive 
disorders in DSM-IV. The response format ranges from “not at all” to “nearly every day” and 
                                                                                                                                                              
1 Some of the models that we compared are nested within one another (i.e., hierarchical model within the bifactor 
and g-factor model within the bifactor model). This implies that one model may be seen as the extension of the other 
model. Thus, a g-factor model or a hierarchical model do not necessarily contradict a bifactor model. Rather, they 
should be seen as extensions that help to model the data structures even better. 
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the PHQ-9 is regarded as a valid and reliable measure for depression (Kroenke et al., 2001).2 
Data Analysis 
Confirmatory factor analyses were performed with MPlus Version 6.11 (Muthén & 
Muthén, 2010). The analyses of the measurement models were conducted with the robust mean 
and variance adjusted weighted least squares (WLSMV) procedure3. Because the χ2 test is 
sensitive to the sample size and the complexity of the model, we used other descriptive fit 
measures for the evaluation of the model fit. As an absolute fit index, we chose the RMSEA 
(Root Mean Square Error of Approximation). Furthermore, the CFI (Comparative Fit Index) and 
the TLI (Tucker-Lewis Index) are reported as incremental fit indices. 
Study 1: Results and Discussion 
The latent structure of somatic symptoms in the PHQ-15. Several models were tested 
on the latent structure of somatic symptom distress: The bifactor model (Figure 1), consisting of a 
general symptom distress factor and four orthogonal symptom-specific factors (pain-, 
gastrointestinal-, cardio-pulmonary-, and fatigue-related symptoms) showed an excellent model 
fit (χ²(54) = 88.38; p = .002; CFI = .992; TLI = .989; RMSEA = .020; 90% CI = .012 –.028). This 
model fitted the data significantly better than a hierarchical factor model with one higher-order 
and four lower-order factors (χ² (64) = 402.03; p < .001; CFI= .926; TLI = .909; RMSEA = .059; 
90% CI = .054 –.065; χ²-difference test: χ² (10) = 221.20; p < .001). The assumption of a general 
factor model resulted in rather poor model fit (χ² (65) = 900.56; p < .001; CFI = .816; TLI = .780; 
RMSEA = .092; 90% CI = .087 –.097). 
                                                 
2 Because the PHQ-9 contains two items (“trouble sleeping” and “feeling tired/low energy”) that are also part of the 
PHQ-15, we used only the remaining seven items for the depression score to avoid item overlap. 
 
3 For model comparisons, we used the DIFFTEST option in MPlus which takes into account that the distribution of 
the WLSMV based Chi-Square differences is not itself Chi-Square distributed. 
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Associations between somatic symptoms and health anxiety. To test the strength of 
associations between the different latent somatic symptom factors derived from the bifactor 
model and the two facets of health anxiety included in the WI (health anxiety; symptoms and 
illness convictions), we computed a structural equation model consisting of the PHQ-15 bifactor 
model and a hierarchical model of the WI consisting of a higher-order factor (general health 
anxiety) and the two lower-order factors “health anxiety” and “symptoms and illness 
convictions.” The model revealed a good fit to the data (χ² (213) = 511.37; p < .001; CFI = .968; 
TLI = .962; RMSEA = .030; 90% CI = .027 –.034). The health anxiety general factor showed 
strong associations to the somatic symptom general factor (r = .622; p <.001; SE = 0.053). 
Additionally, weaker but significant associations were observed between the general health 
anxiety and the cardio-pulmonary symptom factor (r = .264; p =.001; SE = 0.077), as well as 
between the general health anxiety and the gastrointestinal symptom factor (r = .219; p <.001; SE 
= 0.047). Associations between the general health anxiety and the pain symptom factor (r = .067; 
p =.219; SE = 0.054) and the fatigue symptom factor (r = .092; p =.137; SE = 0.062) did not 
reach significance. 
Associations among somatic symptoms, health anxiety, and depression. In order to 
explore the associations of somatic symptom distress and health anxiety with depressive 
symptoms, we added the PHQ-9 to the previous model. This extended structural equation model 
again yielded a good model fit (χ² (382) = 912.28; p <.001; CFI = .964; TLI = .959; RMSEA = 
.030; 90% CI = .028 –.033). The latent depressive symptom factor was strongly related to the 
general somatic symptom-distress factor (r = .615; p <.001; SE = 0.046), to the general health 
anxiety factor (r = .477; p <.001; SE = 0.037), and to the fatigue symptom factor (r = .578; p 
<.001; SE = 0.045), but not to the cardio-pulmonary (r = -.039 p =.590; SE = 0.073), 
gastrointestinal (r = .051; p =.196; SE = 0.052), or pain symptom factor (r = -.082 p =.064; SE = 
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0.044). These findings suggest that for the somatic symptom distress model, only the general 
symptom-distress factor and the fatigue factor are significantly associated with depressive 
symptoms. Specifying a latent regression model in which the PHQ-15 general factor was 
regressed onto the health anxiety and the depression factor yielded significant latent regression 
coefficients for both health anxiety (r = .407; p <.001; SE = 0.089) and depression (r = .542; p 
<.001; SE = 0.061). Together, both constructs account for a total of 67% of explained variance in 
the general somatic symptom factor. We used the Wald test to compare the strengths of 
association in this model (H0: the regression weights of health anxiety and depression are of 
equal size). The Wald test was not significant (p = .333), suggesting that health anxiety and 
depression represent equally powerful predictors of general somatic symptom distress. 
The results of Study 1 showed that a bifactor model offered an excellent model fit and 
outperformed alternative structural models (e.g., a general factor, or a hierarchical factor model). 
The findings mean that most of the symptoms covered in the PHQ-15 are determined by one 
general symptom factor and four symptom-specific factors. Regarding the question of construct 
validity of the different latent somatic symptom factors, the pattern of associations of the somatic 
symptom factors with health anxiety and depression revealed a quite clear pattern: Both 
constructs, health anxiety and depression, had the strongest associations with the general somatic 
symptom factor. It is important to note that the strengths of associations were about of equal size 
for both constructs, suggesting that health anxiety is not more closely related to somatic symptom 
distress than is depression. Regarding the specific somatic symptom factors, a quite different 
pattern of associations was observed, with depression being significantly related only to the 
fatigue factor, and health anxiety being significantly related to the cardio-pulmonary as well as 
the gastrointestinal, but not the pain or fatigue factor. This differential pattern of associations 
regarding depression and healthy anxiety underlines the validity of the different constructs and 
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speaks against the notion that the latent factors (both in the somatic symptom bifactor model and 
the health anxiety and depression model) are just reflections of unspecific negative affectivity. 
Finding the general somatic symptom-distress factor to be most strongly related to psychological 
constructs (e.g., health anxiety and depression) confirms previous suggestions (Witthöft et al., 
2012) that the general factor might rather represent cognitive-affective facets of symptom 
perception, whereas the specific factors might include physical and sometimes perhaps organ-
specific aspects of sensory symptom experience, which might be more strongly related to specific 
functional somatic syndromes (e.g., irritable bowel syndrome, fibromyalgia).  
Study 2: Method 
Participants and Measures 
The study was conducted as a web-based survey at a University in Switzerland. 
Invitations to take part in the study were sent out via administrators of public colleges and 
universities in the German-speaking part of Switzerland. A link to the survey website was posted 
on several Internet platforms that are known to be frequently visited by students. The participants 
were asked to take part in a survey on physical and mental well-being. A total number of N = 
6,206 participants visited the website and about 51% of them finished the survey. After the 
exclusion of implausible datasets (regarding duration, age, etc.) and incomplete SSAS responses, 
N = 3,053 datasets remained for further analyses. About 73% of the participants were female and 
the mean age was M = 24.6 (SD = 5.60). About 76% had at least a high school diploma and 22% 
a university degree; the remaining participants had lower school degrees (22%). 
Patient Health Questionnaire 15 (please see the Method section of Study 1). 
Somatosensory Amplification Scale (SSAS). The German version of the SSAS (e.g., Jasper 
et al., 2013) was used, which asks the respondent to what extent each of the 10 items is 
“characteristic of you in general” (Barsky et al., 1990, p. 325) on a five-point scale from not at all 
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true to extremely true. The 10 items mainly ask for uncomfortable bodily sensations, such as Item 
5, “Sudden loud noises really bother me” (Barsky et al., 1990, p. 327). 
Questionnaire for the Assessment of Functional Somatic Syndromes (FFSS; Nater, 
Fischer, Latanzio, Ruoss & Gaab, 2011). The FFSS assesses 17 functional somatic syndromes 
according to their existing research criteria4. 
Data Analysis 
Please see the Method section of Study 1 for details. 
Study 2: Results and Discussion 
The bifactor model of somatic symptoms presented in Study 1 also revealed an excellent 
fit to the data (χ² (54) = 140.04; CFI= .992; TLI = .988; RMSEA = .023; 90% CI = .018 –.028) in 
Study 2. 
Associations between somatic symptoms and somatosensory amplification (SSA). A 
structural equation model containing the PHQ-15 bifactor model and a general factor 
measurement model for the SSAS obtained good model fit (χ² (211) = 868.94; CFI = .966; TLI = 
.960; RMSEA = .032; 90% CI = .030 –.034) and a strong association (r = .525; p < .001; SE = 
0.033) between the general somatic symptom factor and the SSAS. Associations between the 
SSAS and the specific symptoms factors were of small size (pain: r = .066; SE = 0.040; cardio-
pulmonary: r = .065; SE = 0.050; gastrointestinal: r = .090; SE = 0.035; fatigue: r = .076; SE = 
0.041) and only reached significance for the gastrointestinal symptom factor (p = .009). In order 
to test for specific associations between SSA and somatic symptom distress beyond depression, 
we specified a latent regression model in which the PHQ-15 general somatic symptom factor was 
                                                 
4 (tension-type headache; globus hystericus; whiplash-associated disorders; temporomandibular disorders; persistent 
idiopathic facial pain; chronic low back pain; fibromyalgia syndrome; chronic fatigue syndrome; multiple chemical 
sensitivity; irritable bowel syndrome; functional dyspepsia; chronic abacterial prostatitis; chronic pelvic pain; 
premenstrual syndrome; premenstrual dysphoric disorder; functional chest pain of presumed esophageal origin; 
hyperventilation syndrome). 
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regressed onto SSA and the depression factor. Both SSA (r = .400; p < .001; SE = 0.047) and 
depression (r = .556; p < .001; SE = 0.037) yielded significant latent regression coefficients and 
accounted for a total of 65% of explained variance in the general somatic symptom factor. Thus, 
SSA is specifically related to general somatic symptom distress beyond depressive symptoms. 
To test possible associations between the different factors of somatic symptom distress 
and the existence of functional somatic syndromes, we specified a latent regression model in 
which binary variables that indicated the existence of specific functional somatic syndromes (e.g. 
irritable bowel syndrome) and the existence of any functional somatic syndrome were regressed 
onto the different somatic symptom-distress factors in the PHQ-15 bifactor model. The model 
yielded an excellent fit to the data (χ² (62) = 168.84; p < .001; CFI = .990; TLI = .986; RMSEA = 
.024; 90% CI = .019 – .028) and the general somatic symptom-distress factor turned out to be the 
strongest predictor for the existence of any functional somatic syndrome (r = .487; p < .001; 
SE=0.046). Among the specific factors, only the gastrointestinal factor significantly contributed 
to the prediction of functional somatic syndromes. It was the best predictor of the presence of 
irritable bowel syndrome (r = .83, p < .001; SE=0.109) and significantly predicted the presence of 
any functional somatic syndrome (r = .18; p < .001; SE=0.051). Overall, 28% of the variability of 
functional somatic syndromes could be explained by the different somatic symptom factors.  
The aims of the second study were to test the validity of the bifactor model of somatic 
symptom distress proposed in Study 1 by exploring possible associations between the different 
somatic symptom factors and the trait of SSA, as well as the existence of functional somatic 
syndromes. As expected, SSA was found to be strongly related to the general somatic symptom-
distress factor5. Of further note is the observation that none of the specific symptom factors was 
significantly associated with SSA, suggesting that it might be especially the general symptom-
                                                 
5 This association remained significant even after controlling for individual differences in depression. 
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distress factor that covers cognitive-affective components of symptom perception, as opposed to 
the specific symptom factors, which might rather represent physiological or sensory aspects 
related to symptom perception. Regarding the second question, of possible associations between 
the bifactor model and the existence of functional somatic syndromes, we observed substantial 
positive associations between the general somatic symptom factor and the existence of any 
functional somatic syndrome. This finding suggests that somatic symptom distress, as covered in 
the general factor of the PHQ-15, can be considered as the core feature for functional somatic 
syndromes.  
General Discussion 
The primary aims of the two presented studies were to gain a further understanding of the 
structure of somatic symptom distress and to determine possible associations of the different 
factors to related constructs, specifically depression, health anxiety, the trait of somatosensory 
amplification, and specific functional somatic syndromes. In search of a psychometrically 
adequate and theoretically plausible structural model of somatic symptoms, we were able to 
replicate the recently proposed bifactor model (Thomas & Locke, 2010; Witthöft et al., 2013). 
The bifactor approach may also represent an elegant way to reconcile the long-lasting debate 
about whether qualitatively distinct patterns of somatic symptom distress (i.e., different 
functional somatic syndromes) exist, or whether the common variance among the different 
somatic symptom patterns may outweigh their differences (e.g., Wessley et al., 1999). The 
bifactor model implies that a large proportion of common variance exists between somatic 
symptoms across diverse organ systems. The observation that the general factor is strongly 
associated with psychopathological constructs (i.e., health anxiety and depression in Study 1), as 
well as somatosensory amplification (Study 2) suggests that psychological processes regarding 
the formation and perception of somatic symptom distress (e.g., Brown, 2004; Witthöft & Hiller, 
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2010) may represent individual differences in the general somatic symptom-distress factor. In this 
respect, it appears noteworthy that SSA was specifically (i.e., independently of depression) 
associated with the general somatic symptom factor, but not with the more specific somatic 
symptom-distress factors. Because in previous studies SSA has been found to be either unrelated 
or inversely related to interoceptive accuracy (e.g., Aronson, Barrett, & Quigley, 2001), we 
assume that the general aspect of symptom distress is not associated with a higher interoceptive 
ability, but rather with distortions in the processing of interoceptive stimuli leading to the 
subjective experience of somatic symptom distress. Future studies that experimentally assess 
interoceptive awareness and interoceptive accuracy are needed to confirm this hypothesis. In 
contrast to the general factor, which most likely represents a central affective-motivational and 
evaluative component of symptom perception, the residual or specific symptom factors most 
likely reflect sensory-discriminative aspects of symptom perception which are more specific and 
informative regarding the exact location (i.e., organ system) and type of the respective symptom. 
This important distinction between an affective and a sensory component of symptom perception 
has long been recognized in pain research (Fernandez & Turk, 1992) but comparatively neglected 
in the research on MUS so far. The findings also call into question the novel diagnosis of illness 
anxiety disorder in DSM-5, which is defined by strong health anxiety in the absence of 
distressing somatic symptoms. The findings rather endorse the notion to define somatic symptom 
distress and health anxiety as separate psychometric and diagnostic entities that can co-occur but 
do not necessarily have to do so. 
Limitations. Several limitations of our study have to be considered: First, and perhaps 
most importantly, the current models are based on samples of college students that are not 
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representative of the general population6. However, previous studies suggest that the bifactor 
model of somatic symptoms fits the data well also in samples of the general population, as well 
as in patient samples (Thomas & Locke, 2010; Witthöft et al., 2013). A further limitation 
represents the internet-based mode of administration. No study has so far demonstrated the 
psychometric equivalence of the paper-pencil and the internet version of the PHQ-15 as it has 
been comprehensively done for other psychometric instruments (e.g., Bagby et al., 2014). 
However, the observation that the described bifactor model was also found in previous paper-
pencil administrations of the PHQ-15 in patients’ samples and members of the general population 
(Thomas & Locke, 2010; Witthöft et al., 2013) endorses the notion that the proposed structure is 
not simply and artifact of the chosen mode of administration. Finally, the presented models are 
based on self-report data that do not allow for a definite distinction between medially explained 
and MUS. Analyzes using more elaborate clinician ratings of medically explained vs. 
unexplained somatic symptom distress may come to different conclusions. 
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Figure 1. A bifactor model of somatic symptoms in the PHQ-15 in Study 1 (N = 1,520) with 
standardized factor loadings (circles represent latent variables, squares refer to manifest variables, 
single headed arrows represent factor loadings; all factor loading coefficients printed in bold are 
significant at p < .05; error terms of manifest variables not shown) 
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Figure 2. Upper part: Latent regression model for the prediction of somatic symptoms (bifactor model), 
by health anxiety and depressive symptoms; lower part: SEM for somatic symptoms (bifactor model), 
somatosensory amplification (SSA), and depression (significant association between SSA and cardio-
pulmonary symptoms, r=-.17, p=.034, not shown; all other correlations between SSA factor and symptom-
specific factors: r≤.09; circles represent latent variables, squares refer to manifest variables, single headed 
arrows between manifest and latent variables represent factor loadings; single and double headed arrows 
between latent variables represent latent regression and correlation paths, respectively). 
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6.2 Zusammenfassung 
Funktionelle somatische Syndrome (FSS) sind definiert durch das Vorhandensein somatischer 
Symptome bei gleichzeitiger Abwesenheit von strukturellen oder funktionellen Auffälligkeiten, die eine 
Erklärung der Symptome im Rahmen einer medizinischen Erkrankung nahelegen würden. Es existiert 
eine Vielzahl an Falldefinitionen für verschiedene FSS. Beispiele sind das das chronische 
Erschöpfungssyndrom, das Fibromyalgiesyndrom und das Reizdarmsyndrom. Diese Falldefinitionen 
haben derzeit jedoch nicht den Status nosologischer Entitäten. Der Grund dafür liegt in der unklaren 
Konzeptualisierung von FSS. Dies kann am besten anhand der so genannten „one-versus-many-
Debatte“ illustriert werden: Die Extrempositionen in dieser Debatte sind diejenige der „lumpers“, die 
ein Verständnis von FSS als ein einziges, generelles Syndrom befürworten, und diejenige der 
„splitters“, die für eine Aufteilung in verschiedene, distinkte FSS plädieren 
Ziel der vorliegenden Dissertation war es, Gemeinsamkeiten und Unterschiede von FSS zu 
identifizieren, indem ätiopathogenetische und phänomenologische Merkmale bei einer Reihe von 
Syndromen untersucht wurden. Bezüglich der Ätiopathogenese war insbesondere der Faktor Stress 
von Interesse. Basierend auf der Literatur wurde ein Rahmenmodell postuliert, das die Rolle von 
psychobiologischem Stress in der Entstehung und Aufrechterhaltung von FSS illustriert. Spezifische 
Bestandteile dieses Rahmenmodells sollten empirisch überprüft und integriert werden. Bezüglich der 
Phänomenologie von FSS sollte eine Vielzahl von Syndromen gleichzeitig erfasst werden, um deren 
Überlappung untereinander, die Rolle von Depressivität und Ängstlichkeit und die latente Struktur 
somatischer Symptome zu betrachten. Zur Untersuchung beider Teilfragestellungen wurden 
verschiedene Patientenstichproben rekrutiert und es kamen unterschiedliche Forschungsdesigns 
(experimentell, ambulantes Assessment, Befragungen) zum Einsatz. 
In der ersten Studie wurde die autonome Stressreaktivität bei Patienten mit einem 
chronischen Erschöpfungssyndrom untersucht. In Reaktion auf einen körperlich beanspruchenden 
Stressor (Ergometer) zeigten die Patienten im Vergleich zu einer gesunden Kontrollgruppe eine 
erniedrigte catecholaminerge Stressreaktion. Die Patienten unterschieden sich von den gesunden 
Personen nicht hinsichtlich ihrer Reaktion auf einen pharmakologischen Stressor (Insulin-Toleranz-
Test). 
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Das Ziel der zweiten Studie war es, zu klären, ob Stress im Alltag und stress-responsive 
Systeme, wie das autonome Nervensystem und die Hypothalamus-Hypophysen-Nebennierenrinden-
Achse, in die Exazerbation von Schmerzen bei Patienten mit einem Fibromyalgiesyndrom involviert 
sind. Hierzu wurde ein ambulanter Assessment-Ansatz gewählt. Momentan erlebter Stress sagte die 
Schmerzintensität mehrere Stunden später vorher. Momentane Cortisolkonzentrationen waren mit 
momentaner Schmerzintensität assoziiert. Es zeigte sich kein Zusammenhang zwischen der Aktivität 
von Alpha-Amylase (ein Indikator des autonomen Nervensystems) und der Schmerzintensität. 
In der dritten Studie wurde in einer Stichprobe von scheinbar gesunden jungen Erwachsenen 
ein multidimensionales Modell bezüglich der Rolle von Stress bei FSS getestet. Das Modell 
postulierte, dass Kindheitstraumata zu einer erhöhten Stressreaktivität führen und gleichzeitig mit 
geringerer Resilienz (i.e., psychische Widerstandsfähigkeit) verbunden sind. Eine derartige 
Prädisposition würde dann zu mehr chronischem Stress führen und dieser wäre wiederum auslösend 
und aufrechterhaltend an der Manifestation von FSS beteiligt. Das theoretisch postulierte 
Störungsmodell zeigte in quer- und längsschnittlichen Analysen von Befragungsdaten eine gute 
empirische Passung. 
In der vierten Studie wurden im Rahmen einer Befragung Überlappungsraten innerhalb der 
Kategorie der FSS sowie Prädiktoren für die Inzidenz von FSS sechs Monate später eruiert. Im 
Gegensatz zu bisherigen Studien erfüllten nur wenige Personen die Kriterien für mehr als ein FSS 
gleichzeitig. Prädiktoren für die Entwicklung von FSS allgemein waren die Anzahl körperlicher 
Beschwerden, die damit einhergehende Beeinträchtigung, Somatisierung (i.e., das Ausmaß, indem 
sich Personen durch somatische Symptome gestört fühlen) und Depressivität. 
Das Ziel der fünften Studie war es, die Konsequenzen unterschiedlicher Vorgehensweisen in 
der Diagnostik von FSS zu evaluieren. Der in der epidemiologischen Forschung häufig verwendete 
Ansatz der „symptom-based diagnoses“ führte im Vergleich zum Ansatz der „symptom-and-exclusion-
based diagnoses“ (der zusätzlich zur Abfrage von somatischen Symptomen auch medizinische 
Ausschlussdiagnosen berücksichtigt) zu deutlich höheren Prävalenzraten von FSS. Gleichzeitig 
fanden sich unter Verwendung des ersten Ansatzes höhere Überlappungsraten zwischen einzelnen 
Syndromen. 
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In der sechsten Studie (Studie VI) wurde in zwei Stichproben von scheinbar gesunden jungen 
Erwachsenen die latente Struktur von somatischen Symptomen und deren Bezug zu Depressivität, 
Ängstlichkeit, somatosensorischer Verstärkung (i.e., ein kognitiver Stil, der mit einer verstärkten 
Wahrnehmung somatischer Empfindungen einher geht) und verschiedenen FSS näher beleuchtet. Ein 
Bifaktormodell mit einem generellen Faktor und vier symptomspezifischen Faktoren („fatigue“, „pain“, 
„gastrointestinal“ und „cardio-respiratory“) beschrieb die latente Struktur von somatischen Symptomen 
am besten. Der generelle Faktor war mit Depressivität, Ängstlichkeit und somatosensorischer 
Verstärkung assoziiert. Die symptom-spezifischen Faktoren waren mit verschiedenen FSS assoziiert. 
Die Resultate der Studien I bis III zeigen Stress als prädisponierenden, auslösenden und 
aufrechterhaltenden Faktor bei verschiedenen FSS und weisen auf wichtige Mechanismen hin, die an 
der Übersetzung von Stress in somatische Symptome beteiligt sind. Trotz dieser Gemeinsamkeit 
wurden in den Studien IV und V geringe Überlappungsraten zwischen FSS gefunden, sofern 
medizinische Ausschlussdiagnosen berücksichtigt wurden. Diese scheinbare Diskrepanz spiegelt sich 
in den Befunden von Studie VI wider, in der ein genereller und vier symptomspezifische Faktoren die 
latente Struktur von somatischen Symptomen beschrieben. Gemäß der Befunde der vorliegenden 
Dissertation scheinen FSS „one and many“ zu sein. Es ist denkbar, dass ein hohes Ausmaß an Stress 
während der Kindheit oder im Erwachsenenalter und nachfolgende Veränderungen in stress-
responsiven Systemen sowie der kognitive Stil der somatosensorischen Verstärkung Endophänotypen 
darstellen, die sämtlichen medizinisch unerklärten Beschwerden zugrunde liegen. Falls dies zuträfe, 
wären die identifizierten symptomspezifischen Faktoren als phänomenologische Varianten dieses 
Prozesses zu verstehen. Künftige Klassifikationen sollten den gemeinsamen und spezifischen 
Faktoren Rechnung tragen, um eine adäquate Behandlung und erfolgreiche weitere Erforschung von 
medizinisch unerklärten Beschwerden zu gewährleisten. 
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